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    SYNOPSIS
1The research work incorporated in the thesis with the title “STUDIES ON
HETEROCYCLIC COMPOUNDS OF THERAPEUTIC INTEREST”  has been
described as under.
[A] STUDIES ON PYRAZOLES
[B]   STUDIES ON TRIAZOLES
[C]   STUDIES ON OXADIAZOLES
[A]   STUDIES ON PYRAZOLES
Pyrazole nucleus is endowed with a variety  of  therapeutic activities such as
antiinflammatory, antitumor, fungicidal, antitubercular, amoebicidal, herbicidal,
anticonvulsant, hypnotic, CNS depressant, plant growth regulatory activity etc. Our
efforts are focused on introduction of chemical diversity in the molecular frame work  in
order to synthesizing active molecule of  widely different composition.
Prompted by these facts, we have designed and synthesized some novel
chalcones, pyrazolines, cyclohexenones, aminopyrimidines, thiopyrimidines,
azomethines, barbitones and thiosemicarbazones bearing pyrazole nucleus. The study
is described in the following parts.
PART-I :  STUDIES ON PYRAZOLINES
Among a wide variety of heterocycles that have been explored for developing
biologically active molecules like pyrazolines have played all important role in medicinal
chemistry. Pyrazoline derivatives are associated with wide range of biological activities
like  antibacterial, analgesic, antitubercular and antiinflammatory. These valid
observation led us to synthesise some novel pyrazoline derivatives bearing  1-Phenyl-
3-p-fluorophenyl-4-formyl pyrazole moiety, which have been described as under.
SECTION - I : Synthesis and biological evaluation of 1-Aryl-3-(1',N-phenyl-3'-
 p-fluorophenyl pyrazol-4'-yl)-2-propen-1-ones
2The chalcone derivatives of type (I) have been prepared by  the condensation
of 1-phenyl-3-p-fluorophenyl-4-formyl pyrazole with different aryl ketones in the
presence of 40% NaOH.
SECTION - II : Synthesis and biological evaluation of 3-Aryl-5-(1',N-phenyl-3'-
  p-fluorophenyl pyrazol-4'-yl)-pyrazolines
The pyrazoline derivatives of type (II) have been prepared by the reaction of
chalcones of type (I) with hydrazine hydrate.
SECTION - III : Synthesis and biological evaluation of 1,N-Benzoyl-3-aryl-5-












                                                          Type (II)                   R = Aryl







3The pyrazolines of type (III) have been prepared by the reaction of compounds
of type (II) with benzoyl chloride in pyridine.
SECTION - IV : Synthesis and biological evaluation of 1,N-Nitroso-3-aryl-5-
                  (1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-pyrazolines
The pyrazolines of type (IV) have been prepared by the reaction of compounds
of type (II) with sodium nitrite.
PART-II :  STUDIES ON PYRIMIDINES
Pyrimidine derivatives have attracted due to their diversified biological activity
like plant growth regulators, antibacterial, antitubercular, antifungal, analgesic,
anticonvulsant etc. Led by these considerations, it was contemplated to synthesise
some pyrimidine derivatives which have been described as under.
SECTION - I : Synthesis and biological evaluation of 4-Aryl-6-(1',N-phenyl-3'-
 p-fluorophenyl pyrazol-4'-yl)-dihydropyrimidin-2-thiones
Thiopyrimidines of type (V) have been prepared by the condensation of chalcone
of  type (I) with thiourea in presence of alcoholic KOH.














                                                                Type (V)             R = Aryl
4SECTION - II : Synthesis and biological evaluation of 2-Amino-4-aryl-6-1',N -
               phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-pyrimidines
Aminopyrimidines of type (VI) have been prepared by the condensation of
chalcone of  type (I) with guanidine hydrochloride in presence of alcoholic KOH.
PART-III :  STUDIES ON CYCLOHEXENONES
Cyclohexenone ring systems have a prominent feature in medicinal chemistry
and possess biological activities such as anticancer, antibacterial, antifungal etc. In
view of these facts, it  was contemplated to synthesize cyclohexenone derivatives which
have been described as under.
SECTION - I : Synthesis and biological evaluation of 3-Aryl-5-(1',N-phenyl-3'-
         p-fluorophenyl pyrazol-4'-yl)-6-carbethoxy-2-cyclohexenones
The Cyclohexenone of  type (VII) have been prepared by the condensation of
chalcones of  type (I) with ethylaceto acetate in the presence of anhydrous K2CO3.
                                                          Type (VI)                      R = Aryl















5PART-IV :  STUDIES ON BARBITONES
The group of compounds containing the barbituric ancid ring system have a
prominent feature in medicinal chemistry and possess biological activity such as
hypnotic, herbicidal and anticonvulsant. In view of these valid observations it was
contemplated to synthesise some new barbitones possessing higher biological activity
which have been described has under.
SECTION - I : Synthesis and biological evaluation of 5-[1-Aryl-3-(1',N-phenyl-
  3'-p-fluorophenyl pyrazol-4'-yl)-2-propenylidine]-5-barbituric acids
The compounds of type (VIII) have been prepared by the condensation of
chalcone of type (I) with barbituric acid.
PART-V :  STUDIES ON ARYLAMINOMETHYL
Arylaminomethyl derivatives are the important class of biological activities which
have been deeply studies during search on new potential agents. These have been
reported to be active as antimicrobial, antitubercular, anticancer, insecticidal etc. In
order to develop medicinally important compounds, we have synthesized some new
arylaminomethyl  shown as under.
SECTION - I : Synthesis and biological evaluation of N-Aryl-1,N-phenyl-3-p-
  fluorophenyl pyrazol-4-yl-azomethines
The compounds of type (IX) have been prepared by the condensation of 1,N-

















                                                          Type (VIII)          R = Aryl
                                                              Type (IX)    R = Aryl
6SECTION - II : Synthesis and biological evaluation of 4-Arylaminomethyl 1,N-
   phenyl-3-p-fluorophenyl pyrazoles
The compounds of type (X) have been prepared by the reaction of compounds
of  type (IX) with an. NaBH4.
PART-VI :  STUDIES ON THIOSEMICARBAZONES
The study of  thiosemicarbazone  as  valuable drug  for  the diseases like
tuberculosis, cancer, diabetes, malaria and leprosy is well known. In order to achieving
better potency, different thiosemicarbazones derivatives have been described as under.
SECTION - I : Synthesis and biological evaluation of 1-Aryl-3-(1',N-phenyl-3'-
 p-fluorophenyl pyrazol-4'-yl)-2-propene-1-thiosemicarbazones
The compounds of  type (XI) have been prepared by the condensation of
chalcone of type (I) with thiosemicarbazide.
SECTION - II : Synthesis and biological evaluation of 1-Aryl-3-(1',N-phenyl-3'-














                                                          Type (X)           R = Aryl
                                                          Type (XI)           R = Aryl
In the recent year, MORE (Microwave Induced Organic Reaction Enhancement)
technique has become very popular due to substantial reduction in reaction time,
operational time, operational simplicity and formation of clear reaction products.









[B]   STUDIES ON TRIAZOLES
Compounds bearing 1,2,4-triazole nucleus are endowed with a variety of
biological activities such as amoebicidal, hypnotic,  fungicidal antiinflammatory, CNS
depressant, antitumor, anticonvulsant and plantgrowth regulator activity.
Realizing the importance of triazole nucleus, the synthesis of some novel
thiadiazoles and dihydrothiadiazoles. which have been described as under.
The compounds of type (X) have been prepared by the condensation of chalcone
of type (I) with thiosemicarbazide under microwave irradiation in few minutes.
Type (XI)           R = Aryl
PART-I :  STUDIES ON 1,3,4-THIADIAZOLES
1,3,4-Thiadiazole derivatives represent various biological activities such as
pesticidal, herbicidal, antithyroid, antitubercular, antifungal and antibiotic. With a view
to above findings, it appeared of interest to synthesise thiadiazole derivatives with
better potency  as shown below.









                                                             Type (XII)            R = Aryl
The compounds of type (XII) have been prepared by the condensation of
3-mercapto-4,N-amino-5-(2-methoxy-5-chlorophenyl)-1,2,4-triazole with different
aromatic acids in presence of phosphorous oxychloride.
8SECTION - II : Synthesis and biological evaluation of 6-Aryl-3-(2-methoxy-5-
                            chlorophenyl)-5,6,dihydro-1,2,4-triazolo[4,5-b]-1,3,4-thiadiazole
The compounds of type (XIII) have been prepared by the condensation of
3-mercapto-4,N-amino-5-(2-Methoxy-5-chlorophenyl)-1,2,4-triazole with different








                                                             Type (XIII)           R = Aryl
[C]   STUDIES ON OXADIAZOLES
Oxadiazole derivative are endowed with different therapeutic activities such as
hypnotic, anaesthetic, antibacterial, antifungal, insecticidal and preservatives. In view
of these facts, it was contemplated to synthesize some new oxadiazoles, which have
been described as under.
SECTION - I : Synthesis and biological evaluation of 2-Aryl-5-(2-methoxy-5-
              chlorophenyl)-1,3,4-oxadiazoles
The compounds of type (XIV) have been prepared by the condensation of








                                                             Type (XIV)         R = Aryl
9CHARACTERISATION
The constitution of newly synthesised products have been supported by using
elemental analyses, Infrared and 1H nuclear magnetic resonance spectroscopy and
further supported by mass spectrometry. Purity of all the compounds have been
checked by thin layer chromatography.
In vitro study on multiple biological activities
   (i) All the compounds have been evaluated for their antibacterial activity towards
Gram positive   and  Gram negative  bacterial strains and  antifungal  activity
towards Aspergillus niger at a concentration of 40 µg. The biologicalactivity
of  the synthesised compounds have been  compared with standard drugs.
   (ii) Selected compounds have been evaluated for their in vitro  biological assay
like antitubercular activity towards a strain of  Mycobacterium tuberculosis
H37Rv at a concentration of 6.25 µg/ml using Rifampin as a standard drug,which
have been tested by Tuberculosis Antimicrobial Acquisition Coordination
Facility (TAACF), Alabama,U.S.A.
    STUDIES ON




Heterocyclic chemistry has seen unparalled progress owing to their wide natural
occurance, specific chemical reactivity and broad spectrum utility.
Heterocyclic compounds have great applicability in pharmaceutics because they
have specific chemical reactivity and provides false synthons in biosynthetic process or
block the normal functioning of biological receptors. The inhibition of amide resonance
resulting into more susceptibility of  β-lactam to nucleophile is considered at least in
part responsible for antibacterial property, apparently by acetylating transpeptidase and
thus inhibiting bacterial cell wall biosynthesis.
Most of the alkaloids which are nitrogenous bases occuring in plants and many
antibiotics including penicillin and streptomycin have also heterocyclic ring system. Many
natural pigments such as indigo, haemoglobin and anthocyanin are heterocycles. Most
of the sugars are their derivatives including Vitamin C for intance, exist largely in the
form of five membered. Vitamin B6 (Pyridoxine) is a derivative of pyrimidine essential in
amino acid metabolism. Important drugs, poisons and medicines (both natural and
synthetic) such as sulphathiazole, pyrenthrin, rotenmone, strychnine, reserpine, certain
of the antihistaminics, the ergot alkaloids caeffine, cocaine, barbiturates, etc. are
heterocyclic compounds.
Heterocyclic compounds have great biological significance because :
1. They have a specific chemical reactivity.
2. They resemble essential metabolism and can also provide false synthons in
biosynthetic process.
3. They fit receptors and block their normal working.
4. They provide convenient building blockers to which biologically active substituents
can be attached.
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The interesting biological activities of heterocycles have stimulated considerable
research work in recent years including to the synthetic utility.
Heterocyclic compounds can be synthesised by cyclisation reactions (accompanied
by elemination of small molecules), addition reactions (adduct formation), ring transformation
reactions or replacement involving groups. Formation of heterocycle from acyclic com-
pounds alters the reactivity. Piperidine is reactive than ethyl propylamine due to the
reduction in steric incumbrance of the nitrogen lone pair.
AIMS AND OBJECTIVES
In the pharmaceutical field, there is a need for new and novel chemical inhibitors
of biological functions. Our efforts are focused on the introduction of chemical diversity
in the molecular frame work in order to synthesising pharmacologically interesting het-
erocyclic compounds of widely different composition.
During the course of research work looking to the applications of heterocyclic
compounds, several entities have been designed, generated and characterised using
spectral studies. The aims and objectives of the work carried out are as under.
1. To synthesise pharmacologically active entities like pyrazolines, pyrimidines,
cyclohexenones, barbitones, azomethines and thiosemicarbazones bearing 1-Phenyl-
3-p-fluourophenyl-4-formyl pyrazole nucleus.
2. To synthesise pharmacologically active entities like 1,3,4-Thiadiazoles
bearing 1,2,4-Triazole nucleus.
3. To synthesise pharmacologically active entities like 1,2,4-Oxadiazoles.
4. To characterise these products for structural elucidation using spectroscopic
techniques like IR, PMR and Mass spectral studies.
5. To check the purity of all compounds using thin layer chromatography.
6. To evaluate these new products for better drug potential against different strains
of bacteria and fungi.
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The research work is presented as studies on [A] Pyrazoles and [B] Triazoles
[C] Oxadiazoles.
In a programmed research directed towards the construction of therapeutically
active new heterocycles bearing 1-Phenyl-3-p-fluourophenyl-4-formyl pyrazole nucleus has
been investigated in following parts.
[A] : STUDIES ON PYRAZOLES
PART - I :    STUDIES ON PYRAZOLINES
PART - II :    STUDIES ON PYRIMIDINES
PART - III :    STUDIES ON CYCLOHEXENONES
PART - IV :    STUDIES ON BARBITONES
PART - V :    STUDIES ON ARYLAMINOMETHYLPYRAZOLES
PART - VI :    STUDIES ON THIOSEMICARBAZONES (MICROWAVE)
[B] : STUDIES ON TRIAZOLES
PART - I :    STUDIES ON 1,3,4-THIADIAZOLES
[C] : STUDIES ON OXADIAZOLES
PART - I :    STUDIES  1,2,4-ON OXADIAZOLES





Pyrazole refers both to the class of simple aromatic ring compounds of the
heterocyclic series characterised by a five membered ring structure composed of
three carbon atoms and two nitrogen atoms in adjacent positions (I). Being so
composed and having phamacological effects on humans, they are classified as
alkaloids although they are not known to occur in nature.
Pyrazole exhibits characteristic reactions of pyrrole and pyridine because of
containing pyrrole type and pyridine type nitrogen atoms at the position-1 and
position-2. Pyridine type nitrogen is susceptible to electrophilic attack but it is
less nucleophilic than the pyridine nitrogen atom. The hydrogen atom attached to
the nitrogen atom in pyrazole is more acidic than the pyrrolic N-H in pyrrole and
can be easily removed by nucleophiles.
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Knorr1,2 first synthesised a compound containing this system in 1883 by a
reaction of ethylaceto acetate with phenyl hydrazine which yielded 1-phenyl-3-
methyl-5-pyrazolone (II). Knorr3 introduced the name pyrazole for these compounds
to designate that the nucleus was derived from pyrrole by replacement of carbon by
nitrogen. Pyrazole ring is incorporated in to many of the pharmaceuticals,
agrochemicals and dyestuffs.
SYNTHETIC ASPECTS
Various methods for the preparation of pyrazoles have been cited in literature.
1. L. Knorr4 has synthesised two structrually isomeric pyrazoles by the
condensation of substituted hydrazines with 1,3-dicarbonyl compounds.
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3. R. C. Boruah6 and et. al. suggested one pot synthesis of pyrazoles from
β-formyl enamides.
4. By the reaction of 1,3-dinitroalkanes with hydrazines7.
5. H. V. Pechmann8 has synthesised pyrazoles by the reaction of acetylene
and diazomethane.
THERAPEUTIC IMPORTANCE
Pyrazole derivatives have been reported to be associated with diverse
biological activities.  Drug molecules having pyrazole nulceus with good
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Pyrazole derivatives exhibit broad spectrum of therapeutic activity. Several











Menozzi G. and co-workers19 have synthesised a series of N-substituted 4-
carboxy-1-phenyl-lH-pyrazole-5-propanamides, which  showed a platelet antiaggregating
activity in vitro superior or comparable to that of acetylsalicylic acid, as well as moderate
antiinflammatory, analgesic and antipyretic activities in rats or mice.
Naito H. et. al.20 have synthesised pyrimidinyl pyrazole derivatives which ex-
hibited a potent cytotoxic activity against some tumor cell lines including multidrug re-
sistant cell lines due to the overexpression of P-glycoprotein. Several new 1-methyl-5-
[substituted-4-oxo-1,2,3-benzotriazin-3-yl]-1H-pyrazole-4-acetic acids and their ethyl
ester derivatives were prepared and tested for analgesic and antiinflammatory activities,
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inhibitors of 3α-hydroxysteroid dehydrogenase (3α-HSD) by Giuseppe Daidone21. Ejima
Akio et. al.22 have synthesized pyrazole derivatives as antitumor agents (VIII).
Stevan W. Djuric and co-workers23 have identified a series of bis
(trifluoromethyl)pyrazoles (BTPs) as a novel inhibitor of cytokine production and
even inhibit IL-2 production with a 10-fold enhancement over cyclosporine in an
ex vivo assay.
 Nagaaki Sato et. al.24 have prepared arylpyrazole derivatives and evaluated
as neuropeptide Y5 receptor antagonist. One of the compound with chiral 2,3-
dihydro-1H-cyclopenta[a]naphthalene moiety, showed good binding affinity and
antagonistic activity for the Y5 receptor. Virinder S. Parmar et. al.25 have synthesised
pyrazole derivatives (IX) and studied their antiinvasive activity.
Carbau Romuald and co-workers26 have reported pyrazole derivatives useful
as reverse transcriptase inhibitors for the treatment of HIV infection. J. Scott Sawyer
et. al.27 have developed an interesting series of pyrazole based inhibitors of the
Transforming Growth Factor-β Type I Receptor Kinase Domain. David L. S. et. al.28
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Akihiko Tanitame and co-workers29 have synthesized new pyrazole derivatives
and found that 5-[(E)-2-(5-chloroindol-3-yl)vinyl]pyrazole possesses potent antibacterial
activity and selective inhibitory activity against bacterial topoisomerases. Many of the
synthesized pyrazole derivatives were potent against clinically isolated quinolone or
coumarin-resistant Gram-positive strains.
T. Van Herk et. al.30 have demonstrated pyrazoles as nicotinic acid receptor
(X). Atkinson R. N. et. al.31 have synthesized pyrazoles as sodium channel Blocker
(XI). Pyrazole derivatives as TGF-13 inhibitors have been suggested by Gellibert
Francoise et. al.32.
A series of 3-(4-phenoxyphenyl)-1H-pyrazoles(XII) were synthesized and
characterized as potent state-dependent sodium channel blockers by Ji Yang and
co-workers33.
Zainaba D. et. al.34 have investigated 1-phenyl-3-toluyl-4-[ortho-1’-(N-
ethyl-2’-methylpropylamine)]phenylpyrazole as antifungal agent and showed that
mycelial growth and conidial germination of fungi were blocked by the compound.
Adnan and Tarek35 have synthesised pyrazole derivatives (XIII) and tested for their
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A novel series of 1-thiocarbamoyl-3,5-diaryl-4,5-dihydro-(1H)-pyrazole
derivatives have been synthesised by Franco Chimenti et. al.36 and investigated
for the ability to inhibit selectively the activity of the A and B isoforms of
monoamine oxidase (MAO).
Craig W. Lindsley et. al.37 have investigated positive allosteric Modulators
for the Metabotropic Glutamate Receptor from a series of N-(1,3-diphenyl-1H-
pyrazol-5-yl)benzamides that potentiate receptor function in vivo. Several 5-substituted
pyrazole derivatives have been prepared as potent CB1 antagonists by Raj K.
Razdan38. These compounds have good binding affinities and also they may prove
to be clinically useful for the treatment of obesity. Adrian l. Gill and Martyn
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Recently, Bantwal Holla and co-workers40 have synthesised pyrazole derivatives as
potential antimicrobial agents. The antimalarial activity of 4-(5-trifluoro methyl-1H-
pyrazol-1-yl)-chloroquine analogues has been evaluated in vitro against a chloroquine
resistant Plasmodium falciparum clone by Antoniana U. Krettli et. al.41. Pyrazole
derivatives (XV) with nanomolar activity in the biochemical assay and able to efficiently
inhibit CDK2-mediated tumor cell proliferation have been  obtained by Paolo Pevarello
et. al.42.
Structure–activity relationship (SAR) studies of the novel 2-[3-di and
trifluoromethyl-5-alkylamino pyrazo-1-yl]-5-methanesulfonyl (SO2Me)/sulfamoyl
(SO2NH2)-pyridine derivatives for canine COX enzymes are described by Subas M.
Sakya et. al.43. The studies led to the identification of (XVI) as lead with potent in
vitro activity, selectivity, and in vivo activity in dogs and cats.
Some new pyrazols for potential cytotoxic activity, steroidal pyrazoles as
substrates for bile acid transporters,  DNA binding and cytotoxicity were
synthesized(XVII) by different workers i.e. B. A. Bhat and co-workers44, L. Bhat and






























R = di alkyl amino,
       hydroxy ethyl amino,
       morpholino,
       piperidino,
       pyrazino
                                                                            Pyrazoles . . .
22
Literature survey reveals that the compounds bearing pyrazole moiety possess
potential drug activity. Looking to the diversified biological activity, it appeared of interest
to synthesize some chalcones, pyrazolines, pyrimidines, cyclohexenones, barbitones,
azomethines and thiosemicarbazones bearing pyrazole moiety in order to achieving
compounds having better therapeutic importance. These studies are described in
following parts.
[A] : STUDIES ON PYRAZOLES
PART - I :    STUDIES ON PYRAZOLINES
PART - II :    STUDIES ON PYRIMIDINES
PART - III :    STUDIES ON CYCLOHEXENONES
PART - IV :    STUDIES ON BARBITONES
PART - V :    STUDIES ON ARYLAMINOMETHYLPYRAZOLES
PART - VI :    STUDIES ON THIOSEMICARBAZONES
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Pyrazolines are known to be among those heterocycles which find their utility in
various fields of life. The significance of this moiety has increased due to its
biocompatibility. The chemistry of pyrazoline was reviewed by Jarboe in 1967, which
have been studied extensively for their biodynamic behaviour47, and industrial
applications48.
Pyrazolines can exist in three tautomeric forms depending on position of double
bonds. They are known as 1-pyrazoline(I), 2-pyrazoline(II) and 3-pyrazoline(III). The
stability order of these pyrazoline is 2-pyrazoline > 1-pyrazoline > 3-pyrazoline.
Considerable interest has been focused on the pyrazoline structure, which has
been found to possess a borad specturm of biological activities such as tranquillizing,
muscle relaxant, psychoanaleptic, anticonvulsant, antihypertensive, and antidepressant
activities. The discovery of modern drug development also points out the unpredictability
of biological activity from structural modification of a prototype drug molecule.
SYNTHETIC ASPECT
Different methods for the preparation of 2-pyrazoline derivatives documented in
literature are as follows.



















2. 2-pyrazoline can be prepared by the condensation of α,β-unsatured ketone and
thiosemicarbazide in the presence of basic alumina and K2CO350.
3. 2-Pyrazolines can be also prepared by the condensation of di-bromo derivative
of chalcone with hydrazine hydrates51.
4. 2-Pyrazolines can be constructed by the cycloaddition of diazomethane to
substituted chalcones52.
5. A number of diarylidene cycloalkanones on reaction with hydrazine hydrate
produce pyrazolines53.
6. Epoxidation of chalcones gave epoxy ketones which reacted with hydrazine
hydrate and phenyl hydrazine to give pyrazolines54.
Furthermore, B. Gyassi et al.55 have investigated the one pot synthesis of some
pyrazolines in dry media under microwave irradiation. S. Paul et. al.56 and Dandia Anshu
et. al.57 have also described the microwave assisted synthesis of 2-pyrazolines.
MECHANISM
The following mechanism seems to be operable for pyrazoline by the condensation















































































Nucleophillic attack by hydrazine at the β-carbon of the α,β-unsaturated carbonyl
system forms species (II), in which the negative charge is mainly accommodated by the
electronegative oxygen atom.
Proton transfer from the nitrogen to negative oxygen produces an intermediate
enol which simultaneously ketonises to ketoamine (III). Another intramolecular
nucleophillic attack by the primary amino group of ketoamine on its carbonyl carbon
followed by proton transfer from nitrogen to oxygen leads to carbonyl amine (IV).
The later with a hydroxy group and amino group on the same carbon lose water molecule
to yield the pyrazolines.
THERAPEUTIC IMPORTANCE
From the literature survey, it was revealed that 2-pyrazolines are better therapeutic
agents.
1.   Antiallergic59
2.   Anticonvulsant60,61
3.   Antidiabetic62
4.   Antiimplantation63
5.   Antiinflammatory64
6.   Antitumor65
7.   Antineoplastic66
8.   Antimicrobial67









                                                                            Pyrazolines . . .
26
Ahn J. H. et. al.79 have described the synthesis and DP-IV inhibition of cyano
pyrazoline derivatives as potent antidiabetic agents(I). Jeong T. S. et. al.80 have
synthesized some novel 3,5-diaryl pyrazolines as human acyl-CoA: cholesterol
acyltransferase inhibitors. Nasr M. N. et. al.81 have reported the synthesis of Novel
arylthiazolylpyrazoline derivatives as antiinflammatory agents. Berghot M. A. et. al.82
have prepared for convergent synthesis and antibacterial activity of pyrazole and
pyrazoline derivatives of diazepam.
Maurer Fritz et. al.83 have synthesized pyrazoles and screened for their pesticidal
activity. B. Shivarama Holla et. al.84,85 have synthesized pyrazolines as antibacterial
agent.
Moreover, T. M. Stivenen et. al.86 have also investigated N-substituted pyrazoline
type insecticides. Tanka Katsohori87 have patented pyrazoline derivatives as herbicides
and Johannes et. al.88 have reported as insecticides. Moritaz Z. and Hadol89 to
investigated a semi imperial molecular orbital study on the   reaction of aminopyrazolinyl
azodye with singlet molecular oxygen.
Ashok Kumar et. al.90 have synthesized pyrazolines as anticonvulsant agents
(II). Hiremath S. P. et. al.91 have synthesized pyrazolines as analgesic, antiinflammatory

























   (III)       R1, R2 = Aryl
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Moreover, Guniz Kucukguzel et. al.93 have synthesized pyrazolines as a antimicrobial
and anticonvulsant agents. Almstead J. et. al.94 have prepared pyrazolines as vascularization
agent. Gulhan T. Z. and coworkers95 have prepared pyrazolines as a hypotensive agent.
Tuntawy Atif and co-workers96 have patented 3-methyl-4'-(substituted phenylazo)-
pyrazol-5-ones as antibacterial agent. Shalabh Sharma et. al.97 have synthesized
pyrazolines and tested their antiinflammatory activity (IV).
Gokhan N. et. al.98 have synthesized the pyrazoline derivatives of 1-N-
substituted thiocarbamoyl-3-phenyl-5-thienyl-2-pyrazolines as MAO inhibitors. Matysiak
J. et. al.99 have reported some novel pyrazoline derivatives as antimycotic activity of
N-azolyl-2,4-dihydroxythiobenzamides. Tabarelli Z. et. al.100 have prepared some
pyrazole derivative showed activity of antinociceptive effect of novel pyrazolines in mice.
Tae-Sook Jeong et. al.101 have reported pyrazole as low-density lipoprotein (LDL)
oxidation inhibitor(V)
K. Satyanarayana et. al.102 synthesized 4-[5-Aryl)-4,5-dihydro-lH-pyrazol-3-
yl]-3-phenylsydnones(VI) and tested for antiinflammatory, antiarthritic and analgesic
activity. A series of substituted pyrazolines were synthesized and evaluated for their
anticancer activity and for their ability to inhibit P-glycoprotein-mediated multidrug



















  R1,R2,R3 = Alkyl (V)
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(1H) pyrazoles were synthesized. Y. Rajendra Prasad et. al.104 tested the antidepressant
activity of some 1,3,5-triphenyl-2-pyrazolines and 3-(substituted naphthalen-1-yl)-1,5-
diphenyl-2-pyrazolines (VII) & (VIII). . David G. Jones et. al.105 discovered non-
steroidal mifepristone mimetics like 1-Arylsulphonyl-3,5-diarylpyrazolines which are PR
antagonists.
Recently, Abd E. Amr et. al.106 synthesized and tested antiandrogenic activity
of some new 3-substituted androstano[17,16-c]-5’-aryl pyrazolines. The in vitro
antimycobacterial activity of N’-nicotinoyl-3- (4’-hydroxy-3’-methyl phenyl)-5-(aryl)-
2-pyrazolines(IX) have been tested by M. Shaharyar and co-workers107. The pyrazoline
derivatives were synthesized using 2-(4-formyl-2-methoxyphenoxy) acetic acid as starting
material by M. Shahar Yar and co-workers108.  A.Budakoti and co-workers109 tested
new 1-N-substituted thiocarbamoyl-3,5-diphenyl-2-pyrazoline and their Pd(II)
complexes(X) for antiamoebic activity.
 (VI)






































CONTRIBUTION FROM OUR LABORATORY
S. D. Sorthiya et. al.110 have synthesised and tested the antimicrobial activity of
p-(2',5'-Dibromobenzenesulphonamido)-phenyl-5-aryl-1H/acetyl/phenyl-2-pyrazolines.
Parekh et. al.111 have prepared 1-acetyl-5-aryl-3-[3-(3,4-dihydro-2-methyl-4-one-
3-quinazolinyl)-phenyl]-2-pyrazolines which possess antimicrobial activity.
Parikh et. al.112 have synthesised some antimicrobial pyrazolines. Tejas Upadhyay
et. al.113 and Sohit Rajvaidya et. al.114 have prepared pyrazolines as antimicrobial
agent. A.V. Dobaria and Co-workers115 has discovered pyrazolines bearing
chloroquinoline nucleus which used as antimicrobial agents(XI).
Thus interesting biological activities of a novel heterocycles like pyrazolines have
stimulated considerable research work in recent years leading to the synthetic utility of
the derivatives of this ring system. In our search for new potential antimicrobial compounds,
the reaction series of chalcones with hydrazine hydrate under different conditions has
been investigated and the pharmacological profile of the compounds have been studied
and described as under.
SECTION-I   : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1 - A RY L - 3 - ( 1 ' , N - P H E N Y L - 3 ' -p - F L U O R O P H E N Y L
PYRAZOL-4'-YL)-2-PROPEN-1-ONES
SECTION-II  : SYNTHESIS AND BIOLOGICAL EVALUATION OF
3 - A RY L - 5 - [ 1 ' - N - P H E N Y L - 3 ' -p - F L U O R O P H E N Y L
PYRAZOL-4'-YL]-PYRAZOLINES








SECTION-III : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1 , N - B E N Z O Y L - 3 - A R Y L - 5 - ( 1 ' , N - P H E N Y L - 3 ' - p -
FLUOROPHENYLPYRAZOL-4'-YL)-PYRAZOLINES
SECTION-IV : SYNTHESIS AND BIOLOGICAL EVALUATION OF
1 , N - N I T R O S O - 3 - A R Y L - 5 - ( 1 ' , N - P H E N Y L - 3 ' - p -
FLUOROPHENYLPYRAZOL-4'-YL)-PYRAZOLINES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-[1'-N-PHENYL-
3'-p-FLUOROPHENY PYRAZOL-4'-YL]-2-PROPEN-1-ONES
The chalcones have been found to be useful for the synthesis of variety of het-
erocyclic compounds are as under.
1. Pyrazolines116 and its derivatives can be prepared by the condensation of chalcones
with hydrazine hydrate and acetic acid.
2. Chalcones on condensation with malononitrile and ammonium acetate yields 2-
amino-3-cyano pyridines117.
3. Isoxazoles118 can be prepared by the treatment of chalcones with hydroxylamine
hydrochloride and sodium acetate.
4. Chalcone on condensation with malononitrile in pyridine forms 2-amino-3-
cyanopyrans119.
5. Cha lcones  on  t r ea tmen t  wi th  u rea  in  p resence  o f  a lka l i  a f fo rds  2 -
oxopyrimidines120.
6. Chalcones on reaction with thiourea in presence of alkali/acid yields 2-thieno
pyrimidines121.
7. Chalcones on treatment with guanidine hydrochloride in presence of alkali affords
2-amino pyrimidines122.
8. Chalcones reacts with P2S5 yielding 2-isothiazolines123.
9. Chalcones with sodium nitrile in presence of glacial acetic acid in ethanol produces
2-1H-pyrimidines124.
10. Chalcones with monoethanolamine in ethanol gives 1,4-oxazipines125.
11. Chalcones with 2-amino thiophenol in acetic acid produces 1,5-thiazepines126.
12. Chalcones on reaction with semicarbazide hydrochloride in ethanol affords 1-
carboxamide pyrazolines127.
13. Chalcones on reaction with 2-aminopyrimidine in glacial acetic acid affords pyrido
pyrimidines128.
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14. Oxiran129 can be prepared by the reaction of chalcone with H2O2 in basic
media.
15. Cyanopyridone130 derivatives can be prepared by the condensation of chalcone
with ethylcyano acetate.
16. Chalcones on reaction with barbituric acid gave barbitone131 derivatives.
17. Chalcones gives imine derivatives with amine in presence of sufuric acid as
catalyst132.
MECHANISM
Chalcone formation proceeds through Aldol type of condensation and the process
is catalysed by the presence of alkali133. Following are the steps of the reaction
mechanism.
The intermediate Aldol type of products formed readily undergoes dehydration
even under mild condition, particularly when R and R’ are aryl groups.
THERAPEUTIC INTEREST
Chalcones are potential biocides, some naturally occurring antibiotics and




































































During the past years, considerable evidence has been accumulated to  demonstrate
the efficiency of chalcones in including variety of therapeutic activities. To further assess
the potential of such a class of compounds as antibacterial and antifungal agents, a
series of chalcones of type (I) have been synthesised by the condensation of 1,N-Phenyl






Type (I)            R = Aryl
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The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also. Purity of all compounds have been checked by thin layer
chromatography. The m/z peak at 399 indicates the molecular weight of the compound
1-p-Anisyl-3-(1',N-phenyl-3'-p-flurophenyl pyrazol-4'-yl)-2-propen-1-one and other
mass spectra fragmentation are recorded on page no.42.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The




























   REACTION SCHEME
Type - (I) R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1',N-PHENYL-
3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-2-PROPEN-1-ONES
[A] Synthesis of N-Phenylamino-α-methyl-p-flurophenyl azomethine
A mixture of Phenylhydrazine (1.08 g, 0.01M) and p-flurophenyl acetophenone
(1.38 g, 0.01M) in absolute ethanol was refluxed in water bath for 2 hrs. in presence of
1 ml glacial acetic acid. The crude product was isolated and crystallised from absolute
alcohol. Yield, 90%; m.p., 38oC, (C14H13FN2 ; Found : C, 72.63%, H, 5.70%; N,
12.21%; Required : C, 73.66%; H, 5.74%; N, 12.27%)
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
N-Phenylamino-α-methyl-p-fluorophenyl azomethine (2.27g, 0.01M) was added
to a mixture of Vilsmeir-Haack reagent (prepared by dropwise addition of 3 ml POCl3
in ice cooled 25 ml DMF) and refluxed for 5 hrs. The reaction mixture was poured into
ice followed by neutralization using sodium bicarbonate. Crude product was isolated
and crystallised from ethanol. Yield, 75%; m.p., 155oC, (C16H11FN2O ; Found C,
72.09%; H, 4.12%; N, 10.48%; Required ; C, 72.11%; H, 4.16%; N, 10.52%).
[C] Synthesis of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
2-propen-1-one
To a well stirred solution of 1,N-Phenyl-3-p-fluorophenyl-4-formyl-pyrazole
(2.65gm, 0.01M) and p-methoxyacetophenone (1.5 g, 0.01M) in ethanol (25 ml), 40%
KOH was added till the solution become basic. The reaction mixture was stirred for 24
hrs. The contents were poured into ice, acidified, filtered and crystallised from ethanol.
Yield,78%; m.p.,180oC, (C25H19FN2O2 ; Found : C,75.33%; H, 4.77%; N, 6.94%;
Requires : C, 75.36%; H, 4.81%; N, 7.03%).
Similarly, other substituted chalcones have prepared. The physical data are
recorded in Table No. 1.
[D] Antimicrobial activity of 1-Aryl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-
4'-yl)-2-propen-1-ones
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All the compounds have been evaluated for antimicrobial and antitubercular
activity as described under.
(a) Antimicrobial activity
Antimicrobial activity was carried out by cup-plate agar diffusion method which
has been described as under.
(I) Antibacterial activity
The purified products were screened for their antibacterial activity. The nutrient
agar broth prepared by the usual method, was inoculated aseptically with 0.5 ml of 24
hrs. old subcultures of B. coccus, S. aureus, Aerogenes, Pseudomonas in separate
conical flasks at 40-50oC and mixed well by gentle shaking. About 25ml content of the
flask were poured and evenly spreaded in a petridish (13cm in diameter) and allowed to
set for 2 hrs. The cups (10 mm in diameter) were formed by the help of borer in agar
medium and filled with 0.04ml (40µg) solution of sample in DMF.
The plates were incubated at 37oC for 24 hrs. and the control was also maintained
with 0.04 ml of DMF in a similar manner and the zones of inhibition of the bacterial
growth were measured in millimeter and are recorded in Graphical Chart No.1.
The antibacterial activity data of the synthesised compounds have been
compared with standard antibiotics like Amoxicillin, Benzyl penicillin, Ciprofloxacin and
Erythromycin.
(II) Antifungal activity
A. niger was employed for testing antifungal activity using cup-plate method.
The culture was maintained on sabouraud’s agar slants. Sterilized sabouraud’s agar
medium was inoculated with 72 hrs. old 0.5 ml suspension of fungal spores in a separate
flask. About 25 ml of the inoculated medium was evenly spreaded in a petridish and
allowed to set for two hrs. The cups (10 mm in diameter) were punched and filled with
0.04 ml (40 µg) solution of sample in DMF. The plates were incubated at 30oC for 48
hrs. After the completion of incubation period, the zones of inhibition of growth in the
form of  diameter in mm was measured. Along the test solution in each petridish one cup
was filled with solvent which act as control. The zones of inhibition were compared with





Gram positive bacteria : Bacillus coccus, B. Subtillus
Staphylococcus aureus
Gram negative bacteria : Aerogenes, E. Coli, P. Vulgaris
Pseudomonas
Fungi : Aspergillus niger
Concentration : 40µg/ml
Solvent : Dimethyl formamide
Standard drugs : Amoxicillin, Benzyl penicillin,
Ciprofloxacin, Erythromycin
Greseofulvin
The antimicrobial activity was compared with standard drug viz Amoxicillin,  Benzyl
penicillin, Ciprofloxacin, Erythromycin and antifungal activity was compared with viz
Greseofulvin. The inhibition zones measured in mm.
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 Observed
Alkane C-H str. (asym.) 2931 2975-2950
-CH3 C-H str. (sym.) 2837 2880-2860
C-H i.p.def. (asym.) 1452 1470-1435
C-H o.o.p. def. (sym.) 1357 1390-1370
Aromatic C-H  str. 3068 3080-3030
C=C str. 1525 1585-1480
C-H i.p. def. 1066 1125-1090
C-H o.o.p. def   808    835-810
Pyrazole C=N str. 1606 1630-1590
moiety C-N str. 1220 1230-1020
C-F str.   754    600-800
Ether C-O-C str. (asym.) 1259 1275-1200
C-O-C str. (sym.) 1031 1075-1020
Chalcone C=O str. 1660 1685-1645
CH=CH 3068 3050-3000
                                    (overlapped)
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)




























    (δ ppm)
 RelativeNo.
 of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.89 1H singlet          Ar-OCH3     -
2. 6.95-6.98 2H doublet        Ar-Hgg'        Jgf=8.7
3. 7.16-7.22 2H triplet          Ar-Hdd'       -
4. 7.33-7.40 2H quartet        -CH(h&i)     -
5. 7.48-7.53 2H triplet           Ar-Hee'      -
6. 7.67-7.72 2H multiplet       Ar-Hbb'      -
7. 7.98-7.81 3H triplet          Ar-Hcc'+Ha           -
8. 7.96-7.99 2H doublet        Ar-Hff'        Jfg=8.7
9. 8.34 1H singlet         -CHx           -
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-[1'-N-PHENYL-
3'-p-FLUOROPHENYL PYRAZOL-4'-YL]-PYRAZOLINES
Looking at versatile therapeutic importance and with an aim to getting better
drug, it was considered worthwhile to synthesise some new pyrazolines. The preparation
of 3-Aryl-5-(1',N-phenyl-3'-p-fluorophenyl-pyrazol-4'-yl)-pyrazolines (II) has been
undertaken by cyclocondensation of chalcones of type (I) with hydrazine hydrate.
The constitution of the synthesised products have been characterised by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and mass
spectrometry also. The m/z peak at 412 indicates the molecular weight of the compound
3-p-Anisyl-5-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-pyrazolineand other mass
spectra fragmentation are recorded on page no.52.
The products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strain and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The biological












Type (II)       R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1',N-PHENYL-
3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-PYRAZOLINES
[A] Synthesis of N-Phenylamino-α-methyl-2-p-anisyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
2-propen-1-one
See Part-I, Section-I (C).
[D] Synthesis of 3-p-Anisyl-5-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
pyrazoline
A mixture of 1-p-Anisyl-3-(1',N-phenyl-3'-p-flurophenyl pyrazol-4'-yl)-2-
propen-1-one (3.98 g, 0.01M) in 25 ml of absolute alcohol, and hydrazine hydrate
(0.5g, 0.01M) was refluxed in water bath at temp. 80-90oC for 8 hrs. The reaction
mixture was poured into ice. The product was isolated and crystallised from ethanol.
Yield, 59%; m.p., 140oC, (C25H21FN4O ; Found : C, 72.72%; H, 5.09%; N, 13.52%
; Requires : C, 72.80%; H, 5.13%; N, 13.58%).
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 2.
[E] Antimicrobial activity of 3-Aryl-5-(1',N-phenyl-3'-p-fluorophenyl-pyrazol-
4'-yl-)pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No.2.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-p-ANISYL-5-(1',N-PHENYL-3'-p-FLUORO
PHENYL PYRAZOL-4'-YL)-PYRAZOLINE
 Observed
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
Alkane C – H str.(asym.) 2918 2975–2920 576
–CH3 C – H str. (sym.) 2841 2880–2820 "
C – H i.p. (def.) 1448 1470–1435 "
C – H o.o.p. (def.) 1348 1385–1350 "
Aromatic C – H str. 3074 3080–3030 577
C – H i.p. (def.) 1157 1160–1090 "
1033 1070-1000 "
C – H o.o.p (def.) 835 835–810 "
Pyrazole C = N str. 1602 1650–1600 578
moiety C = C str. 1512 1585–1480 577
C – N str. 1317 1350–1200 578
C – F str. 758 760–710 576
Ether C – O – C (asym.) 1255 1275–1200 "
C – O – C (sym.) 1074 1075–1020 "
Pyrazoline C = N str. 1554 1627–1550 580








PMR SPECTRAL STUDY OF 3-p-ANISYL-5-(1',N-PHENYL-3'-p-FLUORO
PHENYL PYRAZOL-4'-YL)-PYRAZOLINE
Internal Standard : TMS; Solvent : CDCl3: Instrument : BRUKER Spectrometer (300 MHz)
Signal Signal Position Relative No. Multiplicity Inference J Value
No. (d ppm) of Protons In Hz
1. 3.00-3.08 1H d. doublet CHh                Jhi = 7.9
                       Jhj = 8.9
2. 3.35-3.48 1H d. doublet CHi                 Jih = 6.0
                       Jij =10.2
3. 3.83 3H singlet Ar-OCH3 -
4. 5.05-5.22 1H d. doublet CHj                 Jih = 9.4
                       Jji = 9.4
5. 6.88-6.92 2H doublet Ar-Hgg'           Jgf = 8.7
6. 7.10-7.21 2H triplet Ar-Hdd' -
7. 7.25-7.30 2H triplet Ar-Hbb' -
8. 7.35-7.46 2H triplet Ar-Hcc' -
9. 7.60-7.62 2H doublet Ar-Hee'           Jed = 8.7
10. 7.67-7.72 3H triplet Ar-Hff'+Ha      Jfg = 8.4
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SYNTHESIS AND BIOLOGICAL EVALUATION OF  1 , N - B E N Z O Y L -
3 - A R Y L - 5 - ( 1 ' , N - P H E N Y L - 3 ' - p- F L U O R O P H E N Y L PYRAZOL-4'-
YL)-PYRAZOLINES
Pyrazolines are endowed with various biological activities. Looking at their
versatile therapeutic importance and with an aim to getting better drug, it was considered
worthwhile to synthesise some new pyrazolines bearing 1,N-Phenyl-3-p-fluorophenyl-
4-formyl pyrazole nucleus. The preparation of 1,N-Benzoyl-3-aryl-5-(1',N-phenyl-3'-
p-fluorophenyl pyrazol-4'-yl)-pyrazolines (III) have been prepared by the reaction of
compounds of type (II) with benzoyl choride in pyridine.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layerchromatography. The m/z peak at 516 indicates the molecular weight of the
compound 1',N-Benzoyl-3-p-anisyl-5-(1',N-phenyl-p-fluorophenyl pyrazol-4'-yl)-
pyrazoline and other mass spectra fragmentation are recorded on page no.62.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
















SYNTHESIS AND BIOLOGICAL EVALUATION OF 1 , N - B E N Z O Y L - 3 -
A R Y L - 5 - ( 1 ' , N - P H E N Y L - 3 ' - p- F L U O R O P H E N Y L PYRAZOL-4'-YL)-
PYRAZOLINES
[A] Synthesis of N-Phenylamino-α-methyl-2-p-anisyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
2-propen-1-one
See Part-I, Section-I (C).
[D] Synthesis of 3-p-Anisyl-5-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
pyrazoline
See Part-I, Section-I (D).
[E] Synthesis of 1,N-Benzoyl-3-p-anisyl-5-(1',N-phenyl-3'-p- fluorophenyl
pyrazol-4'-yl)-pyrazolines
A mixture of 3-p-Anisyl-5-(1',N-phenyl-3'-p-fluorophenyl  pyrazol-4'-yl)-
pyrazoline (4.12 g, 0.01M) in 25 ml of pyridine, and benzoyl chloride (1.4g, 0.01M)
was stirred at room temperature for an hour. It was then treated with cold diluted
hydrochloric acid. The solid separated was filtered, washed with cold NaOH(2 %) and
water and crystallised from ethanol. Yield, 60%; m.p., 240oC, (C32H25FN4O2 ; Found
: C, 74.38 %; H, 4.85%; N, 10.78% ; Requires : C, 74.40%; H, 4.88%; N, 10.85%).
TLC Solvent System : Ethyl acetate  :  Hexane (4 : 6)
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 3.
57
[F] Antimicrobial activity of 1 , N - Benzoyl- 3 -p-anisyl- 5 - ( 1 ' , N - phenyl- 3 ' -
   p-f l u o r o p h e n y l  pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No.3.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1,N-BENZOYL-3-PHENYL-5-(1’,N-PHENYL-3’-p-
FLUOROPHENYL PYRAZOL-4'-YL)-PYRAZOLINE
 Observed
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode
Alkane C – H str.(asym.) 2918 2975–2920 576
–CH3 C – H str. (sym.) 2850 2880–2820 “
C – H i.p. (def.) 1436 1470–1435 “
C – H o.o.p. (def.) 1382 1385–1350 “
Aromatic C – H str. 3082 3080–3030 577
C – H i.p. (def.) 1095 1160–1090 “
1062 1070-1000 “
C – H o.o.p (def.) 821 835–810 “
Pyrazole C = N str. 1598 1650–1600 578
moiety C = C str. 1504 1585–1480 “
C – N str. 1344 1350–1200 “
C – F str. 752 760–710 576
Pyrazoline C = N str. 1560 1627–1550 580







Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)





    (δ ppm)
 RelativeNo.
  of Protons
Multiplicity Inference    J Value


























1. 3.07-3.14 1H double HC             JCB=12.6
doublet           JCA=4.6
2. 3.63-3.71 1H double HB  JBC=11.5
doublet           JBA=5.7
3. 3.82 3H singlet Ar-OCH3        -
4. 6.01-6.07 1H double HA           JAB=6.9
doublet           JAC=4.4
5. 6.88-6.91 2H doublet Ar-Hii’          Jih=8.6
6. 7.10-7.16 2H triplet Ar-Hbd -
7. 7.21-7.26 1H triplet Ar-Hc -
8. 7.37-7.51 5H multiplet Ar-Hm,k,l,a,e -
9. 7.56-7.59 2H doublet Ar-Hhh’          Jhi=8.6
10. 7.65-7.67 2H doublet Ar-Hff ’          Jfg=8.0
11. 7.78-7.82 2H triplet Ar-Hnj -
12. 7.87 1H singlet CHx -




























Sr. No. R C=O str.
IR SPECTRAL DATA OF 1,N-BENZOYL-3-ARYL-5-(1',N-PHENYL-3'-p-FLUORO
PHENYL PYRAZOL-4'-YL)-PYRAZOLINES
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SYNTHESIS  AND BIOLOGICAL EVALUATION OF  1 , N - NITROSO-
3 - A R Y L - 5 - ( 1 ' , N - P H E N Y L - 3 ' - p- F L U O R O P H E N Y L PYRAZOL-4'-
YL)-PYRAZOLINES
Recently, much interest has been focused on the synthesis and biodynamic
activities of pyrazoline. With a view to obtainng compounds having better therapeutic
activity, we have synthesised  some new pyrazolines bearing 1,N-Phenyl-3-p-
fluorophenyl-4-formyl pyrazole nucleus. The preparation of 1,N-Nitroso-3-aryl-5-(1',N-
phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-pyrazolines (IV) have been prepared by the
reaction of compounds of type (II) with sodium nitrite.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layerchromatography. The m/z peak at 445 indicates the molecular weight of the
compound 1',N-Nitroso-3-p-chlorophenyl-5-(1',N-phenyl-p-fluorophenyl pyrazol-4'-
yl)-pyrazoline and other mass spectra fragmentation are recorded on page no.72.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.

















SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,N-NITROSO-3-ARYL-5-
(1',N-PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-PYRAZOLINES
[A] Synthesis of N-Phenylamino-α-methyl-2-p-anisyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
2-propen-1-one
See Part-I, Section-I (C).
[D] Synthesis of 3-p-Anisyl-5-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
pyrazoline
See Part-I, Section-I (D).
[E] Synthesis of 1,N-Nitroso-3-p-anisyl-5-(1',N-phenyl-3'-p-fluorophenyl
pyrazol-4'-yl)-pyrazolines
A mixture of 3-p-Anisyl-5-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
pyrazoline (4.12 g, 0.01M) was dissolved in 1:1 HCl (2 ml) and cooled in ice bath.
Cold sodium nitrite soluation (6 ml, 10 %) was added drop wise to the mixture with
continuous stirring. The mixture was stirred for further 45 minutes at room temprature.
The solid eparated was filtered, washed with water, dried and  crystallised from ethanol.
Yield, 61%; m.p., 170oC, (C25H20FN5O2 ; Found : C, 68.00%; H, 4.55%; N, 15.82%
; Requires : C, 68.02%; H, 4.57%; N, 15.86%).
TLC Solvent System : Ethyl acetate : Hexane (2 :  8)
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 4.
68
[F] Antimicrobial activity of 1 , N - Nitroso- 3 - p-anisyl- 5 - ( 1 ' , N - phenyl- 3 ' -
   p-f l u o r o p h e n y l  pyrazol-4'-yl)-pyrazolines
Antimicrobial testing was carried out as described in Part-I, Section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No.4.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1,N-NITROSO-3-PHENYL-5-(1’,N-PHENYL-3’-p-
FLUOROPHENYL-PYRAZOL-4'-YL)-PYRAZOLINE
 Observed
Type     Ref.
 Reported








Alkane C – H str.(asym.) 2927 2975–2920 576
–CH3 C – H str. (sym.) 2852 2880–2820 “
C – H i.p. (def.) 1467 1470–1435 “
C – H o.o.p. (def.) 1375 1385–1350 “
Aromatic C – H str. 3035 3080–3030 577
C – H i.p. (def.) 1118 1160–1090 “
1068 1070-1000 “
C – H o.o.p (def.) 831 835–810 “
Pyrazole C = N str. 1614 1650–1600 578
moiety C = C str. 1596 1585–1480 “
C – N str. 1338 1350–1200 “
C – F str. 738 760–710 576
Pyrazoline C = N str. 1614 1627–1550 580
                                     (overlapped)
N = O str. 1514 1511–1495 581
70
Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)





    (δ ppm)
 RelativeNo.
  of Protons
Multiplicity Inference    J Value





















1. 3.26-3.32 1H double HC            JCB=13.7
doublet  JCA=4.4
2. 3.85-3.92 1H double HB  JBC=7.3
doublet  JBA=10.8
3. 5.87-5.91 1H double HA            JAB=6.3
doublet  JAC=4.4
4. 7.11-7.16 2H triplet Ar-Hbd  Jbd=8.6
5. 7.19-7.23 1H triplet Ar-Hc  Jcb=7.3
6. 7.34-7.38 2H triplet Ar-Hae        -
7. 7.44-7.46 2H doublet Ar-Hgg’   Jgf=8.5
8. 7.70-7.77 4H multiplet Ar-Hii’        -
Ar-Hhh’
9. 7.82-7.84 2H doublet Ar-Hff’   Jfg=8.4
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Pyrimidine  derivatives have diversified biological activity like plant growth
regulators, antibacterial, antituberculer, antifungal, analgesic, anticonvulsant etc. The
major general reviews for the pyrimidines chemistry available in the literature by
Albert160, Acheson161, Badger162, Kartritsky and Legowskii163. The biological
activities are reviewed by Chang164.
Led by this considerations it was contemplated to synthesise some pyrimidines
derivatives which have been described as under
SECTION-I   : SYNTHESIS AND BIOLOGICAL EVALUATION OF
4-ARYL-6-(1',N-PHENYL-3'-p-FLUOROPHENYL PYRAZOL
-4'-YL)-1,2-DIHYDROPYRIMIDIN-2-THIONES
SECTION-II   : SYNTHESIS AND BIOLOGICAL EVALUATION OF
2-AMINO-4-ARYL-6-(1',N-PHENYL-3'-p-FLUOROPHENYL
PYRAZOL-4'-YL)-PYRIMIDINES
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SYNTHETIC ASPECTS
First  primary  synthesis  of  thiopyrimidine derivatives  from  aliphatic fragments
was carried out by Frankland and Kolbs in 1848. Since then a many distinct primary
synthetic method have been devised165-169.
Different method reported are  as  under.
1. Rasaki170 synthesised  2-aminopyrimidne  by  the  reaction  of  chalcone epoxides
with guanidine carbonate in xylene.
2. The  reaction  of  chalcone  with  guanidine  hydrochloride  in  presence  of
potassium-t-butoxide  in  t-butanol  yielded  corresponding  2-aminopyrimidine
derivatives171.
SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-(1',N-PHENYL
-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-1,2-DIHYDROPYRIMIDIN -2-THIONES
The alkyl thiopyrimidines are still used widely as intermediates as the derived
sulphones are much better leaves groups. There fore it is often wise to oxidised a thio
ether to a sulphone prior to nuclephilic replacement. The 2-mercapto pyrimidine can be
represent in tautomeric form or disulfides.
It is also known as pyrimidine 2-thione. The mercapto pyrimidine can be derived
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3. Abd-El-gail, E. Amr172 synthesised  aminopyrimidines  by  the reaction  of
chalconeswith guanidine hydrochloride  in presence of NaOH.
4. 2-Mercaptopyrimidines can be synthesised by G. W. Anderson173 through condensation
of thiourea and substituted â-keto ester in presence of sodium ethoxide.
5. By  the  condensation  of  â-aldehydro  nitrile  with  formamidine  and thiourea174.
6. By the condensation of â-dinitrile with thiourea and guanidines175.
7. By the condensation of â-keto ester with N-methyl thiourea176.
8. Wang Jinjun177 have  prepared some  new  benzo[C]  pyrano  [4,3-d] pyrimidine
derivatives (II).
REACTION MECHANISM
Mechanism of formation of aminopyrimidines is illustrated as under178.











R = Ph, 4-ClC6H4




































R2 = NH2, SH
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THERAPEUTIC IMPORTANCE
Literature survry revealed that various thiopyridines have resulted in many potential
drugs and are known to exhibit a broad spectrum of biological activity such as
1. Antiinflammatory and analgesic179-181,
2. Antileishmanial182-184
3. Anticancer and herbicidal185,186
4. Antineoplastic187,188





3. Inhibitor  and proliferation199
4. Dopamine D4 antagonists200
5. Cardiovascular201
8. Tyrosine Kinase Inhibitor202
9. Adrenaline a  receptor  blocker203
A. S.  Noravyan et. al.204 synthesised some thiopyrimidine derivatives as
anticonvulsant  agent.  Hozien  Z. et. al.205  studied  thiopyrimidine  derivatives and
evaluated  them  for  their  antifungal  and  antibacterial  activity.  Moreover, Mohran M.
et. al.206 assessed some thiopyrimidine derivatives (III) as antitumor and  antibacterial
agent.
Erker T. et. al.207 have prepared thiopyrimidines which have been shown to
possess muscle relaxant activity. Breozowskii  Z.208 found thiopyrimidine as anti-HIV.
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Leone M. et. al.210 have studied some thiopyrimidines showing antibiotic activity.
Takatani  M. et. al.211  and  Scott  K. et. al.212 have  synthesised thiopyrimidines
associated with  marked  hypolipemics  and  hypoglycemic, anticonvulsant activities
respectively. Schiafella. et. al.213 adn Shafiee A. et. al.214  prepared  thiopyrimidines
and  evaluated  for  antifungal  and antiinflammatory activity  respectively.
Abou El otooh et.  al.215  prepared thiopyrimidine derivatives (IV) which showed
anticancer activity.
N. M. Saleh and co-workers216 have prepared pyrimidine derivatives (V) and
reported  their pharmacological  activity. Burbuliene M.  M. et. al.217 synthesised some
pyrimidine  derivatives and repor ted  them  as  antiinflammatory  agent.  Okamura  and
co-workers218 evaluated pyrimidine derivatives for their adenosine A3 receptor affinity
agent. S. El-Essa and M. Salama219 have synthesised some thiopyrimidine
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Considerable attention has been focussed on the development and synthesis of
4-Aryl-6-(1',N-phenyl -3'-p-fluorophenyl pyrazol-4'-yl)-1,2-dihydropyrimidin-2-thiones
derivatives of  type  (V ) for  obtaining biologically  potent molecules which have been
prepared by the cyclocondensation of  chalcones of type (I) with thiourea in alc.KOH
solution as depicted in reaction scheme below.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layerchromatography. The m/z peak at 455 indicates the molecular weight of the
compound 4-p-Anisyl-6-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-1,2-
dihydropyrimidin-2-thiones and other mass spectra fragmentation are recorded on page
no.86.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYL-6-(1',N-PHENYL
-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-1,2-DIHYDROPYRIMIDIN -2-THIONES
[A] Synthesis of N-Phenylamino-α-methyl-2-p-anisyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
2-propen-1-one
See Part-I, Section-I (C).
[D] Synthesis of 4-p-Anisyl-6-(1',N-phenyl -3'-p-fluorophenyl pyrazol-4'-yl)-
1,2-dihydropyrimidin -2-thiones
To a mixture of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
2-propen-1-one (3.98 g, 0.01M)  and thiourea (0.76 g, 0.01 M) alc. KOH was added
and refluxed for 12 hrs. The contents were then poured  onto  crushed  ice and  neutralised
with  dil. HCl solution.  The  product  obtained  was  isolated,  filtered  and  crystallised
from ethanol. Yield, 64%; m.p,. 240oC, (C26H19FN4OS ; Found : C, 68.70 %; H,
4.15%; N, 12.31% ; Requires : C, 68.71%; H, 4.18%; N, 12.33%).
TLC Solvent System : Ethyl acetate:Hexane (4 : 6)
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 5.
[E] Antimicrobial activity of 4-Aryl-6-(1',N-phenyl -3'-p-fluorophenyl pyrazol-
4'-yl)-1,2-dihydropyrimidin -2-thiones
Antimicrobial testing was carried out as described in Part-I, Section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 5.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF   4-p -ANISYL-6-(1' ,N-PHENYL-3'-p -FLUORO
PHENYL-PYRAZOL-4'-YL)-1,2-DIHYDROPYRIMIDIN-2-THIONE
 Observed
Alkane C-H str. (asym.) 2924 2975-2950
-CH3 C-H str. (sym.) 2851 2880-2860
C-H i.p.def. (asym.) 1461 1470-1435
C-H o.o.p. def. (sym.) 1350 1390-1370
Aromatic C-H  str. 3084 3080-3030
C=C str. 1546 1585-1480
C-H i.p. def. 1085 1125-1090
C-H o.o.p. def   819     835-810
Pyrazole C=N str. 1601 1630-1590
moiety C-N str. 1157 1230-1020
C-F str.   755     600-800
Ether C-O-C str. (asym.) 1214 1275-1200
C-O-C str. (sym.) 1030 1075-1020
Thio C-N str.   1237      1230-1020
pyrimidine N-H str.   3423      3400-3250
C=S str.   1175      1250-1020
Type     Ref.
 Reported


























Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)





    (δ ppm)
 RelativeNo.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 5.56 1H singlet Ar-Hj        -
2. 7.10-7.20 4H multiplet Ar-Hgg’        -
Ar-Hii’
3. 7.29-7.44 1H triplet Ar-Hc        -
4. 7.46-7.53 2H multiplet Ar-Hbd        -
5. 7.77-7.79 2H doublet Ar-Hae   Jab=7.7
6. 7.84-7.90 2H multiplet Ar-Hhh’        -
7. 7.92-7.96 2H multiplet Ar-Hff ’                  -
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SYNTHESIS AND BIOLOGICAL EVALUATION OF  2-AMINO-4-ARYL-
6-(1',N-PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-PYRIMIDINES
Large  numbers  of  drugs  possess  aminopyrimidine  ring  system.  Well-known
antimalarial agents like trimethoprim (I) and pyrimethamine, hypotensive agent like

















Hisaki Masakatsu220 synthesised some aminopyrimidines which are useful in
the  treatment  of  rotaviral  diseases.  Robson  C.  et.  al.221  prepared  aminopyrimidine
derivatives  as  antifungal  agents  in  P9P  and  MRP  over  expressive tumor  cell  lines.
Leanne  M.  et.  al.222  have  prepared  aminopyrimidines  and reported  them  as
antiviral  agent.  Yamada  K.223  synthesised  some aminopyrimidines (IV) and tested
for endothelin antagonists. Suto M. et. al.224 prepared some aminopyrimidines which
were found to possess antiinflammatory, anticancer, antirheumatoid  activities. Gangjee
A. et. al.225 synthesised aminopyrimidines which possess antitumor activity. Ugarkar
B. et. al.226  found  aminopyrimidines  in  the  inhibition  of  cardiovascular  and
ceribrovascular  disorders.
(II) (III)






Hernan dez et. al.227 and Secrist J. et. al.228 prepared aminopyrimidines showing
antitumor  activity.  Glazier  A.  et.  al.229 and  Singh  J.230  found aminopyrimidines as
antiviral agents. Pan S.231 prepared 2-methylthio-4-amino-6-(3,5-diacetylphenylamino)
pyrimidines  which  show  antiHIV  activity  in  H9 cell  cultures. Aminopyrimidine
derivatives  also possess  antimicrobial232, antiHIV233 and antitumor234 activities.
Bargiotti  et. al.235  prepared  aminopyrimidines  (V)  showing  anticancer activity.
















R1,R2 = H, Substituted Ph,
   naphthyl, heteroaryl etc.
R   = 4-NO2C6H4
Z    = 5
R1 = H
Jianming Zu. et. al.237 synthesised N-{4-[2-(2-amino-4-ethylpyrrolo-[2,3-d]
pyrimidin-5-yl)ethyl]  benzoyl}-L-glumatic  acid  (VII)  its  6-ethyl  derivative as potential
dual inhibitors of thymidylate synthesis and dihydrofolate reductase and  as  potential
antitumor  agents.  Tsutsumi  et.  al.238 have  prepared  some aminopyrimidines (VIII)
which found to possess adenosine receptor antagonists activity.

















Looking  to  the  diversified activities  exhibited  and  in  continuation  of  our
work  on  the  synthesis  of  biologically  active  heterocycles,  the  synthesis  and
biological screening of aminopyrimidine derivatives have been described as under.
Aminopyrimidine derivatives have been prepared by  the  reaction  of  the  chalcones  of
type  (I)  with  guanidine  hydrochloride  in presence of  KOH as catalyst.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layerchromatography. The m/z peak at 406 indicates the molecular weight of the
compound 2-Amino-4-phenyl-6-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
pyrimidines and other mass spectra fragmentation are recorded on page no.97.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 2-AMINO-4-ARYL-6-(1',N-
PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-PYRIMIDINES
[A] Synthesis of N-Phenylamino-α-methyl-2-p-anisyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
  2-propen-1-one
See Part-I, Section-I (C).
[D] Synthesis of 2-Amino-4-aryl-6-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-
yl)-pyrimidines
To a mixture of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
2-propen-1-one (3.98 g, 0.01M)  and guanidine  hydrochloride(1.10 g, 0.01 M), alc.
KOH was added and refluxed for 12 hrs. The contents were then poured  onto  crushed
ice and  neutralised  with  dil. HCl solution.  The  product  obtained  was  isolated,
filtered  and  crystallised  from ethanol. Yield, 68%; m.p., 225oC, (C26H20FN5O;
Found : C, 71.36 %; H, 4.60%; N, 15.98% ; Requires : C, 71.38%; H, 4.61%; N,
16.01%).
TLC Solvent System : Ethyl acetate : Hexane (3 : 7)
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 6.
[E] Antimicrobial activity of 2-Amino-4-aryl-6-(1',N-phenyl-3'-p-fluorophenyl
pyrazol-4'-yl)-pyrimidines
Antimicrobial testing was carried out as described in Part-I, Section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No.6.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 2-AMINO-4-p-CHLOROPHENYL-5-(1' ,N-PHENYL-
3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-PYRIMIDINE
 Observed
Alkane C-H str. (asym.) 2922 2975-2950
-CH3 C-H str. (sym.) 2851 2880-2860
C-H i.p.def. (asym.) 1450 1470-1435
C-H o.o.p. def. (sym.) 1341 1390-1370
Aromatic C-H  str. 3033 3080-3030
C=C str. 1505 1585-1480
C-H i.p. def. 1107 1125-1090
C-H o.o.p. def   828     835-810
Pyrazole C=N str. 1580 1630-1590
moiety C-N str. 1024 1230-1020
C-F str.   754    800-600
Primary amine   N-H str.(asym.)   3413      3550-3350
          N-H str. (sym.)   3312      3450-3250
Pyrimidine        C=N str.   1577      1580-1520
          C-N str.   1269      1350-1200
Type     Ref.
 Reported
























Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)





    (δ ppm)
 RelativeNo.
  of Protons
Multiplicity Inference    J Value


















1. 3.85 3H singlet Ar-OCH3        -
2. 5.56 2H singlet -NH2        -
3. 6.88 1H singlet CHx        -
4. 6.92-6.94 2H doublet Ar-Hii’    Jih=6.9
5. 7.16-7.22 2H triplet Ar-Hgg’        -
6. 7.33-7.37 1H triplet Ar-Hc        -
7. 7.47-7.52 2H triplet Ar-Hbd                  -
8. 7.67-7.70 2H multiplet Ar-Hae        -
   9. 7.72-7.74 2H doublet Ar-Hhh’     Jhi=9.7
  10. 7.82-7.84 2H doublet Ar-Hff ’     Jfg=9.3
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Cyclohexenone is the parent of a series of compounds that is important in
agricultural and  medicinal  chemistry.  Cyclohexenones  are  derivatives  of cyclohexane
with  carbonyl group at 1-position and  double  bond  at  2-position (I). Cyclohexenones
can be conveniently synthesised by the treatment of á,â-unsaturated carbonyl compounds
with  ethylacetoacetate in  basic media.
In  recent  years  cyclohexenone  derivatives  have  gained  lots  of  interest
because of  its prominent pharmaceutical properties.
SYNTHETIC ASPECT
Different methods for the synthesis of cyclohexenone derivatives have been
described in literature.239-245
1. N. Nanjundaswami  et  al.246  have  prepared 6,7-dimethoxy-1-aryl-4-oxo-
2-naphthoate  derivatives(II)  by  the  reaction  of  dimethoxyphenyl aryl ketone
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2. Eman H. A. et al.247 have been prepared cyclohexenone derivatives (III) from
chalcones.
3. Shklyaev A. S. et al.248 have synthesized 1-substituted (R,S)-8-(2-methoxy-
5-methyl phenyl )-3,3,9-trimethyl-2-azaspiro[4,5]deca-1,7-dien-6-ones (IV).
4. A review of the earlier literature by Gerald et al.249 described representative
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5. Page Philip C. and co-workers250 have prepared substituted cyclohexenone
derivatives(VI).
MECHANISM
The  addition  reaction  between  ethylacetoacetate  and  á,â-unsaturated ketone
give cyclohexenone via. Michael addition. This reaction has been carried out in basic
media by using sodium ethoxide or anhy. K2CO3 in acetone. During the reaction
nucleophillic  addition  of  carbanion take  place  to  the  C=C  of  the acceptor.  The
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THERAPEUTIC IMPORTANCE
Cyclohexenones  and  its  derivatives  are  widely  used  in  pharmaceutical
industry.  Considerable  interest  has  been  shown  in  the  chemistry  of cyclohexenones










Cyclohexenone derivatives which possess plant growth regulatory activity have
been  reported.261,262 Nagao  et  al.263 have  reported  antiarrhythmic cyclohexenones.
Collins  and co-workers264  have documented cyclohexenone derivatives  which  possess
estrogenic  activity.  Tvanov  et  al.265 have  reported antimicrobial  activity of  some
cyclohexenone derivatives.  V.  K.  Ahluwalia  and co-workers266  have  assessed
cyclohexenone  derivatives for anti HIV-I, gastric secretion inhibitors and pesticidal
activity. Cyclohexenone derivatives have been reported  to  be  active  as  allergy
inhibitors,  platelet  aggregation  inhibitors  and fibrinogen  antagonist.267
Rheinheimer J. et. al.268 have synthesised 5-(dioxabicyclohept-6-yl)
cyclohexenone oxime ethers as herbicides and plant growth regulators. Harimaya and
co-workers269 have synthesised new cyclohexenone derivatives possessing progesteron
receptor  binding inhibitory activity. The  herbicidal activity  of cyclohexenone derivatives
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Antimicrobial  activity  of  cyclohexenone  derivatives  has  been  studied  by
Salama  and  Atshikh271.  Takehiro  and  co-workers272  have  reported cyclohexenones
possessing neutropeptide γ-receptor antagonist activity. Kimura and  co-workers273
have  prepared  cyclohexenones  which  possess  inhibitoryactivity of penienone and
they exhibit the remarkable inhibitory activity against the  growth  of  lettuce  seedlings.
Broughton  H.  et  al.274 have  demonstrated cyclohexenones as GABAα5 receptor
ligands for enhancing cognition properties.
Hermann S. et al.275 have  reported  cyclohexenones as  herbicides.
Anticonvulsant activity of  some  cyclohexenone  derivatives  (VIII) have  been reported
by Natalie D. et al.276  Bastiaan and co-workers277 have synthesised novel
cyclohexenone  derivatives  (IX)  which  are  useful  in the  treatment  of perkinson’s
disease.  Cyclohexenones (X)  as  anticancer and antiinflammatory agents have been
investigated.278
Moreover, H. H. Parekh and co-workers279 have synthesised 6-carbethoxy-5-
(4'-cinnamoyloxyphenyl)-3-aryl-2-cyclohexenones and all the  products have been
evaluated for their antimicrobial activity. Zhang C. et al.280 have prepared tricyclic
heterocycles, containing furan  and cyclohexenone nucleus for treating hyper-proliferative
disorders.
With  a  view  to  getting  better  therapeutic  agent,  it  was  contemplated  to
synthesise cyclohexenones bearing furan nucleus to enhance the overall activity of resulting
compounds, which have been  described as under.
(VIII)  R, R1 = Alkyl
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SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
3-ARYL-5-(1',N-PHENYL-3’-p-FLUOROPHENYL PYRAZOL
-4'-YL)-6-CARBETHOXY-2-CYLCOHEXENONES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF  3-ARYL-5-(1',N-PHENYL -
3’-p-FLUOROPHENYL PYRAZOL-4'-YL)-6-CARBETHOXY-2-CYLCOHEXEN ONES
Cyclohexenone derivatives have considerable attention in view of their potential
pharmacological properties such as antimicrobial, anticonvulsant, anticancer, etc. led by
these considerations, the preparation of cyclohexenone derivatives of type-(VII) has
been undertaken. The synthesis was carried out by the condensation of 1-Aryl-3-[1',N-
phenyl-3'-p-fluorophenyl-pyrazol-4'-yl]-2-propen-1-one of type-(I) with ethylaceto
actate shown in presence of basic catalyst like K2CO3  shown as under.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layerchromatography. The m/z peak at 510 indicates the molecular weight of the
compound 3-p-Anisyl-5-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-6-carbethoxy-
2-cyclohexenone and other mass spectra fragmentation are recorded on page no.113.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
















Type-(VII)     R = Aryl
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 3-ARYL-5-(1',N-PHENYL
-3’-p-FLUOROPHENYL PYRAZOL-4'-YL)-6-CARBETHOXY-2-CYLCOHEXENONES
[A] Synthesis of N-Phenylamino-α-methyl-2-p-anisyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl-pyrazol-4'-yl)-
2-propen-1-one
See Part-I, Section-I (C).
[D] Synthesis of 3-p-Anisyl-5-(1',N-phenyl-3’-p-fluorophenyl pyrazol-4'-yl)-6-
carbethoxy-2-cylcohexenones
A mixture of 1-p-Anisyl-3-[1',N-phenyl-3'-p-fluorophenyl-pyrazol-4'-yl]-2-
propen-1-one (3.98 g, 0.01M), ethylaceto acetate (1.3 ml, 0.01 M) and K2CO3 (1.38
g, 0.01 M) was taken into dry acetone (30-40 ml) and then the mixture was stirred at
room temperature till  the acetone is evaporated off. The contents were then poured into
crushed ice and neutrallised with HCl. The product separated was filtered and crystallised
from ethanol. Yield, 58%; m.p., 280oC, (C31H27FN2O4 ; Found : C, 72.90%; H,
5.30%; N, 5.45% ; Requires : C, 72.93%; H, 5.33%; N, 5.49%).
TLC Solvent System : Ethyl acetate : Hexane (3 : 7)
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 7
[E] Antimicrobial activity of 3-Aryl-5-(1',N-phenyl-3’-p-fluorophenyl pyrazol
-4'-yl)-6-carbethoxy-2-cylcohexenones
Antimicrobial testing was carried out as described in Part-I, Section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No.7.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 3-p-ANISYL-5-(1' ,N-PHENYL-3'-p-FLUORO
PHENYL PYRAZOL-4'-YL)-6-CARBETHOXY-2-CYCLOHEXENONE
 Observed
Alkane C-H str. (asym.) 2923 2975-2950
-CH3 C-H str. (sym.) 2839 2880-2860
C-H i.p.def. (asym.) 1456 1470-1435
C-H o.o.p. def. (sym.) 1344 1390-1370
Aromatic C-H  str. 3022 3080-3030
C=C str. 1502 1585-1480
C-H i.p. def. 1153 1125-1090
C-H o.o.p. def   839     835-810
Pyrazole C=N str. 1598 1630-1590
moiety C-N str. 1095 1230-1020
C-F str.   759    600-800
Ether C-O-C str. (asym.) 1224 1275-1200
C-O-C str. (sym.) 1060 1075-1020
Cyclohexe- C = O str. of ester 1739 1750-1725
none C = O str. of 1716 1720-1690
                                   cyclohexenone
Type     Ref.
 Reported



























Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)





    (δ ppm)
 RelativeNo.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 1.09-1.13 3H triplet -OCH2CH3    JCH3=7.0
2. 1.39-144 3H triplet -OCH2CH3    JCH3=7.2
3. 2.73-2.80 1H double Ar-HA                    -
doublet
4. 3.05-3.11 1H double Ar-HB          -
doublet
5. 3.70-3.73 1H doublet Ar-HD          -
6. 4.03-4.18 5H multiplet -OCH2CH3          -
Ar-HC
7. 6.51 1H singlet Ar-HE          -
8. 6.88-6.90 2H doublet  Ar-Hii’     Jih=7.0
9. 7.12-7.16 2H triplet Ar-Hbd’                    -
  10. 7.30-7.32 1H triplet Ar-Hc          -  11. 7.42-7.48 4H multiplet Ar-Hhh’          -
Ar-Hae
  12. 7.68-7.73 4H multiplet Ar-Hgg          -
Ar-Hff ’






















































































IR SPECTRAL DATA OF 3-ARYL-5-(1',N-PHENYL -3’-p-FLUOROPHENYL
PYRAZOL-4'-YL)-6-CARBETHOXY-2-CYLCOHEXENONES
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Barbitones, which belongs to an important group of nitrogen containing
heterocyclic compounds, have been extensively explored for their application in the field
of medicine. Most important is the effect of barbiturates on CNS. Barbituric aicd
derivatives constitute an important class of compounds possessing diverse type of
biological properties including hyphotic, sedative, anticonvulsant, cardiovascular etc.
Barbituric acid usually represented as the trione (I, R1=R2=H) was first made
about 1864 and it has no hypnotic properties. The origin of the name is lost, although
there are several plausible explanations associated with St. Barbara’s feast day, a favourite
Munchen Kellnerin rejoicing in that given name, and even the barba which is a beard of
the business end of a key.
SYNTHETIC ASPECT
Different methods are used for the preparation of barbitones in literature281,282
1. Cao-Yan Weu et. al.283 have prepared barbitones by reaction of different
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2. M. R. Mahmoud et. al.284 have synthesised barbituric acid derivatives from
chalcone.
3. Ogus Funda et. al.285 have prepared barbitones by the reaction of acetone
and barbituric aicd.
THERAPEUTIC IMPORTANCE
The first hyphotic barbiturate, 5,5-diethyl barbituric acid (barbital, Veronal ; I;
R1R2=Et) was made in 1904, was introduced into medicine in 1905, and is still used
sometimes; the second was 5-ethyl-5-phenylbarbituric acid (phenobarbital, Luminal, I;
R1=Et, R2=Ph), also prepared in 1904 but used as a long acting CNS depressant only
from 1912 until the present day. Several thousand active barbiturates were made
subsequently but scarcely a dozen are still used to any extent. Among these are
pentobarbital (Nembutal; I;R1=C2H5, R2=CHMePr), amobarbital (Amytal ; I;
R1=C2H5, R2=CH2CH2CHMe2), secobarbital (Seconal; I; R1=CH2 CH=CH2,
R2=CHMePr), hexobarbital (Sombulex/Evipal; II), thiopental (Pentothal ; III). The whole
subject is well reviewed286-288.
The ‘pseudo-barbi turate’ ,  2-methyl-3-o-tolylquinazol in-4(3H)-one
(methaqualone, Revonal; IV) has an ever winder spectrum of activities that do the
barbiturates proper; it appears to be quite widely used as a sedative, hyphotic,






























(II)                        (III)                         (IV)
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Some barbituric acid derivatives used as sedative and hyphotic is carbubarb290,
which is used as veternary anaesthetics. Some isoxazolo pyrimidines have been studied
because of their potential as pesticidal291,292 activity. Some barbiturates showing
cardiovascular293-295 and analgesics and antiinflammatory activities296 have been
reported.
Ulf Wellmar et. al.297 have synthesised some uracil derivatives and screened for
antiviral activity298,299. Raymond et. al.300 have synthesized some barbiturates (V),
which showed anticancer activity. Mahmoud et. al.301 synthesised barbituric acid
derivatives and reported their antimicrobial activity.
Some isoxazolopyrimidines have been extensively studied and reported as
antagonist302 and antitumor303 activity. Wolf-Gang et. al.304 have reported 5-(3-
Benzylthiazolidin-2-ylidene)-1,3-dimethyl hexahydropyrimidin-2,4,6-trione having
agricultural activity. Andre Roland et. al.305 demonstrated some barbituric acid derivatives
used as herbicidal and insecticides.
Omar M. T.306 has synthesised barbitone derivatives, showing antimicrobial
activity. Sakai et. al.307 have synthesised new barbitones which were assessed for bone
and cartilage disease. Ambrogio Oliva et. al.308 have synthesized barbitones possessing
antimetastatic and antitumor activity. Weber W et. al.309 have synthesised barbitones
as main metabolite (VI). Frank Grams et. al.310 have synthesised barbitones and found
to be metalloprotease inhibitors. R T Pardasani et. al.311 have synthesised new
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Levesque D. L. et. al.312 have synthesised barbitones as uridine phosphoralase
inhibitors. Wyzlic I. M. et. al.313 have synthesised and tested barbitones as anticonvulsant
agent. Shivanyuk A. N. and co-worker314 have prepared barbitones as Porphyrin
Melamine Calixarene receptor. Gursu Esin et. al.315 have prepared barbitone as
biological activity agent. Bosies Elmar and co-worker316 have prepared barbitones as
metalloproteinase inhibitor (VIII).
Abdel Hamide S. G. et. al.317 have prepared barbitone as anticonvulsant agent
(IX). Li Laizhong et. al.318 have synthesised barbitones and screened for their
anticonvulsant activity.
Recently, Geppert Dangmar et. al.319 have synthesised barbitones and tested
















































R1, R2 = H, Halo, R3 = CH3, Et. Ph
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These observations led us to explore barbitone chemistry by synthesizing its
derivatives in order to achieve better therapeutic agents. It has been described as under.
SECTION - I : SYNTHESIS AND BIOLOGICAL EVALUATION OF
5-[1-ARYL-3-(1' ,N-PHENYL-3’-p -FLUOROPHENYL
PYRAZOL-4'-YL)-2-PROPENYLIDINE]-BARBITURIC ACIDS
                                                                            Barbitones. . .
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-[1-ARYL-3-(1',N-
PHENYL-3’-p-FLUOROPHENYL PYRAZOL-4'-YL)-2-PROPENYLIDINE]-
BARBITURIC ACIDS
Barbiturates have received considerable attention in the field of medicinal
chemistry due to wide range of pharmaceutical activities exhibited by them. Prompted
by these facts, the preparation of barbitone of type (VIII) was carried out by the reaction
of chalcone of type (I) with barbituric acid in glacial acetic acid.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layerchromatography. The m/z peak at 492 indicates the molecular weight of the
compound 5-[1-p-Tolyl-3-(1' ,N-phenyl-3’p-fluorophenyl pyrazol-4'-yl)-2-
propenylidine]-barbituric acid and other mass spectra fragmentation are recorded on
page no.128.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.


















SYNTHESIS AND BIOLOGICAL EVALUATION OF 5-[1-ARYL-3-(1',N-
PHENYL-3’p-FLUOROPHENYL PYRAZOL-4'-YL)-2-PROPENYLIDINE]-
BARBITURIC ACIDS
[A] Synthesis of N-Phenylamino-α-methyl-2-p-anisyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl-pyrazol-4'-yl)-2-
propen-1-one
See Part-I, Section-I (C).
[D] Synthesis of 5-[1-p-Anisyl-3-(1',N-phenyl-3’p-fluorophenyl pyrazol-4'-yl)-
2-propenylidine]-barbituric acids
A mixture of 1-p-Anisyl-3-[1',N-phenyl-3'-p-fluorophenyl-pyrazol-4'-yl]-2-
propen-1-one (3.98 g, 0.01 M), barbituric acid (1.28 g, 0.01 M) in glacial acetic acid
was refluxed for 12 hrs. in oil bath. The contents were poured into ice and product was
isolated, crystallized from DMF. Yield, 67%; m.p., 250oC, (C29H21FN4O4 ; Found :
C, 68.48 %; H, 4.15%; N, 11.00% ; Requires : C, 68.50%; H, 4.16%; N, 11.02%).
TLC Solvent System : Ethyl acetate : Hexane (3 : 7)
Similarly other substituted pyrazolines have been prepared. The physical data
are recorded in Table No. 8
[E] Antimicrobial activity of 5-[1-p-Anisyl-3-(1',N-phenyl-3’p-fluorophenyl
pyrazol-4'-yl)-2-propenylidine]-barbituric acids
Antimicrobial testing was carried out as described in Part-I, Section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No.8.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 5-[1-p-ANISYL-3-(1' ,N-PHENYL-3'-p -FLUORO
PHENYL PYRAZOL-4'-YL)-2-PROPENYLIDINE]-BARBITURIC ACID
 Observed
Alkane C-H str. (asym.) 2916 2975-2950
-CH3 C-H str. (sym.) 2841 2880-2860
C-H i.p.def. (asym.) 1450 1470-1435
C-H o.o.p. def. (sym.) 1352 1390-1370
Aromatic C-H  str. 3053 3080-3030
C=C str. 1502 1585-1480
C-H i.p. def. 1160 1125-1090
C-H o.o.p. def   839     835-810
Pyrazole C=N str. 1605 1630-1590
moiety C-N str. 1095 1230-1020
C-F str.   758    600-800
Ether C-O-C str. (asym.) 1211 1275-1200
C-O-C str. (sym.) 1034 1075-1020
Barbitone N-H str. 3312 3450-3250
C = O str. 1739 1750-1700
C = O str. 1709 1750-1700
C = C str. 1569 1590-1550
Vinyl HC = CH str. 3007 3050-3000
Type     Ref.
 Reported





























Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)





    (δ ppm)
 RelativeNo.
  of Protons
Multiplicity Infer-
ence
   J Value






















1. 3.89 3H singlet Ar-OCH3        -
2. 6.96-6.98 2H doublet Ar-Hii’    Jih=8.9
3. 7.17-7.21 2H triplet Ar-Hgg’        -
4. 7.36-7.40 1H doublet CHz (vinylic)   Jzy=15.6
5. 7.49-7.53 2H triplet Ar-Hbd        -
6. 7.68-7.71 2H multiplet Ar-Hae        -
7. 7.78-7.80 2H doublet Ar-Hhh’              Jhi=8.4
8. 7.82-7.64 1H doublet CHy (vinylic)   Jzy=15.6
   9. 7.97-7.99 2H doublet Ar-Hff ’    Jfg=8.8
























Sr. No. R C=O str.
IR SPECTRAL DATA OF 5-[1-ARYL-3-(1',N-PHENYL-3’-p-FLUOROPHENYL
PYRAZOL-4'-YL)-2-PROPENYLIDINE]-BARBITURIC ACIDS
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Azomethine derivatives have been found to be potent drug in pharmaceutical
industries and possess a wide spectrum of biological activity. Azomethines are also
known as Schiff’s base and they are well known interemediate for the preparation of
azetidinone, thiazolidinone, formazone, arylacetamide and many other derivatives.
These are the compounds contain characteristic -C=N group. B. S. Holla  et. al.320
have documented azomethine (I) having triazole moiety and possess good antibacterial
activity.
Azomethines are obtained mainly by warming the aldehyde & aromatic amine
togethar. However, it is more convenient to work in a solvent such as alcohol, dilute
acetic acid or glacial acetic acid. Some time the reaction is aided by traceof acid in
other cases the hydrochloride of the amines can be used in the synthesis.
In general Schiff’s bases do not react further with either of the reagents used in
their preparation as do most of the other types of simple intermediates.
SYNTHETIC ASPECT
Different methods for the preparation of azomethine derivatives documented in
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1. General account of the summary of reaction of aldehydes with amine (aromatic
or aliphatic) has been reviewed by Murray321.
2. Strache322 and Van Alphen323 have prepared imine in two steps.
a.  Addition of the amine to the carbonyl group of the aldehyde gives aldol.
The aldol is rerely capable of isolation.
b.  The loss of water to give an imine (azomethine), this corresponds to the
 “crotonaldehyde stage” of the aldol condensation.
3. A new one pot procedure for the generation of azomethinevia chlorominium salt
has been investigated by Rosaleen J. Anderson and co-workers324.
4. Oddo & Tognacchini325 have introduced the comparative rates of formation
of  Schiff base from aniline & substituted aniline & aromatic aldehyde using
a cryscopic method follow the course of reaction.
R H
O
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THERAPEUTIC IMPORTANCE
Literature survey reveals that various azomethines have resulted in many potential







7. Plant harmone activity332
Smalders, et. al.333 synthesized some new azomethine  to give potential antitumor
reagent phosphonates. Yadawe M. S. and Patil S. A.334 have synthesized azomethine
derivative of type shown as below.
Mehta R. H. and et. al.335 have synthesized coummarin schiff’s base derivatives
of type (II) and examined for their antibacterial activity.
Khalafallah A. K. and Hassan M. E.336 have prepared some styryl Schiff’s bases
spiro derivatives as potential antibacterial and antifungal activity. Sharaf El-Din, and
Nabaweyal337 have synthesized some azomethine derivatives (III) having good
antibacterial activity.
Chohan et. al.338 have synthesized azomethines, which have been  screened and
compared for their antibacterial action against bacterial  species Escherichia coli,
Pesudomonus aeruginoase and Klebisella  pneumoniase.
R  =   Ph, 4-Br-C6H4, 4-NO2-C6H4,
           2-Cl-C6H4CONH
R  =   3,4 -OH, 3, 4-NO2
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Das Joydip & Singh, Anilk339 have synthesized azomethine shown as below.
All-trans-N-refinylidene-n-butylamine (IV) can be stabillized in liposomes of
phophatidylcholine. The rate of formation of the Schiff’s base is found to decrease with
increasing cholesteral concentration in the membrane.
Deshmukh M. D. and Doshi A. G.340 prepared some new  Schiff’s bases show
good antimicrobial activity against test organism S. aureus, E. coli, Saigella dysenteridse
and salmonella typhi.
Wang, Yangang; Ye, Wenta; Yang, Jun;Lou,Aihony341havesynthesize
dazomethines having good plant hormone activity. Das Arima et. al.342 have prepared
Schiff’s bases of  aminohydroxy guanidine (SB-AHG5) were tested  for antiviral  activity
against herper simplex virus type I (HSV-1) and adenovirus type-5 (Ad-5)  alone with
11 other heterocyclic SB-AHG5 some compounds has good  antiadenoviral activity.
Solankee Anjani; Mistry, Pankaj; Patel V. M.343 have synthesized some new
Schiff’s bases having good antibacterial activity.
Ram, Tilak et. al.344 have synthesized some Schiff’s bases, thiazolidinones 4-
triazolines, and formazones of  2-chloro phenothiazines and screened against carrageenin-
induced edema in albino rats. The thiazolidinones showed promising antiinflammatory
activity.
Ali, yousif et. al.345 have synthesized some Schiff’s base derivatives of glucose
contg. acetylenic bond were also prepared Hydroxybenzaldehydes were first  converted
to o-prop-2-ynyl-benzaldehydes followed by their condensation with glucosamine. The
prepared Schiff base were tested for their bactericidal activity against E. coli and
staphylococcus aureus.
Cascaval Alexandru et. al.346 have synthesized azomethines, which have good
analgesic and antipyratic properties. Pandeya S. N. et. al.347 have synthesized Schiff
bases showed good activity against vibrio cholerae, shigella boydii, Enterococcus faecalis
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found to be active against salmonellalyphi and vibro  cholerae-0, (mic 25-150 µg/ml).
Omar and et. al.348 have determined cyclocondensation of azomethines  having
good antischistosomal activity.
Pawar R. P. et. al.349 have synthesized azomethines by the condensation of
iodovanillin with different substituted aromatic amines. The good antibacterial activity
was determined.
Chohan and co-workers350 have synthesized a novel class of acetyl ferrocene
derived Schiff bases possess antimicrobial activity.
Ergenc and co-workers351 have synthesised azomethine derivatives having
antifungal activity.
Holla B. S. et. al.352 have prepared mannich bases. Pandey, Taruna et. al.353
prepared azomethines and their boron complexes and screened for their antifungal  and
antibacterial properties. It is evident that azomethines alone were quite toxic but their
activity increased after complexation.
Yadav Bodke & S. S. Sangapure354  have synthesised some azomethines and
tested for their biological activity. B. Shivarama Holla et. al.355  have prepared some
new Schiff’s bases having anticancer activity. Ravindra V. Chambhare et. al.356  have
prepared some azomethines of type and tested for their antimicrobial activity. B. Shivarama
Holla., et. al.357  have synthesized azomethines of type (V) having antibacterial and
anti-inflammatory activity.
Iana Vazzana et. al.358  have synthesised derivatives (VI) and reported them as
antinflammatory agents. Neslishan and Reyhan359  have synthesised azomethines and
studied their antitumor activity. R. S. Varma360  has been synthesised a series of new
azomethines and evaluated them for antileishmanial activity.
















X     = N; Y,Z = CH
X,Y  = CH
Z     = N, CF, OCH3
R’   = 3-CF3, 4-SO2NH2,
         4-SO2CH3
(VI)
Recently, Parumal P. Selvam and co-workers361  have synthesised azomethine
derivatives and reported their antimicrobial activity. Zhanyong Guo et. al.362,363 have
synthesised schiff’s base of carboxymethyl chitosan and reported their in vitro antifungal
and antioxident activity. Sham M. Sondhi et. al.364 have synthesised azomethine
derivatives(VII) and documented their anti-inflammatory, analgesic and kinase (CDK-
1, CDK-5, and GSK-3) inhibition activity.
Jayendra Patole et. al.365  have reported schiff’s base (VIII) conjugates of p-
Amino salicyclic acid containing hydroxyl-rich side chains show enhanced
antimycobacterial activity against mycobacterium smegmatis and mycobaterium bovis
BCG. Alaaddin Cukurovali et. al.366  have design and synthesized azomethine derivatives
and investigated their antibacterial and antifungal activity. Anti-HIV ativity of schiff’s
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Thus with an effort to capitalize the biological potential of the heterocyclic system and to
provide more interesting compounds for biological study, we have undertaken the synthesis of
azomethines bearing pyrazole nucleous.
SECTION-I   : SYNTHESIS AND BIOLOGICAL EVALUATION OF
N-ARYL-1,N-PHENYL-3-p-FLUOROPHENYL PYRAZOL
-4-YL-AZOMETHINES
SECTION-II  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-
ARYLAMINOMETHYL 1,N-PHENYL-3-p-FLUOROPHENYL
PYRAZOLES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF  N-ARYL-1,N-PHENYL-
3-p-FLUOROPHENYL PYRAZOL-4-YL-AZOMETHINES
The growing patent literature of recent years demonstrates that the azomethine
derivatives are used as better therapeutic agents. In view of these findings, it appeared
of interest to synthesise Schiff’s base of the type (IX) by the condensation of 1,N-
Phenyl-3-p-fluorophenyl-4-formyl pyrazole  with various aromatic amines in order to
study their biodynamic behavior.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layerchromatography. The m/z peak at 410 indicates the molecular weight of the
compound N-3,4-Dichlorophenyl-1,N-phenyl-3-p-fluorophenyl pyrazol-4-yl-
azomethine and other mass spectra fragmentation are recorded on page no.144.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.














SYNTHESIS AND BIOLOGICAL  EVALUATION OF N-ARYL-1,N-PHENYL-
3-p-FLUOROPHENYL PYRAZOL-4-YL-AZOMETHINES
[A] Synthesis of N-Phenylamino-α-methyl-2-p-anisyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of N-p-Tolyl-1, N-phenyl-3-p-fluorophenyl pyrazol-4-yl-
azomethine
 A mixture of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole (2.66g, 0.01M)
and p-toludine(1.07g, 0.01M)dissolved in DMF (20 ml) was refluxed  for 16 hrs.
gl.aceticacid is used as catalyst. The contents were cooled and product isolated was
crystallised from DMF. Yield, 55%; m.p., 212oC, (C23H18FN3; Found : C, 78.03%;
H, 5.31%; N,11.80%; Requires : C, 78.08%; H, 5.36%; N, 11.82%).
TLC Solvent System : Ethyl acetate : Hexane  (3.5 : 6.5)
Similarly, other nitriles were prepared. The physical constants are recorded in
Table No. 9.
[D] Antimicrobial activity of N-p-Tolyl-1,N-phenyl-3-p-fluorophenyl pyrazol-
4-yl-azomethine
Antimicrobial testing was carried out as described in Part-I, Section-II (C). The
zone of inhibition of the test solution are recorded in Graphical Chart No. 9.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
 Observed
Alkane C-H str. (asym.) 2931 2975-2950
-CH3 C-H str. (sym.) 2868 2880-2860
C-H i.p.def. (asym.) 1448 1470-1435
C-H o.o.p. def. (sym.) 1361 1390-1370
Aromatic C-H  str. 3057 3080-3030
C=C str. 1541 1585-1480
C-H i.p. def. 1097 1125-1090
C-H o.o.p. def   817     835-810
Pyrazole C=N str. 1595 1630-1590
moiety C-N str. 1157 1230-1020
C-F str.   761     600-800
Ether C-O-C str. (asym.) 1222 1275-1200
C-O-C str. (sym.) 1037 1075-1020
Schiff ’s base C=N str.   1620      1660-1580
Type     Ref.
 Reported
Frequency in cm-1 Vibration
Mode




























    (δ ppm)
 RelativeNo.
  of Protons
Multiplicity Inference    J Value
    In Hz
PMR SPECTRAL STUDY OF N-p-TOLYL-1,N-PHENYL-3-p-FLUROPHENYL
-PYRAZOL-4-YL-AZOMETHINE
1. 2.36 1H singlet Ar-CH3        -
2. 7.06-7.10 2H doublet Ar-Hii’        -
3. 7.14-7.20 4H multiplet Ar-Hhh’        -
Ar-Hbd
4. 7.32-7.37 1H triplet Ar-Hc        -
5. 7.46-7.51 2H triplet Ar-Hab        -
6. 7.69-7.73 2H multiplet Ar-Hgg’        -
7. 7.79-7.83 2H doublet Ar-Hff ’   Jfg=3.07
8. 8.47 1H singlet CHx        -
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 4-ARYLAMINOMETHYL
1,N-PHENYL-3-p-FLUOROPHENYL PYRAZOLES
The efficiency of arylaminomethyl derivatives as chemotherapeutic agents is well
established. To further assess the pharmacological profile of such a class of compounds,
we have synthesised arylaminomethyl derivatives of type (X) by selective reduction of
(Imine group) shiff’sbase of (IX) with sodiumborohydride in controlled experimental
condition as shown in the reaction schime.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layerchromatography. The m/z peak at 377 indicates the molecular weight of the
compound 4-p-Chlorophenyl-aminomethyl-1,N-phenyl-3-p-fluorophenyl pyrazoles and other
mass spectra fragmentation are recorded on page no.153.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
biological activities of the synthesised compounds were compared with standard drugs.
















SYNTHESIS AND BIOLOGICAL  EVALUATION OF 4-ARYLAMINOMETHYL
1,N-PHENYL-3-p-FLUOROPHENYL PYRAZOLES
[A] Synthesis of N-Phenylamino-α-methyl-2-p-anisyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of  4-p -Anisyl -aminomethyl -1,N-phenyl-3-p-fluorophenyl
pyrazol
Sodium borohydride (0.15M, 0.57g) was added to a methanolic solution of
N-p-Anisyl-1,N-phenyl-3-p-fluorophenyl pyrazol-4-yl-azomethine (0.01M, 3.71gm)
over a period of 30 minutes at tempeture 5-10oC. The reaction mixture then kept over
night at room tempeture. The excess borohydride was neutralized by adding water and
the product was extracted with ether.The ether extract was washed with water untill
extract become neutral, then dried over anhydrous Na2SO4 and finally the ether was
evaporated to give aminomethyl derivatives. Yield, 54%; m.p., 218oC, (C23H20FN3O;
Found : C, 73.95; H, 5.38; N, 11.24 %; Required : C, 73.98%; H, 5.40%; N, 11.25%).
TLC Solvent System : Ethyl acetate : Hexane  (3 : 7)
Similarly, other nitriles were prepared. The physical constants are recorded in
Table No. 10.
[D] Antimicrobial activity of 4-p-Anisyl-aminomethyl-1,N-phenyl-3-p-fluoro
phenyl pyrazol
Antimicrobial testing was carried out as described in Part-I, Section-II (C). The
zone of inhibition of the test solution are recorded in Graphical Chart No. 10.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 4-p-ANISYL-AMINOMETHYL-1,N-PHENYL-3-p-
FLUOROPHENYL PYRAZOLE
 Observed
Alkane C-H str. (asym.) 2966 2975-2950
-CH3 C-H str. (sym.) 2854 2880-2860
C-H i.p.def. (asym.) 1446 1470-1435
C-H o.o.p. def. (sym.) 1384 1390-1370
Alkane C-H str. (asym.) 2916 2936-2916
-CH2 C-H def. 1492 1485-1445
Aromatic C-H  str. 3051 3080-3030
C=C str. 1546 1585-1480
C-H i.p. def. 1095 1125-1090
C-H o.o.p. def   840     835-810
Pyrazole C=N str. 1598 1630-1590
moiety C-N str. 1155 1230-1020
C-F str.   754     600-800
Ether C-O-C str. (asym.) 1222 1275-1200
C-O-C str. (sym.) 1035 1075-1020
Type     Ref.
 Reported





























    (δ ppm)
 RelativeNo.
  of Protons
Multiplicity Inference    J Value
    In Hz
PMR SPECTRAL STUDY OF 4-p-ANISYLAMINOMETHYL-1,N-PHENYL-3-p-
FLUROPHENYL-PYRAZOLE
1. 3.85 3H singlet Ar-OCH3        -
2. 4.17 2H singlet -CH2-NH        -
3. 6.93-6.96 2H doublet Ar-Hii’ Jih=8.42
4. 7.06-7.12 2H triplet Ar-Hbd        -
5. 7.35-7.40 1H triplet Ar-Hc        -
6. 7.50-7.60 4H multiplet Ar-Hae,        -
Ar-Hff ’        -
7. 7.82-7.85 4H doublet Ar-Hgg’,        -
Ar-Hff ’
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Thiosemicarbazones, also known as amino derivatives of thiourea, have found
their way into almost every branch of chemistry, commercially they are used as dyes,
photographic films, plastic and in textiles industry.
Thiosemicarbazone derivatives are of special importance because of their
versatile biological and pharmacological activities. Thiosemicarbazone derivatives
have found applications in drug development for the treatment of central nervous
system disorders, of bacterial infections, as well as analgesic and antiallergic agent.
They are potent intermediates for the synthesis of pharmaceutical and bioactive
materials.
The clinically active drug methisazone and related compounds have shown
activity against DNA viruses, principally the Orthopoxviruses, both in vitro and
in vivo.
SYNTHETIC ASPECT
The reaction between thiosemicarbazide and carbonyl compounds have
aroused a great attention because of the interesting nature of resulting compounds
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Different methods for the synthesis of thiosemicarbazones are available in
literature.368-371
1. A. B. Tomchin372 has synthesised thiosemicarbazones by the recyclisation of
2-amino-5-(2-aminoaroyl)-1,3,4-thiadiazoles.
2. Perumal Y. and co-workers373 have prepared thiosemicarbazones by
the condensation of 6-chlorobenzothiazolyl-2-thiosemicarbazide with aldehydes
or ketones.
3. A. K. Bhatt and co-workers374 have synthesised thiosemicarbazones by the
condensation of chalcones with thiosemicarbazide.
THERAPEUTIC IMPORTANCE
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W. Deteng and co-workers387 have prepared thiosemicarbazones (III) and
documented their usefulness as sodium channel blockers.
Magalhaes N. et. al.388 have synthesised some new thiosemicarbazones the
compounds were tested in vitro by the Lepidium Sativum Phytotest. All compounds
showed higher activity than 5-fluorouracil, an anticancer compound used as reference.
Toxicity and fungiocity of some novel thiophene-2-carboxaldehyde thiosemicarbazones
have been evaluated by Teoh-Siang-Guan et. al.389
Rajasekaran A. and co-workers390 have prepared some new thiosemicarbazone
(IV) and reported their antimicrobial activity. Duffy K. J.391 prepared some new
thiosemicarbazones (V) and reported them as thrombopoietin mimetics. Some of the
compounds were found to stimulated the proliferation of BAF-3/TPO-responsive human
cell lines with full TPO efficacy and with EC50 values below 100 ì M.
The new thiosemicarbazones (VI) derived from 2-(1-adamantyl carbonyl)pyridine
and 1-acetyladamantane were synthesized and evaluated for their inhibitory effect on
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Amir Azam et. al.393 have synthesised 5-nitrothiophene-2-carboxaldehyde
thiosemicarbazone derivatives and reported their antiprotozoal activity. In which some
of the compounds exhibited better antitrichomonial and antiamoebic activity  respectively
comparable to that of metronidazole. The inhibitory effect of several thiosemicarbazones
was investigated against Junin Virus, an arenavirus agent of Argentine haemorrhagic fever
by Damonte E. B. et. al.394 Hugo Cerecetto et. al.395 have reported in vitro growth
inhibition activity of thiosemicarbazone derivatives against the protozoan parasite
Trypanosoma cruzi, the causative agent of American trypanosomiasis.
Sznol M. et. al.396 have suggested 3-amino pyridine-2-carboxaldehyde
thiosemicarbazone as a new and potent inhibitors of ribonucleotide reductase, increases
the cellular uptake, DNA incorporation and cytotoxicity of gemcitabine in tumor cell
line. P. Yogeeswari and co-workers397 have synthesised 6-substituted benzothiazolyl-
2-thiosemicarbazone derivatives and screened for their anticonvulsant activity in maximal
electroshock induced seizure and subcutaneous pentylenetetrazole induced seizure
models in mice and neurotoxicity was also observed.
R. Kiplin Guy et. al.398 have reported the synthesis and evaluation of a series of
thiosemicarbazones as potential inhibitors of cysteine proteases relevant to parasitic
diseases. Alexandre J.S. Goes and co-workers399 have prepared some new





R = 2-pyridyl, methyl(VI)
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Dharmarajan Sriram and co-workers400 have prepared isatin 2-thiosemicarbazone
derivatives (VIII) and reported their anti-HIV activity in HTLV-IIIB strain in the CEM
cell line. Wei-xiao Hu and co-workers401 have synthesised thiosemicarbazone
derivatives and reported their anticancer activity.
Thus the important role displayed by thiosemicarbazones for various
physiological activities prompted us to prepare a series of thiosemicarbazones having
pyrazole nucleus as parent molecule which has been described as under.
SECTION : I SYNTHESIS AND BIOLOGICAL EVALUATION OF  1-ARYL-
3-(1',N-PHENYL-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-
2-PROPENE-1-THIOSEMICARBAZONES
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1',N-PHENYL
-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-2-PROPENE-1-THIOSEMICARBAZONES
We have synthesised thiosemicarbazones of type (XI) by the condensation of
1-Aryl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-2-propen-1-ones with
thiosemicarbazide.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography. The m/z peak at 520 indicates the molecular weight of the
compound 1-p-Bromophenyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
2-propene-1-thiosemicarbazones and other mass spectra fragmentation are recorded
on page no.167.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
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EXPERIMENTAL
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1',N-PHENYL
-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-2-PROPENE-1-THIOSEMICARBAZONES
[A] Synthesis of N-Phenylamino-α-methyl-2-p-anisyl-azomethine
See Part-I, Section-I (A).
[B] Synthesis of 1,N-Phenyl-3-p-fluorophenyl-4-formyl pyrazole
See Part-I, Section-I (B).
[C] Synthesis of 1-p-Anisyl-3-(1'-N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
2-propen-1-one
See Part-I, Section-I (C).
[D] Synthesis of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-
2-propene-1-thiosemicarbazone
A mixture of 1-p-Anisyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-2-
propen-1-one (3.98 g, 0.01 mol) and thiosemicarbazide (0.91g, 0.01 mol) in ethanol
(20ml.) containing catalytic amount of acetic acid was refluxed for 10 hrs. on water
bath. The reaction mixture was poured on to crushed ice and product was isolated and
recrystallised from ethanol. Yield, 72%; m.p., 270oC, (C26H22FN5OS; Required : C,
66.22; H, 4.70; N, 14.85;  Found : C, 62.20; H, 4.68; N, 14.84%).
TLC Solvent System :  Ethyl acetate : Hexane (6 : 4)
Similarly other substituted thiosemicarbazones have been prepared. The physi-
cal data are recorded in Table No. 11.
(E) Antimicrobial activity of 1-Aryl-3-(1',N-phenyl-3'-p-fluorophenyl
pyrazol-4'-yl)-2-propene-1-thiosemicarbazone
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 11.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 1-p-ANISYL-3-(1',N-PHENYL-3'-p-FLUOROPHENYL
PYRAZOL-4'-YL)-2-PROPENE-1-THIOSEMICARBAZONE
 Observed
Alkane C-H str. (asym.) 2929 2975-2950
-CH3 C-H str. (sym.) 2837 2880-2860
C-H i.p.def. (asym.) 1459 1470-1435
C-H o.o.p. def. (sym.) 1384 1390-1370
Aromatic C-H str. 3038 3080-3030
C=C str. 1543 1585-1480
C-H i.p. def. 1107 1125-1090
C-H o.o.p. def   837     835-810
Pyrazole C=N str. 1605 1630-1590
moiety C-N str. 1213 1230-1020
C-F str.   755     800-600
Ether C-O-C str. (asym.) 1236 1275-1200
C-O-C str. (sym.) 1030 1075-1020
Thiosemi- N-H str. (asym.) 3418 3550-3350
carbazone N-H str.  (sym.) 3257 3450-3250
C=N str. 1574 1630-1580
C=S str. 1175 1220-1050
Type     Ref.
 Reported




























Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)





    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.81 3H singlet Ar-OCH3        -
2. 6.90-6.92 2H doublet Ar-Hii’    Jihj=9.8
3. 7.10-7.15 2H triplet Ar-Hgg’        -
4. 7.26-7.30 1H triplet Ar-Hc        -
5. 7.41-7.45 2H triplet Ar-Hbd        -
6. 7.50-7.54 1H doublet CHz (vinylic)   Jzy=15.4
7. 7.60-7.64 2H multiplet Ar-Hae’                  -
8. 7.69-7.72 1H doublet CHy (vinylic)   Jzy=15.5
9. 7.78-7.80 2H doublet Ar-Hhh’    Jhi=9.6
  10. 7.96-7.98 2H doublet Ar-Hff ’    Jfg=9.7
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The term microwave was introduced just before World war-II. Microwave
radiation is a descriptive term used to identity electromagnetic waves in frequency
spectrum ranging from 1 GHz (109 Hz) to 30 GHz. These waves present several
interesting and unusual features not found in other portions of the electromagnetic
spectrum. These features make”microwaves” uniquely suitable for several useful
applications like industrial, scientific, domestic and medicinal.
In the last few years Microwave induced Organic Reaction Enhancement (MORE)
chemistry has gained popularity as a non-conventional technique for rapid organic
synthesis402 and a large number of papers has appeared proving the synthetic utility of
MORE chemistry in routine organic synthesis. It can be termed as “e-chemistry’ because
it is easy, effective, economical and eco-friendly and is believed to be a step towards
green chemistry. The advantages of microwave heating are decreased in rate of reaction
and time, cleaner reactions, easier work up and better yields. It is also generally observed
that the purity of products is improved due to shorter reaction period at high temperature
and the absence of local overheating on the reaction walls which occurs under conventional
heating.
Microwave heating is distinguished primarily by being a radiant process. Its
relationship to ordinary heat is of much interest. Regular heat rays differ in frequency
and properties. In the conventional method, heat is generated by molecular collisions
which accomplish the energy transfer while microwaves cause heating through the
absorption of energy quanta. Microwave generate instantaneous “ incore” heating of
materials, in a homogeneous and selective manner, especially those with poor heat
conduction properties.
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When molecules with permanent dipole are submitted to an electric field, they
become aligned. If this field oscillates, the orientation changes at each alternation. The
strong agitation provided by the reorientation of molecules, in phase with the electrical
field excitation, caused an intense internal heating, upto 10oC per second, when powerful
waves are used.
The main interests can thus be listed as the rapid transfer of energy into the bulk
of the reaction mixture. Without inertia since only the product is heated and the ease of
utilisation. Further more, as the depth of magnitude as the wavelength microwaves interact
with substances of appreciable thickness (about 10 cm).
The interfacial polarisation, the Maxwell-Wagner effect, may also contribute to
the heating effect when the conducting particles are in contact with a non conducting
medium, e.g. in heterogenous reactions. It is particularly convenient that qualitatively
the larger the dielecric constant, the greater the coupling with microwaves. Thus solvents
such as water, methanol, DMF, ethyl acetate, chloroform, acetone, acetic acid,
dichloromethane and R-spirit are all heated when irradiated with microwaves. Non-
polar solvents like CCl4, toluene, xylene, diethylether do not couple and therefore do
not heat with microwave irradiation.
It has been reported that the rate of variety of organic reaction such as Diels
Alder403,404, Claisen reaction405,406, Oxidation407-409, Reduction410,
Diacetylation411-413,  Esterification414 Hydrolysis of esters415,416, Doenr Condensation417,
Knoevenagel condensation418 could be enhanced by microwave irradiation.
Generally, commercial microwave oven is being used in the chemical laboratory
at a frequency of 2450 MHz. The first application of microwave oven in organic synthesis
began very recently. By the first experiments of Gedye and Giguere, the evidence for
dramatic acceleration in some classical organic reactions established, and these were
ascribed to temperature and pressure effects, when performed in closed Teflon vessels.
The reaction can be carried out in teflon, polystyrene and glass vessels since these are
transparent to microwaves. Microwave irradiation has also been applied for carrying
out reactions in open vessels using organic solvents. The relatively low cost of modern
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domestic microwave oven makes them reasonably readily available to academic and
industrial chemists.
 Since solvents were used in these experiments, some problems with safe
operation appeared and sometimes explosion resulted. Further development
demonstrated the potential of solvent free reaction to solve these problems and to
facilitate the scale-up of preparative runs. Recently, reactions under dry conditions using
inorganic reagents are gaining more attention because of their enhance selectivity and
milder conditions than those associated with conventional homogeneous reaction
procedures. It should be noted that some of the inorganic additives reach temperatures
in excess of 1000oC very rapidly and decomposition
of materials may be problematic, therefore some precautions regarding superheating
and associated fire hazards or explosions are taken.
Detail review on “Microwave Assisted Reactions” by S. Caddick419, involves
variety of unusual chemical reactions like,
1. Aromatic Substitution Reactions
2. Alkane Functionalisation






Successfully leading to the path way from non traditional approach to the
experimental setup of organic reactions, the concept of “Microwave Induced Organic
Reaction Enhancement” (MORE) chemistry has been utilized for rapid and efficient
synthesis of thiasemicarbazones
                                                                            Microwave. . .
174
SECTION - II
SYNTHESIS AND BIOLOGICAL EVALUATION OF 1-ARYL-3-(1',N-PHENYL
-3'-p-FLUOROPHENYL PYRAZOL-4'-YL)-2-PROPENE-1-THIOSEMICARBAZONES
BY MICROWAVE METHOD
As a part of our research programme towards the non traditinal approach to the
experimental set up of organic reactions, the concept of “Microwave induced Organic
Reaction Enhancement” (MORE) chemistry has been utilised for rapid and efficient
synthesis of some thiosemicarbazones which is described as under. The synthesis was
carried out by irradiating condensation of 1-Aryl-3-(1',N-phenyl-3'-p-fluorophenyl
pyrazol-4'-yl)-2-propen-1-ones with thiosemicarbazide.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography. The m/z peak at 520 indicates the molecular weight of the
compound 1-p-Bromophenyl-3-(1',N-phenyl-3'-p-fluorophenyl pyrazol-4'-yl)-2-
propene-1-thiosemicarbazones and other mass spectra fragmentation are recorded on
page no.167. All the spectral data are identical with Section-I.
Q. Pro-M Microwave Oven, Questron Technologies corporation-CANADA,
sample preparation system : 220 VAC, 60 Hz is used as a microwave irradiation source
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TABLE NO. 11a : COMPARISION OF CONVENTIONAL AND MICROWAVE
ENHANCED SYNTHESIS OF THIOSEMICARBAZONES
11a C6H5- 10 66 9 70 160
11b 4-OCH3-C6H4- 10 72 10 75 270
11c 4-CH3-C6H4- 10 61 9 66 237
11d 4-Cl-C6H4- 10 68 9 70 231
11e 4-Br-C6H4- 10 56 11 61 128
11f 4-OC2H5-C6H4- 10 49 9 60 148
11g 4-F-C6H4- 10 62 10 66 177
11h 4-NO2-C6H4- 10 65 7 68 201
11i 3-NO2-C6H4- 10 60 11 68 211
11j 4-NH2-C6H4- 10 61 9 69 266
11k 2-OH-C6H4- 10 66 11 70 166
11l 4-OH-C6H4- 10 50 9 65 243
Comp.
  No.














Triazole is one of the class of heterocyclic compounds with composition C2H3N3
having five membered diunsaturated ring sytem containing three nitrogen and two carbon
atoms. Triazole molecule is having following  isomers viz õ-trizoles or 1,2,3-triazoles
(I), s-triazoles or 1,2,4-triazoles (II).
The chemistry of 1,2,4-triazoles deal briefly in the earlier publications.420,421
The first 1,2,4-triazole derivative was synthesised by Bladin in 1885. An alternative
name for the ring system, introduced in 1889 by Andreocci is pyrrodiazole, which is
regarded as a member of a class of compounds analogous to pyrrole. A most intensive
investigation of the chemistry of 1,2,4-triazoles, especially by Andreocci’s successors in
Rome, followed the pioneering work of these two investigators.
1,2,4-Triazoles are important as reagents. 1,2,4-Triazole is useful as a catalyst
for transacylation reactions, e.g. for the synthesis of peptides from N-protected amino-
4-nitrophenyl esters and amino acids without racemization. Nitron (III), a mesoionic
1,2,4-triazole, forms an almost insoluble nitrate and is used for the detection and
gravimetric determination of nitrate ions. Nitron forms a covalent compound with poly(4-
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1,2,4-Triazoles have not yet been found in nature. Semisynthetic ß-lactam
antibiotics with a 1,2,4-triazolyl substituent have been prepared and are in clinical use.
However, the most important application of 1,2,4-triazoles is as biocides. 3-Amino-
l,2,4-triazole (amitrole, amizol) is an unselective herbicide. Triadimenol (IV) is one of
the most effective fungicides. Its configuration (IS, 2R) is essential for its action422. The
1,2,4-triazole fungicides inhibit the biosynthesis of ergosterol in fungi.
SYNTHETIC ASPECTS
Several methods have been reported in the literatures for the preparation of 1,2,4-
triazoles.423-427 We have synthesised 1,2,4-triazoles by the methode of  Reid and
Heindel428 i.e. by the action acid hydrazide with CS2 and KOH. The dithiocarbamate
is cyclised by hydrazine hydrate(V).
THERAPEUTIC IMPORTANCE
1,2,4-Triazole derivatives have been reported to be associated with diverse
biological activities. Drug molecules having 1,2,4-triazole nucleus with good activity
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3-Amino-1,2,4-triazole known as amitrole was the first triazole manufactured on
large scale from aminogunidine formate, useful as herbicides especially in wineyards and
orchards and brain catalase activity429. Therapeutic activity of 1,2,4-triazoles are listed
as under.
1. Anthelmintics430












14. Plant growth regulator443
Neikamura Hiroshi and co-workers444 have investigated 1,2,4-triazole
derivatives which is useful for treatment of hyperuricemia. Balkovee et. al.445 have
formulated triazoles as antidiabetic agent. Biologically active triazoles (XI) were reported
by Chepal P. V. and co-workers.446 Aoki Satosh et. al.447 have investigated triazoles
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Yaseen A. et. al.448 have prepared 1,5-dialkyl-3-(5-mercapto-4,N-aryl-1H-
1,2,4-triazol-3-yl-methylene)-1H-1,2,4-triazole which exhibited remarkable activity
against nine types of cancer and also antiviral activity. Neslihan Demirbas and his
co-workers449 have documented antimicrobial activity of some newly synthesised 1,2,4-
triazole derivatives.
Krzysztof W. et. al.450 have discovered 1,2,4-triazoles and reported their
antimycobacterial activity. Dae-Kee Kim et. al.451 have synthesised 1,2,4-triazole
derivatives and screened for their significant ALKS inhibitory activity in the luciferase
reporter assays (XIII).
Neslihan Demirbas et. al.452 have screened triazole derivatives for their anti
inflammatory, anticancer, antituberculosis and antihypertensive acitivities. Marie-Odile
Contour-Galcera et. al.453 have synthesised 3-thio-1,2,4-triazoles (XIV) and reported
as non-peptidic human somatostatin receptor subtypes 2 and 5 agonists. K. M.
Basavaraja and co-workers454 have prepared triazole derivatives (XV) and reported
their antibacterial activity.
Recently, Guru S. Gadaginamath and co-workers455 have documented  anti       mi-
crobial activity of new triazole derivatives. Synthesis and antioxidant activities of
some 4-benzylidenamino-4,5-dihydro-1H-1,2,4-triazol-5-one derivatives has been
investigated by Haydar Yuksek et. al.456 Abbas Shafiee and co-workers457 have
synthesised 1,2,4-triazole derivatives (XVI) and screened for their antibacterial activity.
Nawal A. El-Koussi et. al.458 have prepared a series of 5-phenyl-1-(3-pyridyl)-
1H-1,2,4-triazole-3-carboxylic acid derivatives. Some of the compounds were found
to be equipotent or more potent than Indomethacin and Celecoxib as reference drugs at








                                                                              Triazoles. . .
182
These valid observations led us to synthesise several derivatives like 1,3,4-
thiadiazepines, 1,3,4-thiadiazines and dihydrothiadiazoles bearing 1,2,4-triazole nucleus
in order to achieving better therapeutic agents which have been described as under.
[B] STUDIES ON TRIAZOLES
PART-I    : SYNTHESIS AND BIOLOGICAL EVALUATION OF 1,3 ,4-
THIADIAZOLES









R1 = NH2, NHR, SH, SMe
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1,3,4-Thiadiazole derivatives have been found to be potent drug in
pharmaceutical industries and exhibited various biological activities due to the presence
of the -N=C-S group459. In thiadiazole ring system one sulphur and two nitrogen atoms
are present in a five membered ring. According to their position, thiadiazole systems are
classified as 1,2,3-thiadiazoles (I), 1,2,4-thiadiazoles (II), 1,3,4-thiadiazoles (III), and
1,2,5-thiadiazoles (IV).
1,3,4-Thiadiazoles were first described in 1882 by Fischer and further developed
by Busch and his co-workers. The advent of sulfa drugs and their discovery of mesoionic
compounds greatly accelerated the rate of progress in the field of thiadiazoles.
SYNTHETIC ASPECT
Literature survey reveals that several publications and patents460-466 for
the synthesis of 1,3,4-thiadiazoles. We have synthesised 1,3,4-thiadiazoles by the action

































R = 2,3,4-Cl, 2,3,4-Br
3,4-Me, 2,4-OMe
(V)
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THERAPEUTIC IMPORTANCE
1,3,4-Thiadiazole heterocyclic entities that are very interesting components in
terms of their biological properties, several thiadiazole derivatives are reported to possess
pharmacological activity whose structures are shown below.
From the literature survey it was revealed that thiadiazole derivatives are better
therapeutic agents as shown under.
































































M. Kidwai and co-worker501 synthesized 1,3,4-thiadiazoles(VI) by Microwave-
Assisted method and tested for antitubercular acticvity. Li-Xue Zhang and co-workers
have been synthesized 3-(2-furanyl)-6-aryl-1,2,4-triazolo[3,4-b]-1,3,4-thiadiazoles(VII)
and  compounds possess significant growth promoting effects on mung bean radicles.502
N. Demirbas et. al.503 have prepared [1,2,4]triazolo[3,4-b][1,3,4]thiadiazoles
(VIII) possessing potent antibacterial activity against  Gram positive and Gram negative
organisms.
A.Farghaly and co-werkers504 have been synthesized 6-substituted 3-(1-
adamantyl)-1,2,4-triazolo[3,4-b][1,3,4]thiadiazoles derivative  (IX) tested for antiviral
activity. K. S. Rangappa and co-worker505 synthesized 4,6-disubstituted 1,2,4-triazolo-
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Y = , , ,
(XI)
CONTRIBUTION FROM OUR LABORATORY
Parikh et. al. have used substituted thiazolidinone506, substituted benzthiazole
and s-triazine507,508 4-pyridyl509 moieties at 5-position (Y) in 1,3,4-thiadiazole ring
system and at 2-position (X) was substituted by aryl, amino and s-triazine.510 H. H.
Parekh and co-workers have synthesised 1,3,4-thiadiazole having dapson511,512 bis
moiety at 5-position (Y) and benzalamino, benzoylamino and sulphonamido513, aryl514
moiety substituted at 2-position (X). H. H. Parekh et. al.515 have formulated some new
thiadiazoles as biologically active agents. General structure for above references are as
under.
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In view of the pronounced biological activities of triazoles and 1,3,4-thiadiazoles,
it was contemplated to synthesise 1,3,4-thiadiazoles in search of agents possessing higher
biological activity with least side effects, which have been described as under.
SECTION-I  : SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-
3-(2-METHOXY-5-CHLOROPHENYL)-1,2,4-TRIAZOLO-
[4,5-b]-1,3,4-THIADIAZOLES
SECTION-II  :  SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-
     3-(2-METHOXY-5-CHLOROPHENYL)-5,6,DIHYDRO-1,2,4-
    TRIAZOLO-[4,5-b]-1,3,4-THIADIAZOLES
                                                                            Thiadiazoles. . .
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SECTION - I
SYNTHESIS AND BIOLOGICAL EVALUATION OF  6-ARYL-3-(2-METHOXY-
5-CHLOROPHENYL)-1,2,4-TRIAZOLO-[4,5-b]-1,3,4-THIADIAZOLES
The thiadiazole derivatives are valuable drugs for various diseases. These valid
observations led us to synthesise 1,3,4-thiadiazolo triazole of type (XII) by the cyclisation
of 3-Mercapto-4, N-amino-5-(2-methoxy-5-chlorophenyl)-1,2,4-triazole with different
aromatic acids in presence of phosphorous oxychloride.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography. The m/z peak at 372 indicates the molecular weight of the
compound 6-p-Anisyl-3-(2-methoxy-5-clorophenyl)-1,2,4-triazolo-[4,5-b]-1,3,4-
thiadiazole and other mass spectra fragmentation are recorded on page no.195.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
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SYNTHESIS AND BIOLOGICAL EVALUATION OF 6-ARYL-3-(2-METHOXY-
5-CHLOROPHENYL)-1,2,4-TRIAZOLO-[4,5-b]-1,3,4-THIADIAZOLES
[A] Synthesis of Methyl 5-chloro-2-methoxybenzoate516
A mixture of 5-Chlorosalicyclic acid (1.72 g, 0.01M) in acetone (20 ml) and
anhydrous potassium carbonate (7 g.) was refluxed for 20 min. Dimethyl sulphate (3.78
ml.0.03 M) was then slowly added  refluxed for 6 hrs. The reaction mixture was cooled
and solid filtered off, and then the acetone was removed . Distillation under reduced
pressure. Yield, 55%; b.p., 135-138oC.
[B] Synthesis of 5-Chloro-2-methoxybenzohydrazide517
A mixture of Methyl 5-chloro-2-methoxybenzoate (2.00 g, 0.01M) in ethanol
(15 ml) and hydrazine hydrate (0.5 g, 0.01M) was refluxed for 7 hrs. The reaction mixture
was poured into ice cold water. The product was isolated and crystallised from Ethanol.
Yield, 87%; m.p., 200oC.
[C] Synthesis of Potassium 5-chloro-2-methoxybenzoyl dithiocarbamate
A mixture of Potassium hydroxide (0.84 g, 0.015M) in absolute ethanol (25
ml), 5-chloro-2-methoxybenzohydrazide (2.00 g, 0.01M) and carbon disulfide (1.14ml,
0.015M) was stirred for 22 hrs. The product was precipitated by adding diethyl ether
(50 ml). Yield, 90%.
[D] Synthesis of 3-Mercapto-4,N-amino-5-(5-Chloro-2-methoxyphenyl)-
1,2,4-triazole
A suspension of Potassium 5-chloro-2-methoxybenzoyl dithiocarbamate (3.14
g, 0.01M) hydrazine hydrate (95%, 1ml, 0.02M) and water (1 ml) was refluxed with
stirring for 7 hrs. The content was diluted with water and acidified with glacial acetic
acid to get the product. It was crystallised from DMF/Ethanol. Yield, 55%; m.p., 256oC,
(C9H9ClN4OS : required : C, 42.11; H, 3.53; N, 21.82; found : C, 42.10;  H, 3.50; N,
21.80%).
TLC solvent system : Ethyl acetate : Hexane (3 : 7).
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[E] Synthesis of 6-p-Anisyl-3-(2-methoxy-5-clorophenyl) -1,2,4-triazolo-[4,5-b]
-1,3,4-thiadiazole
A mixture of 3-Mercapto-4,N-amino-5-(5-Chloro-2-methoxyphenyl)-1,2,4-
triazole  (2.56 g, 0.01 M) and p-methoxy benzoic acid (1.52 g, 0.01M) in phosphorous
oxychloride (20 ml) was refluxed for 10 hrs. The resulting mixture was poured onto
crushed ice and neutralised with sodium bicarbonate. The product was crystallised from
ethanol.  Yield, 64%; m.p., 228oC, (C17H13ClN4O2S : Required : C, 54.77; H, 3.51;
N, 15.03; Found : C, 54.74; H, 3.48; N, 15.00%).
TLC solvent system : Ethyl acetate : Hexane (3 : 7).
Simi lar ly  o ther  subst i tu ted  1 ,3 ,4-Thiadiazole were  synthes ised.The
physical data are recorded in Table No. 12.
[F] Antimicrobial activity of 6-Aryl-3-(2-methoxy-5-clorophenyl) -1,2,4-
triazolo- [4,5-b]-1,3,4-thiadiazole
Antimicrobial testing was carried out as described in [A] Part-I, section-I (D). The
zone of inhibition of the test solutions are recorded in Graphical Chart No. 12.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 6-p-ANISYL-3-(2-METHOXY-5-CHLOROPHENYL)-
1 , 2 , 4 - TRIAZOLO[4,5-b]-1,3,4-THIADIAZOLE
Alkane C-H str. (asym.) 2923 2975-2950  576
-CH3 C-H str. (sym.) 2854 2880-2860   “
C-H i.p.def. (asym.) 1461 1470-1435   “
C-H o.o.p. def. (sym.) 1384 1390-1370   “
Aromatic C-H  str. 3035 3080-3030  577
C=C str. 1581 1585-1480   “
C-H i.p. def. 1107 1125-1090   “
C-H o.o.p. def   829     835-810   “
Triazole C=N str. 1608 1612-1593  576
moiety C-N str. 1184 1220-1020   “
N-N str. 1018 1050-1010   “
C-N-C str. 1141 1146-1132   “
C-Cl str.   779     600-800   “
Ether C-O-C str. (asym.) 1261 1275-1200   “
C-O-C str. (sym.) 1022 1075-1020   “
Thiadiazole N-H str. 3375 3450-3200   “
N-H def. 1608 1650-1580   “
                                               (overlapped)
C-S-C str.   659                   720-570  577
















Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF 6-p -CHLOROPHENYL-3-(2-METHOXY-5-




    (δ ppm)
Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.92 3H singlet Ar-OCH3                         -
2. 7.07-7.12 3H multiplate Ar-Hc           -
Ar-Hdd’           -
3. 7.33-7.34 1H double Ar-Hb     Jba=2.7
doublet     Jbc=8.8
4. 7.91-7.94 2H doublet Ar-Hee’    Jed=8.8
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SYNTHESIS AND BIOLOGICAL EVALUATION OF  6-ARYL-3-(2-METHOXY-
5-CHLOROPHENYL)-5,6 ,DIHYDRO-1,2,4-TRIAZOLO-[4,5-b]-1 ,3 ,4-
THIADIAZOLES
We have synthesised a series of 1,3,4-thiadiazole of type (XIII) have been
prepared by the condensation of 3-Mercapto-4,N-amino-5-(2-methoxy-5-chlorophenyl )-
1,2,4-triazole with different aromatic aldehydes in the presence of p-toluene sulphonic
acid.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all the compounds have been checked by
thin layer chromatography. The m/z peak at 404 indicates the molecular weight of the
compound 6-3,4-Dimethoxyphenyl-3-(2-methoxy-5-clorophenyl)-5,6-dihydro-1,2,4-
triazolo-[4,5-b]-1,3,4-thiadiazole and other mass spectra fragmentation are recorded
on page no.205.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains
and antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml.
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SYNTHESIS AND BIOLOGICAL EVALUATION OF  6-ARYL-3-(2-METHOXY-
5-CHLOROPHENYL)-5,6 ,DIHYDRO-1,2,4-TRIAZOLO-[4,5-b]-1 ,3 ,4-
THIADIAZOLES
[A] Synthesis of Potassium 5-Chloro-2-methoxybenzoyl dithiocarbamate
See [B] Part-I, Section-I (C).
[B] Synthesis of 3-Mercapto-4,N-amino-5-(5-Chloro-2-methoxyphenyl)-
1,2,4-triazole
See [B] Part-I, Section-I (D).
[C] Synthesis of 6-p-Anisyl-3-(2-methoxy-5-clorophenyl)-5,6-dihydro-1,2,4-
triazolo-[4,5-b]-1,3,4-thiadiazole
A mixture of 3-Mercapto-4,N-amino-5-p-hydroxyphenyl-1,2,4-triazole (2.56 g,
0.01 M), p-anisaldehyde (1.36g, 0.01M) in dry DMF (20 ml) and p-toluene sulphonic
acid (50 mg) was refluxed for 12 hrs. The reaction mixture was poured onto crushed
ice. The product was isolated and crystallised from ethanol. Yield, 65%; m.p., 248oC,
(C17H15ClN4O2S : Required : C, 54.47; H, 4.03; N, 14.95; Found : C, 54.45; H,
4.00; N, 14.90%).
TLC solvent system : Ethyl acetate : Hexane (3 : 7).
Similarly  other derivatives were synthesised. The physical data are recorded in
Table No. 13.
[D] Antimicrobial activity of 3-p-Hydroxyphenyl-5,6-dihydro-6-aryl-[1,2,4]-
triazolo-[3,4-b][1,3,4]-thiadiazoles.
Antimicrobial testing was carried out as described in [A] Part-I, Section-I (D). The
zone of inhibition of test solutions are recorded in Graphical Chart No. 13.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 6-p-ANISYL-3-(2-METHOXY-5-CHLOROPHENYL)-
5,6-DIHYDRO-[ 1 , 2 , 4 ] - TRIAZOLO[3,4-b] [1,3,4]- THIADIAZOLE
 Observed
Alkane C-H str. (asym.) 2927 2975-2950
-CH3 C-H str. (sym.) 2842 2880-2860
C-H i.p.def. (asym.) 1465 1470-1435
C-H o.o.p. def. (sym.) 1373 1390-1370
Aromatic C-H  str. 3035 3080-3030
C=C str. 1569 1585-1480
C-H i.p. def. 1122 1125-1090
C-H o.o.p. def   810     835-810
Triazole C=N str. 1600 1612-1593
moiety C-N str. 1184 1220-1020
N-N str. 1018 1050-1010
C-Cl str.   763     600-800
Ether C-O-C str. (asym.) 1261 1275-1200
C-O-C str. (sym.) 1018 1075-1020
                                     (overlapped)
Thiadiazole N-H str. 3305 3450-3200
N-H def. 1600 1650-1580
                                     (overlapped)
C-S-C str.  644                 720-570
Type     Ref.
 Reported






























Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)
PMR SPECTRAL STUDY OF   6-p -CHLOROPHENYL-3-(2-METHOXY-5-





    (δ ppm)
 RelativeNo.
of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.66 3H singlet Ar-OCH3                          -
2. 3.83 3H singlet Ar-OCH3             -
3. 6.91-6.94 2H double Ar-Hdd’      Jab=8.6
doublet
4. 7.25-7.30 3H multiplate Ar-Hb             -
Ar-Hc
5. 7.43-7.47 3H multiplate Ar-Hee’            -
Ar-Ha
8. 7.56 1H singlet -CHf            -
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Thermally stable neutral aromatic1,3,4-oxadiazole518 have been known for
about 80 years. They have been subject to intensive investigations perticularly in the last
decade because of an important class of heterocyclic compounds which have been well
documented throughout the literature due to their biological importance. Oxadiazoles
are nonnaturally occurring five-membered aromatic heterocycles with utility in synthetic
medicinal, agriculture and dyestuff industries. 1,3,4-oxadiazoles(I) also have been useful
in diverse areas like drug synthesis, heat resistant, fluroescent whiteners and UV
absorbing polymers.The literature priorto 1965 is surveyed in comprehensive reviews519.
SYNTHETIC ASPECT
Most 1,3,4-Oxadiazoles are best obtained by synthesis from acyclic precursors.
Such reactions are ‘one bond’ or ‘two-bond’ cyclisation. Different methods for the
synthesis have been cited in literature520-527.
1. Hansong Chen et. al.528 have synthesised oxadiazoles by the reaction of
hydrazide and aromatic acid in presence POCl3.
2. D. Ramesh and B. Sreenivasan529 have synthesised 1,3,4-oxadiazoles from
semicarbazide in presence of POCl3.
O
N N
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3. K. Mogilaiah and B. Sakram530 have prepared 1,3,4-oxadiazole from
acetophenone-2-trifluoromethyl-1,8-naphthyridine-3-carbonyl hydrazone in
presence of acetic anhydride.
THERAPEUTIC IMPORTANCE
2,5-Disubstituted-1,3,4-oxadiazole derivatives have been tested for various










10. Antiviral & anticancer542
11. Cardiovascular543
12. Herbicidal544



































16. Nematocidal and Insecticidal548
Erhan Palaska, Milda Malvina Burbuliene and co-worker549-551 have
synthesized 1,3,4-oxadiazole of (VI),(VII) and (VIII) and tested for anti-inflammatory
activity in the compounds of  (VI) the anti-inflammatory and ulcerogenic activities of the
compounds were compared with naproxen, indomethacin and phenylbutazone. Side effects
of the compounds were examined on gastric mucosa, liver and stomach and none of the
compounds showed significant side effects compared with reference nonsteroidal anti-
inflammatory drugs (NSAIDs). The compounds of  (VII) i.e. 1,3,4-oxadiazole-2-thiones
and their 3-morpholinomethyl derivatives were tested in vivo  exhibited anti-inflammatory
activity more than acetylsalicylic acid. The compounds of (VIII), some derivative are
more active compared to acetylsalicylic acid and ibuprofen.































NR1R2 =       ,         ,N N N O
(VIII)
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Ali Almasirad et. al. and  Afshin Zarghi et. al.552,553  have tested anticonvul-
sant activity of some new oxadiazole of (IX) and (X)  in compound of (IX) when R=NH2
showed considerable anticonvulsant activity both in PTZ and MES model.
Ali A. El-Emam and co-worker554 have synthesised 5-(1-adamantyl)-1,3,4-
oxadiazoline-2-thione and 3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones and
tested for antimicrobial, and anti-HIV-1 activity some of the compound showed anti-
HIV-1 activity at the concentrations of 50, 10, and 2 ìg/mL. Xiaohu Ouyang and twenty
two co-worker555 have synthesised oxadiazoles (XI) and evaluated for their ability to
inhibit tubulin polymerization and to cause mitotic arrest in tumor cells. The most potent
compounds inhibited tubulin polymerization at concentrations below 1 ìM. Lead analogs























R = NH2, SH, SCH3, OH
    R1 = H, F, Cl,
R2 = NH2, SH, SCH3, SC2H5, SBz
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Theresa May Chin Tan and co-worker556  have synthesized 2-benzene
sulfonylalkyl-5-substituted-sulfanyl-[1,3,4]-oxadiazoles (XI) and tested as potential anti-
hepatitis B virus agents current treatments for chronic hepatitis B virus (HBV) infection
include the use of interferon-á and of nucleoside analogs lamivudine, adefovir and
entecavir. S.L. Gaonkar and co-worker557 have synthesized 2-[substituted pyridin-2-
yl) ethoxy] phenyl}-5-substituted-1,3,4-oxadiazoles (XII) and aroylhydrazines. The
synthesized compounds were evaluated for their antimicrobial activity. The minimum
inhibitory concentration of some compounds was in the range of 8–26 ìg ml–1 against
bacteria and 8–24 ìg ml–1.
Recently, Güniz Küçükgüzel and co-worker558 have synthesized 2-
cyclohexylamino-5-(22 ,42 -difluoro-4-hydroxybiphenyl-5-yl)-1,3,4-oxadiazole (XIII)
and 2-aryl-5-substituted thiazolidinones-2-yl-imino-1,3,4-oxadiazoles (XIV) were
screened for their antimycobacterial activity against Mycobacterium tuberculosis H37Rv,
















    R1 = alkyl, H
R2 = alkyl, arylalkyl, substituted
         pyrazinyl alkyl etc.
  (XIV)
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Yan Li and co-worker559 have synthesized (E)-á-(methoxyimino)-benzeneacetate
derivatives having 1,3,4-oxadiazole (XV) ring system stereo selective and fungicidal
activity.
CONTRIBUTION FROM OUR LABORATORY
Parikh et. al. have synthesised 1,3,4-Oxadiazoles having substitution of aryl
sulphonamido,560 aryl,561 mercapto,562 quinolinyl,563 and amino564 at 2-position
(Y) and 4'-pyridyl, benzenesulphonamido phenyl, diiodoquinolinoxy and aryl
sulphonamidophenyl at 5-position (X) as antimicrobial agents. H. H.Parekh and
coworkers have prepared 1,3,4-oxadiazoles having substituted triazine,565 phenyl,
sulphonyl,566 2-isopropyl-5'-methyl phenoxy methyl,567 dapson,568 moieties at 5-
position (X) and aryl, arylamino, arylsulphonamido, substituted benzalamino moieties at
2-position (Y) and screened their antimicrobial activity. General Structure for above
references are as under.
  (XV)













N SO2NHX  = , ,
SO2NH.R
, aryl
Y = NH-SO2-R,    Aryl,    -SH,     -NH2,    -NHCO-R,    -N = CH - R
  (XVI)
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H. Parekh et. al.569-574 have formulated some new oxadiazole as biologically
active agents. New 2,5-di substituted oxadiazoles were synthesized and assessed for
antimicrobial activity by Parikh et.al.575
1,3,4-Oxadiazole ring is associated with many types of biological properties, it
was contemplated to synthesise some new 1,3,4-oxadiazoles in search of agents
possessing higher biological activity with least side effect, which have been described as
under.
SECTION - I  :  S Y N T H E S I S  A N D  B I O L O G I C A L E VA L U AT I O N  O F
      2 -ARYL-5- (2-METHOXY-5-CHLOROPHENYL)-1 ,3 ,4-
     OXADIAZOLES
                                                                           Oxadiazoles. . .
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SECTION - I
S Y N T H E S I S  A N D  B I O L O G I C A L E VA L U AT I O N  O F 2-ARYL-5-(2-
METHOXY-5-CHLOROPHENYL)-1,3 ,4-OXADIAZOLES
Oxadiazole derivatives have drawn the attention of chemists due to diversified
biological activities associated with it. In view of these facts, it was contemplated to
synthesise some newer oxadiazole derivatives with better potency. Oxadiazoles of type
(XIV) have been prepared by condensation of 5-Chloro-2-methoxybenzohydrazide
 with different aromatic acid in presence of POCl3.
The constitution of the synthesized products have been characterized by using
elemental analyses, infrared and 1H nuclear magnetic resonance spectroscopy and further
supported by mass spectrometry. Purity of all compounds have been checked by thin
layer chromatography. The m/z peak at 355 indicates the molecular weight of the
compound 2-3,4-Dichlorophenyl-5-(2-methoxy-5-chlorophenyl)-1,3,4-oxadiazole and
other mass spectra fragmentation are recorded on page no.222.
All the products have been screened for their in vitro biological assay like
antibacterial activity towards Gram positive and Gram negative bacterial strains and
antifungal activity towards Aspergillus niger at a concentration of 40 µg/ml. The
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S Y N T H E S I S  A N D  B I O L O G I C A L E VA L U AT I O N  O F 2-ARYL-5-(2-
METHOXY-5-CHLOROPHENYL)-1,3 ,4-OXADIAZOLES
[A] Synthesis of Methyl 5-chloro-2-methoxybenzoate
See [B] Part-1, Section-(A)
[B] Synthesis of 5-Chloro-2-methoxybenzohydrazide
See [B] Part-1, Section-(B)
[C] Synthesis  of  2-p -Chlorophenyl-5-(2-methoxy-5-chlorophenyl)-1 ,3 ,4-
oxadiazole
A mixture of  5-Chloro-2-methoxybenzohydrazide (2.00g, 0.01M) and 4-cholro
benzoic acid (1.56g, 0.01M) in phosphorous oxychloride (10 ml) was refluxed for 6
hrs. The content was cooled and poured onto crushed ice. It was neutralised with sodium
bicarbonate solution. Product was isolated and crystallised from ethanol. Yield, 69%;
m.p., 268oC, (C15H10Cl2N2O2 : required : C, 56.10 ; H,3.14 ; N, 8.72, found : C,
56.08; H, 3.10 ; N, 8.71%).
TLC solvent system : Ethyl acetate : Hexane(4 : 6).
Similarly other 2-Aryl-5-(2-methoxy-5-chlorophenyl)-1,3,4-oxadiazoles have
been prepared. The physical data are recorded in Table No. 14.
[D] Antimicrobial activity of 2-Aryl-5-(2-methoxy-5-chlorophenyl)-1,3,4-
oxadiazoles
Antimicrobial testing was carried out as described in [A] Section-I [D]. The zone
of inhibition of test solutions are recorded in Graphical Chart No.14.
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Instrument  :  SHIMADZU-FT-IR 8400-Spectrophotometer ; Frequency range : 4000-400 cm-1 (KBr disc.)
IR SPECTRAL STUDY OF 2-p-ANISYL-5-(2-METHOXY-5-CHLOROPHENYL)-
1,3,4-OXADIAZOLE
 Observed
Alkane C-H str. (asym.) 2920 2975-2950 576
-CH3 C-H str. (sym.) 2846 2880-2860 “
C-H i.p.def. (asym.) 1427 1470-1435 “
C-H o.o.p. def. (sym.) 1380 1390-1370 “
Aromatic C-H  str. 3082 3080-3030 577
C=C str. 1496 1585-1480 “
C-H i.p. def. 1172 1125-1090 “
C-H o.o.p. def   833     835-810 “
Oxadiazole C=N str. 1612 1612-1593 576
N-N str. 1029 1050-1010 “
C-O-C str. 1099 1140-1070 “
C-Cl str.   752     800-600 “
Ether C-O-C str. (asym.) 1257 1275-1200 “
C-O-C str. (sym.)   975 1075-1020 “
Type     Ref.
 Reported









Internal Standard : TMS; Solvent : CDCl3; Instrument : BRUKER Spectrometer (400 MHz)





    (δ ppm)
 Relative No.
  of Protons
Multiplicity Inference    J Value
    In Hz
1. 3.81 3H singlet Ar-OCH3 -
2. 7.01-7.04 2H doublet Ar-Hdd’ Jde=8.8
3. 7.32-7.35 1H double Ar-Hb        Jba=2.7
doublet Jbc=9.0
4. 7.48-7.50 1H doublet Ar-Hc Jcb=8.6
5. 7.79 1H double Ar-Ha Jab=2.5

































































































































































































































































































































































































































































































































































































































































































   
   
 4
   
   
   
 : 

















































































































































































































































































   
   
























   
   













   
   
  1
   
   
   
2
   
   
   
   
   
  3
   
   
   
4
   




































































































































































































































































   






































Ger. Pat., 26, 429 (1983) [Friedander, 1, 208].
2. Knorr;
Ber., 16, 2597 (1887).
3. Knorr and Blank;
Ber., 18, 311 (1885).
4. L. Knorr;
Ber., 16, 2587, (1883).
5. Y. F. Suen, H. Hope, M. H. Nantz, M. J. Haddadin and M. J. Kurth;
J. Org. Chem., 2005, 70(21), 8488-8471
6. A. Saikia, M. G. Barthakur, M. Borthakur, C. J. Saikia, U. Bora and R. C. Boruah;
Tetrahedron Lett., Vol. 47, No.1 pp. 43-46   (2006)
7. F. Gabrera Escribano, M. P. Deyri Alcantara and A. Gomez-Senchez;
Tetrahedron Lett., Vol. 29, No. 46, pp. 6001-3004, (1988).
8. H. V. Pechmann; Ber., 31, 2950 (1898).
9. Y. Zikan and S. Rad;
Chem. Abstr., 109, 170344b (1988).
10. Y. Zikan and S. Rad;
J. Heterocycl. Chem., 34, 601 (1997).
11. Ikeda Masazumi, Maruyama Kazumi, Nobuhara Youichi and Yamado Toshihiro;
Chem. Pharm. Bull., 44(9), 1700 (1996).
12. E. V. Pimenova, R. A. Khamatgaleev and E. V. Voronina;
Khim-Farm. Zh., 32(8), 272g (1998); Chem. Abstr., 130, 66441d (1999).
13. Haiza Mohammed;
Al. Azhar Bull. Sci., 8(2), 445 (1997).
14. A. I. Eid and S. Rashad;
Egypt J. Pharm. Sci., 20(1-4), 107 (1979); Chem. Abstr., 109, 170344b (1988).
15. Takashima, Yoriyaki, Nasumo Ichiro and Yamamoto Hiroshi;
Chem. Abstr., 126, 7984 (1997).
16. M. D. Treadway and Wu Tai Teh;
PCT Int. Appl. WO 98, 56767; Chem. Abstr., 130, 52416n (1999).
17. S. sharma and M. S. Bhatia;
J. Indian Chem. Soc., 66, 116 (1989); Chem. Abstr., 112, 98439d (1992).
18. Banks Bernard Joseph, Richard Webster and Andrew Bentley;
Eur. Pat. Appl. EP. 95, 9071 (1998); Chem. Abstr., 131, 351325w (1999).
227
19. G. Menozzi, L. Mosti, P. Schenone, M. D’Amico, C. Falzarano and F. Rossi;
Farmaco, 48(4), 539-549 (1993).
20. H. Naito, M. Sugimori, I. Mitsui, Y. Nakamura, M. Iwahana, K. Hirotani, E. Kumazawa and
A. Ejima;
Chem. Pharm. Bull. (Tokyo), 47(12), 1679-84 (1999).
21. Giuseppe Daidone, Benedetta Maggio, Salvatore Plescia, Demetrio Raffa, Domenico
Schillaci, Onofrio Migliara, Antonella Caruso and Maria Amico-Roxas
IL Farmaco, 53(5), 350-356 (1998).
22. E. Akio and O. Satory;
PCT Int. Appl. wo 98, 32, 739 (Cl. C07D231/12); Chem. Abstr., 128, 154079f (1998).
23. Stevan W. Djuric, Anwer Basha, Huaqing Liu, Jay R. Luly and Madar J. David et. al.;
J. Med. Chem. , 43, 2975-2981(2000).
24. Sato Nagaaki, Toshiyaki Takahash, Takunobu and Shibata;
J. Med. Chem., 46, 666 (2003).
25. Virinder S. Parmar, Nawal K. Sharma, Motazzal Husain, Arthur C. Watterson, Jayant
Kumar et. al.;
Bioorg. and Med. Chem., 11(6), 913-926, March (2003).
26. Carbau Romuald, Mocohray Clhorles Erie, Perros, Manousses, Shipple Paul Anthens and
Wood Antheny;
PCT Int. Appl. WO 02, 04, 424 (Cl. CO7D 231/12); Chem. Abstr., 136, 118445d (2002).
27. J. Scott Sawyer,  Bryan D. Anderson, Douglas W. Beight, Robert M. Campbell et. al.;
J. Med. Chem., 46(19), 3953-3956 (2003).
28. L. S. David, Brummell G. David et al.;
J. Med. Chem., 44, 78-93 (2001).
29. Akihiko Tanitame, Yoshihiro Oyamada, Keiko Ofuji, Mika Fujimoto et. al.;
J. Med. Chem., 47 (14), 3693 -3696 (2004).
30. Herk T. Van, J. Brussec, A. M. C. H. Vanden and Nienwendisk;
J. Med. Chem., 46, 3945 (2003).
31. R. N. Atkinson and M. F. Gross;
PCT Int. Appl. WO 03 37,274 (Cl. A Cl. K) (2003); Chem. Abstr., 138, 368888z (2003).
32. Gellibert Francoise and Jeanne Glaxo;
PCT Int Appl. WO 02 62781 (Cl. CO7D401/14); Chem. Abstr., 137, 169514d (2002).
33. Ji Yang, Parviz Gharagozloo, Jiangchao Yao, Victor I. Ilyin, Richard B. Carter, Phong
Nguyen, Silvia Robledo, Richard M. Woodward  and Derk J. Hogenkamp;
J. Med. Chem.,47(6), 1547-1552  (2004).
228
34. Zainaba Dardani, Mohammed Beudaima, Abdelfatah Sebban, Abdelmejid Bahioul, Said
Kitane and Mohamed Berrader;
IL Farmaco, 59(9), 673-678, Sep. (2004).
35. Adnan A. Bekhit and Tarek Abdel Aziem;
Bioorg. and Med. Chem., 12(8), 1935-1945, April (2004).
36. Franco Chimenti, Elias Maccioni, Daniela Secci, Adriana Bolasco, Paola Chimenti et. al.;
J. Med. Chem., 48(23), 7113-7122 (2005).
37. Craig W. Lindsley, David D. Wisnoski, William H. Leister, Julie A. O’brien, et. al.;
J. Med. Chem. 47, 5825-5828 (2004).
38. Olga O. Alekseeva, Anu Mahadevan, Jenny L. Wiley, Martin R. Billy and Raj K. Razdan;
Tetrahedron Letters, 46(12), 2159-2161 (2005).
39. Adrian l. Gill, Martyn frederickson, Anne Cleasby, Steven j. Woodhead et. al.;
J. Med. Chem. 48, 414-426 (2005).
40. Bantwal Shivarama Holla , Manjathuru Mahalinga, Mari Sitambaram Karthikeyan, Padiyath
Mohamed Akberali and Nalilu Sucheta Shetty;
Bioorg. and Med. Chem., 14(6), March 2040-2047 (2006)
41. Antoniana U. Krettli, Isabela O. Freitas, Rodrigo P. P. Soares et. al.;
Bioorg. and Med. Chem. Letters, 16(3), 649-653 (2006).
42. Paolo Pevarello  Daniele Fancelli, Anna Vulpetti, Raffaella Amici  et. al.;
Bioorg. and Med. Chem. Letters, 16(4), 1084-1090 (2006).
43. Subas M. Sakya, Kristin M. Lundy DeMello, Martha L. Minich, Bryson Rast et. al.
Bioorg. and Med. Chem. Letters, 16(2), 288-292 (2006).
44. B. A. Bhat, K. L. Dhar et. al.;
Bioorg. and Med. Chem. Letters, 15, 3177-3180 (2005).
45. Laxminarayan Bhat et. al.;
Bioorg. and Med. Chem. Letters, 15, 85-87 (2005).
46. J .H. Tan et. al.;
European J. Med. Chem., xx,xxx (2006).
47.   J. Elguero;
  In Comprehensive Heterocyclic Chemistry, eds., A. R. Katritzky and C. W. res., Vol 5, 168 (1984).
48.   R. S. Theobald;
  Rodd’s Chemistry of Carbon Compounds, Ed. M. F. Ansell, Vol. IV, Part C, Ch. 16 2nd
  Edition, (Elsenier Science Publishers B. V., Amsterdam) 59 (1998).
49.   A. M. Fahmy, M. Hassan, A. A. Khalf and R. A. Ahmed;
  Rev. Roum. Chim., 33(7), 755-61 (1988); Chem. Abstr., 111, 77898 (1989).
229
50.      Vimesh M. Patel and Kishor R. Desai;
           ARKIVOC (2004) (i) 123-139.
51. A. K. Padya, K. Jaggi, V. Lakshminarayana and C. S. Pande;
J. Indian Chem. Soc., 75(2), 104-105 (1998).
52. V. Gohanmukkala, A. Subbaraju, R. Naykula and D. Parmeswara;
Indian J. Heterocyclic Chem., 4, 87-92 (1994).
53. R. A. Kabli, A. H. Kaddah, A. M. Khalil and A. A. Khalof;
Indian J. Chem., 25B, 152-156 (1986).
54. M. A. El. Hashsh, M. El-Kady, M. A. Saiyed and  A. A. Elsawy;
Egypt. J. Chem., 27(6), 715-21 (1985); Chem. Abstr., 105, 20868u (1986).
55. G. Gyassi, K. Bourin, M. Lamiri and M. Soufiaoui;
New Journal of Chemistry, 22(12), 1545-1548 (1998).
56. S. Paul and R. Gupta;
Indian J. Chem., 37B, 1279-1282 (1998).
57. A. Dandia, H. Taneja and C. S. Sharma;
Indian J. Heterocycl. Chem., (1999); Chem. Abstr., 132, 265161d (2000).
58. A. K. Reda, A. A. Khalaf, M. T. Zimaltu, A. M. Khalil and  A. M. Kaddah;
J. Indian Chem. Soc., 68, 47-51 (1991).
59. B. Roman;
Pharmazie, 45, 214 (1990).
60. Z. Brozozowsk and E. Pormarnacka;
Acta. Pol. Pharm., 37(4), 1378-80 (1980); Chem. Abstr., 25, 80807 (1981).
61. Archana Shrivastava V. K.; Chandra Ramesh and Kumar Ashok;
Indian J. Chem., 41B, 2371-75 (2002); Chem. Abstr., 138, 271582 (2003).
62. H. G. Garg and P. P. Singh;
J. Chem. Soc., 2, 1141 (1936).
63. D. B. Reddy, T. Senshuna and M. V. Ramma Reddy;
Indian J. Chem., 30B, 46 (1991).
64. Ashok Kumar, R. S. Verma and B. P. Jagu;
J. Ind. Chem. Soc., 67, 120 (1990).
65. W. I. Ronald and  A. Adriano;
Chem. Abstr., 126, 181346f (1997).
66. H. M. Mokhtar and H. M. Faidallah;
Pharmazie, 42, 482 (1987).
230
67. J. Panda, S. V. Srinivas and M. E. Rao;
J. Indian Chem. Soc., 79(9), 770-1 (2002); Chem. Abstr., 138, 153499n (2003).
68. Delay Francois (Fermenich S. A.) and Patent Schrift (Switz);
Chem. Abstr., 117, 90276f (1992).
69. G. Aysel, D. Seref, C. Gultaze, E. Kevser and V. Kamil;
Eur. J. Med. Chem., 35, 359-64 (2000).
70. P. Desaea; A. Nunrich; M. Carderny and G. Devaux;
Eur. J. Med. Chem., 25, 285 (1990).
71. Kalluraya Balakrishna, R. Chimabalkar, G. Rai, R. Gururaja and S. Shenoy;
J. Indian Coun. Chemi., 18(2), 39-43 (2001); Chem. Abstr., 138, 238061 (2003).
72. Y. Hiroyuti and O. Mocoto, et al.;
Eur. Pat. Appl. Ep 295695 (Cl. C07D 401/6) (1988); Chem. Abstr., 111, 23510 (1989).
73. K. Zalgislaw, and A. Seffan ;
Acta. Pol. Pharm., 36(6), 645 (1979); Chem. Abstr., 93, 204525e (1980).
74. S.S. Nayal and C.P. Singh;
Asian J. Chem. 11, 1, 207-212 (1999).
75. K. Wellinga, H. H. Eussen and Jacobus;
Eur. Pat. Ep. 269 141 (Cl C07D 231/06) (1988); Chem. Abstr., 110, 8204 (1989).
76. K. Trena and Zolzislaw;
Acta. Pol. Pharm., 36 (3), 227 (1979); Chem. Abstr., 93, 4650r (1980).
77. D. Bhaskar Reddy, T. Senshuma, B. Seehaiha and M.V. Ramma Reddy;
Indian J. Chem., 30(B), 46 (1991).
78. B. Hans, R. Rolf and R. Rudolf;
US. Pat. 3, 822, 283 (1974); Chem. Abstr., 81, 105494r (1974).
79. J. H. Ahn, H. M. Kim,  S. H. Jung, S. K. Kang, K. R. Kim, S. D. Rhee, S. D. Yang,
H. G. Cheon and S. S. Kim;
Bioorg. Med. Chem. Letter 14(17), 4461-5 (2004).
80. T. S. Jeong, K. S. Kim, S. J. An, K. H. Cho, S. Lee and W. S. Lee;
Bioorg. Med. Chem. Letter 14(11), 2715-7 (2004).
81. M. N. Nasr and S. A. Said;
Arch Pharm (Weinheim). 336(12), 551-9 (2003).
82. M. A. Berghot and E. B. Moawad;
Eur. J. Pharm. Sci. 20(2), 173-9 (2003).
83. Maurer Fritz, Fuchs Rainer, Erdelen Chritoph and A. Turberg;
PCT Int. Appl. WO 03 59, 887 (Cl. C07 D231/28) (2003); Chem. Abstr., 139, 117441z (2003).
231
84. B. Shivarama Holla, M. K. Shivananda, P. M. Akabar Ali and M. Shalini Shenoy;
Indian J. Chem., 39B, 440-47 (2000).
85. B. Shivarama Holla, M. K. Shivananda and B. Veerendra;
Ind. J. Heterocyclic Chem., 12, 135-138 (2002).
86. T. M. Stavenson, D. W. Piotrowski, M. A. H. Fahmy, R. L. Lowe and K. L. Monaco;
Chem. Abstr., 130, MAR Part - I, 29 AGRO (1999).
87. T. Katsushori, A. Hiroyuki and K. Masumij;
PCT Int. Appl. WO 98, 56, 760; Chem. Abstr., 130, 66492w (1999).
88. K. Johannes, J. Fuchs and R. Erdelen;
U.S. US 5, 525, 622 (cl. 514-403; A 0N 43/56). Jun. 1996, DE Appl. 4, 128, 564, Aug.
1991; 574; Chem. Abstr., 125, 1427199 (1996).
89. Z. Moritaz and S. Hadolj;
Dyes and Pigmenta, 41, 1-2, 1-10 (1999).
90.  V. K. Srivastava, Archana and Ashok Kumar;
Arzneimittel. Forschung, 52(11), 787-91 (2002); Chem. Abstr., 138, 353758 (2003).
91. S. P. Hiremath, K. Rudresh and A. R. Saundane;
Indian J. Chem., 41(B), 394-399 (2002).
92. V. Malhotra, S. Pathak, R. Nath, D. Mukherjee and K. Shanker;
Indian J. Chem., 41(B), 1310-13 (2002); Chem. Abstr., 137, 370021j (2002).
93. Guniz Kucukguzel, Sevin Rollas, Habibe Erdeniz, Muammer Kiraz and A. Cevdet Ekinci,;
Eur. J. Med. Chem., 35, 761-77 (2000).
94. Ji - In Kim, Almstead and D. R. Jones;
PCT Int. Appl. WO 02 89, 799 (Cl. A61K31/4439) (2002); Chem. Abstr., 137, 370086j (2002).
95.  T. Z. Gulhan, Pierre Chevallet, S. K. Fatma and Kevser Erol.;
Eur. J. Med. Chem., 35, 635-41 (2000).
96. A. M. Abdela, Tuntawy, Atif, Fatema;
Chim Pharm. J., 47(1), 37-45 (1995); Chem. Abstr., 123, 228016d (1995).
97. Shalabh Sharma, Virendra Kishor Srivastava and Ashok Kumar;
Eur. J. Med. Chem., 37, 689-97 (2002).
98. N. Gokhan, A. Yesilada, G. Ucar, K. Erol and A. A. Bilgin;
Arch Pharm (Weinheim). 336(8), 362-71 (2003).
99. J. Matysiak and A. Niewiadomy;
Bioorg. Med. Chem. 11(10), 2285-91(2003).
100. Z. Tabarelli, M. A. Rubin, D. B. Berlese, P. D. Sauzem, T. P. Missio and M. V. Teixeira;
Braz. J. Med. Biol. Res. 37(10), 1531-40 (2004).
232
101. Tae-Sook Jeong, Kyung Soon Kim, Ju-Ryoung Kim, Kyung-Hyun Cho, Sangku Lee and
Woo Song Lee; Bioorg. Med. Chem. letters 14(11), 2719-2723 (2004).
102. K. Satyanarayana and M.N.A. Rao;
European J. Med. Chem., 30, 641-645 (1995).
103. Manna Fedele et. al.;
Bioorg. and Med. Chem. Letters, 15, 4632-4635 (2005).
104. Y. Rajendra Prasad, A. Lakshmana Rao, L. Prasoona, K. Murali and P. Ravi Kumar;
Bioorg. and Med. Chem. Letters, 15, 5030-5034 (2005).
105. Jones David et. al.;
Bioorg. and Med. Chem. Letters, 15, 3203-3206 (2005).
106. Abd E. Amr, Nehad A. Abdel-Latif and Mohamed M. Abdalla;
Bioorg. and Med. Chem., 14, 373-384 (2006).
107. Mohammad Shaharyar et. al.;
Bioorg. and Med. Chem. Letters, 16, 3947-3949 (2006).
108. M. Shaharyar et. al.;
Bioorg. and Med. Chem. Letters, xx, xxx (2006).
109. Asha Budakoti, Mohammad Abid and  Amir Azam;
European J. Med. Chem., 41, 63-70 (2006).
110. S. D. Sorthiya, V. B. Patel and A. R. Parikh;
Indian J. Chem. Soc., 24, 238 (1997).
111. Oza Haresh, Joshi Dharti and Parekh Hansa;
J. Inst. Chem. (India) (1998); Chem. Abstr.,130; 139682 (1999).
112. Akhil Bhatt, H. H. Parekh and A. R. Parikh;
Heterocyclic Commun., 4(4), 361-66, (Eng.); Chem. Abstr., 130, 25006x (1999).
113. Tejas A. Upadhyay, Jawalant A. Shastri and H. H. Parekh;
Orient. J. Chem., 18(1), 175-76, (2002).
114. Sohit Rajvaidya, Jaladhi Vasavada and  H. H. Parekh;
Ind. J. Chem., 42 B, 906-908, (2004).
115. A. V. Dobaria, J. R. Patel and H. H. Parekh;
Ind. J. Chem., 42 B, 2019, (2003).
116. M.A. El. Hashan, M. El-Kady, M.A. Saiyed and A.A. Elsawy;
Egypt. J. Chem., 27(6), 715-21 (1985) (Eng.); Chem. Abstr., 105, 208684 (1986).
117. A. Sammour, Y. Akhnookh and H. Jahine;
U.A.R. J. Chem., 13(4), 421-37, (1970); Chem. Abstr., 77, 101348q (1972).
233
118. L. S. Crawley and W. J. Fanshawe;
J. Heterocycl. Chem., 14, 531, (1977).
119. A. Chan Seng and Brimble Margaret;
Aus. J. Chem., 1998; Chem. Abstr.; 129, 16105f (1998).
120. A. Khalafallah;
Asian J. Chem., 8(4), 951-96 (1996).
121. D. J. Brown;
Heterocycl. Compd., 16.
122. E. C. Taylor and R.W. Morrison;
J. Org. Chem., 32, 2379 (1967).
123. Ms. B. S. Hastak and B.J. Ghiya;
Indian J. Heterocycl. Chem., 2, 133-135 (1992).
124. P. A. Mehta and H. B. Naik;
Oriental J. Chem., 14(1), 159-60 (1998); Asian J. Chem., 10(4), 1017-8 (1998).
125. E. A. Mohamed, R. M. Abdel Rahman, A. A. Sayed and M. M. Ismail;
Indian J. Chem., Soc., 69, 82 (1992).
126. K. P. Jadhav and D. B. Ingle;
Indian J. Chem., 22B, 180 (1983).
127. P. S. Utale, P. B. Raghuvanshi and A. G. Doshi;
Asian J. Chem., 10(3), 597-99 (1998).
128. S. W. Pfleiderer and H. Mosthafa;
Synthetic Org. Chem., B90, 738 (1957).
129. Rasaki Abayomi Osisany and James Olabisi Oluwadiya;
J. Heterocycl. Chem., 26, 947 (1989).
130. K. Folkers and S. A. Harris;
J. Am. Chem. Soc., 61, 1245 (1939).
131. M. R. Mahmoud, Awatef E. F. E., M. S. Abd-El-Halim and A. M. Radwan;
Indian J. Heterocycl. Chem., 4, 131-36 (1994).
132. A. Y. Deshmukh, P. B. Raghuwanshi and A. G. Doshi;
Oriental J. Chem., 18(1), 101-104 (2002).
133. P. L. Nayak and N. K. Rout ;
J. Indian Chem. Soc., 52, 801 (1975).
134. V. R. Mudaliar and V. Joshi ;
Ind. J. of Chem., 34(B), 456 (1995).
234
135. Tashio Pharmaceutical Co. Ltd. ;
Japan, kokai Tokkyo Koho Jp. 59, 12, 094 (84, 12, 094) (Cl A 61 K 31/215); Chem. Abstr.,
101, 54722j (1984).
136.  R. De Vincenzo, Seambla G. Panici, P. Benedess and F. O. Remelletti;
Anticancer drug. Res., 10(6), 481-90 (1995); Chem. Abstr., 124, 247r (1996).
137. Ha Rui and Gu Zong;
Chem. Abstrt., 128, 110862b (1998).
138. Ni Liming,  K. J. Worsencrott, M. D. Weingarten,  C. Q. Meng and J. A.Sikorski;
U. S. US WO 02 41336 (2002); Chem. Abstr., 139, 85160 (2003).
139. Ko Horng-Huey, Tsao Lo-Ti, Yo Kun-Lung, Cheng-Tsung, J. P. Wang and C. N.Lin;
Bioorg.  & Med. Chem., 11(1), 105-111 (2003); Chem. Abstr., 139, 30144 (2003).
140. S. R. Modi and H. B. Naik ;
Orient J. Chem., 10(1), 85-6 (1994); Chem. Abstr., 112, 81186c (1995).
141. A. Attia, O. J. Abdetsulan and Abo-Ahalia;
Egypt J. Chem., 1995; Chem. Abstr., 125, 10570z (1996).
142. V. M. Gaurav and D. B. Ingle ;
Indian J. Chem., 25B, 868 (1986); Chem.Abstr., 107, 39321h (1987).
143. A. K. Pedersen and G. A. Fitz Gerald ;
J. Pharm. Sci., 74(2), 188 (1985); Chem. Abstr., 103, 87592m (1985).
144. D. Binder, C. R. Noe, W. Holzer and B. Rosenwirth ;
Arch. Pharm. 318(1),48 (1985); Chem. Abstr., 102, 149025u (1985).
145. M. R. Bell ;
US Appl. , 637, 931 (1984); Chem. Abstr., 113, 211828t (1990).
146. E. T. Ogansyan et al. ;
Khim. Farm. Zh., 25(8), 18 (1991); Chem. Abstr., 115, 247497n (1991).
147. S. Satoshi, N. Yasunori and U. Hiroki;
J. Med. Chem., 1993, 3904-9 (Eng.); Chem. Abstr., 120, 133956j (1994).
148. Kammei, Hideo, Koide, Tatsurou; Hashimato Yoko, Kojima, Takashi, Hasegawa and Makoto;
Chem. Abstr., 126, 258666v (1997).
149. Kumar Srinivas K.,  E. Hager, C. Pettit, H. Gurulingappa, N. E. Davidson and S. R. Khan;
J. Med. Chem., 46(14), 2813-15 (2003); Chem. Abstr., 139, 117464 (2003).
150. Li Rongshi, Chen. Xiawa., Gong Baogung, Qominguez and Jose N. et al.;
J. Med. Chem., 38(26), 5031-7 (1995); Chem. Abstr., 124, 232f (1996).
151. O. Toru, O. Yoshihito and S. Shoji;
Jpn. Kokai Tokkyo Koho JP 11 349, 521; Chem. Abstr., 132, 22752t (2000).
235
152. Nakahara Kazuhiko, Torakoontiwakon G., Kameyama M., Ono Hiroshi and Yoshida Mitsuru;
Jpn. Kokai Tokkyo Koho JP 03 040829 (2003); Chem. Abstr., 138, 158753 (2003).
153. F. S. Nielsen and S. B. Chirstensen;
J. Med. Chem., 41, 4819-4832 (1998).
154. Ezio Bombardelli and V. Piero;
PCT Int. Appl. WO 98, 58,913; Chem. Abstr., 130, 95382r (1999).
155. S. Elichi and K. Koji;
PCT Int. Appl. WO 99 61, 403; Chem. Abstr., 132, 12199d (2000).
156. Opletalova Veronika, L. Jahodar, D. Jun and L. Opletal;
Ceska a Slovenska Farmacie, 52(1), 12-19 (2003); Chem. Abstr., 138, 265043 (2003).
157. N. N. Mateeva, R. N. Kode and K. K. Redda;
J. Heterocycl. Chem., 39(6), 1251-58 (2002); Chem. Abstr., 138, 401568 (2003).
158. Wu Jiu-Hong, Wang Xi-Hong, Yi Yang-Hua and Lee Kuo-Hsiung;
Bioorg. & Med. Chem. lett., 13(10), 1813-1815 (2003); Chem. Abstr., 139, 146483 (2003).
159. A. L. Barry;
The Antimicrobial susceptibility Test principle and practises edited By illus Lea and
Febiger; (Philadelphia pel. U.S.A.) 180; Bio Abstr., 64, 25183 (1970).
160. Albert Adrien;
Heterocyclic Chemistry 2nd Ed. Athlane Press, London 1968.
161. R. M. Acheson;
An Introduce to the Chemistry of Heterocyclic Compound 2nd Ed. Interscience 1967.
162. G. M. Badger;
The Chemistry of Heterocyclic Compound, Academic Press, New York 1981.
163. Karritzsky and Logowskii;
The Principle of Heterocyclic Chemistry, Mathaen, London 1967.
164. C. C. Chang;
Progress in Medicinal chemistry, 1969.
165. S. Inoue, A.J. Saggimoto and E.A. Nodiff;
J. Org. Chem., 26, 4504 (1961).
166. H. Bredereck, Effenberger and H.J. Treiber;
Chem. Ber; 96, 1505 (1963).
167. P. Krohnke, E. Schmidt and W. Zocher;
Chem. Ber., 97, 1163 (1964).
168. E. C. Taylor and Jr. R.W. Morrison;
J. Org. Chem., 32, 2379 (1967).
236
169. D. J. Brown;
Chem. Heterocycl, Compd., 16-51, 20 (1970).
170. Rasaki Abayomi Osisanya and  James  Olabisi  Oluwadiya;
J.  Heterocyclic Chem.,  26, 947 (1989).
171. Y. L. N. Murthy and G. Jagmohan;
Indian  J.  Heterocyclic Chem., 8, 277-80 (1999).
172. Abd El-Gail, and E. Amr.;
Indian  J.  Heterocyclic Chem., 10,  49-58 (1999).
173. G. W. Anderson, I. T. Halverstadt, W. H. Milier and Jr. R. O. Roblin;
J. Amer. Chem. Soc, 67, 2197 (1945).
174. C. W. Whitehead and J. J. Traverso;
J. Am. Chem. Soc., 78, 5294 (1956).
175. V. N. Berezovskil et. al.;
Xurkevich Zh. Ohschch. khim.,  32, 1655 (1962).
176. D. J. Brown and P. Waring;
Aust. J. Chem.,  30, 621 (1977).
177. W. Jinjun, Z. Jianmin, and C. Bingzi;
Huazue Tonghao.,  10, 48-50 (1977).
178. N. R. El-Rayyes;
Jou. of Heterocyclic Chem.,  Vol. 19,  p. 415,  (1982).
179. S. Sarangam and S. Samshekara;
J. Indian Chem. Soc.,  53 (1976), Chem. Abstr., 99, 139889 (1983).
180. Z. Machan and V. Krystyna;
Acta. Pol. Chem., 42(B), 516 (1985).
181. R. P. Verma, S.M. Sondhi, Nidhi Singhal, V. K. Sharma, R. Shukla, and G. K. Pathaik;
Phosphorous sulfur, silicon Relat. Elem., 118, 7-19 (1996).
182. V. J. Ram, D. A. Vanden Bergne, and A. J. Viietinck;
Liebigs Ann. Chem.,  797 (1987).
183. V. J. Ram;
J. Prakt. Chem.,  331, 893 (1989).
184. V. J. Ram, N. M. Haqu, and P. Y. Guru;
Eur, J. Med. Chem.,  27, 851 (1992).
185. M. Ali, A. G. Hamma and S. Mohmad.;
J. Phosphorus and sulfur.,  39, 24 (1988).
237
186. A. G. Hamman. S. M. Husain and I. R. Kotab;
J. Phosphorous, Sulfur and Silicon.,  47, 47 (1990).
187. C. R. Petric, H. B. Cotton and P. A. Mekerman;
J. Med. Chem.,  28, 1010, (1988).
187. C. Hansch, P. G. Sammes and J. B. Taylor;
Comprehensive Medicinal Chemistry., Vol. 21st Addition P. G. Sammer 323-324 (1990).
188. K. Deo, K. Avasthi, R. Pratap and D. S. Bhukumi;
Indian J. Chem.,  28(B),  237 (1998).
189. A. Mishra, L. M. Ojha, R. P. Tripathi, R. L. Pratap and D. S. Bhakumi;
Indian J. Heterocycl. Chem.,  1, 51 (1991) Chem Abstr.,  117, 48457, (1992).
190. Jureg Zimmermann;
U.S. 5, 521, 184 (Cl.  514-252; C07  D239/92) ;  Chem. Abstr.,  125, 114681c  (1996).
191. Walter and  Herald;
PCT  Int.  Appl.WO  99 14,  202  (Cl. C07  D239/00)(1999); GB  Appl.  97/19,  411  (1997);
Chem. Abstr., 131, 252368k (1999).
192. V.K Ahluwalia, R. Batia, A. Khurana. and R. Kumar;
Indian J. Chem.,  29(B) 1141 (1990).
193.  A. L. Kovalenko, V. I. Krutika, M. M. Zolotukhina and L. E. Alekseava;
Zh.  Obsch.  Khim, 62(6),  1363-66 (1992);  Chem. Abstr., 118, 101909r (1993).
194. A. S. K. Anjaneyulu, G.  Sudha Rani, U. V. Mallavadhani and  Y.  L. N. Murthy;
Indian  J.  Heterocyclic Chem., 4, 277-80 (1995).
195. M. Okabe, R. C. Sun and G. Zenchoff ;
J. Org. Chem.,  56, 4393, (1991).
196. N. Dhanapalam; Wong an et. al.;
PCT Int. Appl. WO 97 17, 969 (Cl  A61K  311505), 22 May 1997, vs Appl. 648, 770, 16
May 1996; Chem. Abstr., 127,  5, 657837 (1997).
197. K. Nicholas, M. Premji and T. Stephem;
PCT Int. Appl., WO 98 54, 180 (Cl. C07D417106) Dec. 1998; Chem Abstr., 130, 38394
(1999).
198. Robert, Gerhard, Markus, Olaf and Cryill;
PCT Int. Appl., WO 99 31, 091 (Cl. CO7D413/04) 24 June, 1999; Chem. Abstr., 130,
58844t (1999).
199. Harris Boschelli Diane, Ellen  Mura Dobrusin and Annette Marian Doherty;
PCT Int. Appl. WO 98 33, 798; Chem. Abstr., 129, 3700a (1998).
238
200. Jean Paul Bosmas,  Marie Andre Rene and Christopher  John;
EP 97 43,  279; Appl. 96/201,  283; Chem. Abstr., 128, 34778m (1998).
201. K. G. Bothara,  S. S. Kadam; V. Sai Shivram;
Indian  Drugs  35(6)  (1998);  Chem. Abstr., 129,  245107a (1998).
202. Kitano, Yasunori; Kawahara, Eiji; Takayanagi, Hisao,  Suzuki, Takeshi,  Ohya, Atsushi;
Hara and Hiroto;
Jpn.  Kokai Tokkyo Koho  JP  11,  80, 131 (Cl.  C07  D239/74)(1999);  Appl.  97/251,  348;
Chem. Abstr., 131, 267450e (1999).
203. Hashimoto,  Shinsuke;  Shirochi,  Tatamitsu,  Shintani,  Telsuya;  Ishikawa,  Masayuki;
Jpn. Kokai Tokkyo Koho  JP  11, 92,  458 (Cl. C0 7D239/42)  (1999);  Appl.  97/254, 393;
Chem. Abstr., 130, 237595p  (1999).
204. A. S. Noravyan,  Sr. A. Oranisyan, G. O. Grigoryan and S. Vartanyan;
Chem. Abstr., 126, 70176f (1997).
205. A. Hozein Zeinab, A. A.  Abdel Wahab and K. M. M. Hassan;
Pharmazie, 52(10), 753-58 (1997).
206. Mona Mohran, A El-Sherbeny Megda, El-Obaid, M. A. Abdul-Rahman, and Badria arid;
J. Pharm. Sci., 12(1), 39-44 (1998).
207. Erker Thomas,  Heistracher Peter,  Gruber Rosu Lemtnens, Andreas Lexer, and Maria
Schreder Austria;
Austria AT  403, 918 (1998); Chem. Abstr., 129, 260462n (1998).
208. Breozowski Zdzislaw;
Po l .  PL  173, 244; Chem. Abstr., 129, 148982z (1998).
209. Nakatsuka Masashi, Okada Shinichiro, Shimano Kazuori and Watanake Shoji;
PCT Int. Appl. WO  98, 42688 (1998); Chem. Abstr., 129, 275918h (1998).
210. Mario Leone, Maurizio Zenoni, Serra Maurizio and Filippi Mauro;
PCT Int. Appl. WO 99, 23, 082 (Cl. C07D 277/16) (1999); Chem. Abstr., 131, 352134z
(1999).
211. Muneo Takatani, Yasuo Sugiyama, Tetsuji Kawamoto and Koji Adachi;
PCT Int. Appl. WO 99, 20, 632 (Cl. C07D513/16) (1999); Chem. Abstr., 131, 31179w
(1999).
212. Kenneth R. Scott, Mia L. Laws, Ralph R. Roberts and Jesse M. I.Nicholson;
PCT Int. Appl. WO  99, 21, 560 (Cl. A61K31/54) (1999); Chem. Abstr., 131, 311808j
(1999).
213. Schiafella Fansto, Guarruci Alessia, Fringuell, and Renak, Pitzurra Lucia;
Med. Chem. Res., 1999, Chem. Abstr., 132, 78519g (2000).
239
214. A. Shafiee and B. Ahadzadeh;
J. Sci. Islamic Repub. Iron 1998; Chem. Abstr., 132, 122558c (2000).
215. Abou El otooh, G. Hamman, A. M. Sharaf and N. A. Abd El-Hafez;
Indian J. Chem., 40B, 213-221 (2001).
216. N. M. Saleh, N. M. Shieis and S. A. Mohamed;
Chem. Abstr., 136, 118422u (2002).
217. M. M. Burbuliene, E. Udrenaite, P. Gaidelis and P. Vainilavicius;
Polish Journal of Chemistry 76(4), 557-563 (2002); Chem. Abstr., 137, 154892b (2002).
218. Okamura, Takashi, Kurogi, Yasuhisa; Nishikawa and Hiroshi;
PCT Int. Appl. WO 02, 62, 801 (Cl. C07D 487/14) 15. Aug. 2002, J. P. Appl. 2001/28,
831, 5 .eb. 2001; 77 pp.; Chem. Abstr., 137, 154943u (2002).
219. S. A. El-Essa and M. A. Salama;
Indian Journal of Chemistry, 41B, Jan. 2003, 173-179.PCT Int. Appl. WO 03 40, 141
(Cl. C07D 413/14); Chem. Abstr., 138, 24, 860 (2003).
220. Hisaki Masakatsu, Ohta Yochiro and  Kawanishi  Kenji;
Eur. Pat. Appl. EP 97,  806, 418; JP Appl., 96/115, 147; Chem. Abstr., 128, 22917f (1998).
221. Robson Claire, Wright Karenk,  Peter R. Twentymen and Peter Lambert;
Biochim.  Pharmcol., 56(7),  807-16  (1998); Chem. Abstr., 128,  22917t (1998).
222. Robert Leanne; Steven M. Hannick;  Michael Rasmussen;  Tien and Heh J. Jien;
PCT  Int.  Appl.  WO  98  34,  917  (Cl.  C07  D73/00)  (1998);  US  Appl.  908,  754  (1997);
Chem. Abstr., 129, 175918q  (1998).
223. Yamada Kouichiro; Yasuda  Kosuke;  Yoshikawa Kokei, Kono and Rikako;
Jpn. Kokai Tokkyo Koho JP 10 226, 649 (Cl. A61 K31/505) (1998); JP Appl. 96/331, 701
(1996); Chem. Abstr., 129,  216624m  (1998).
224. Mark J. Suto; Leah M. Gayo; Moorthy S. S. Palanki; Fong Ransone and J. Lynn;
PCT  Int.  Appl.  WO 98 38,  171  (Cl.  C07  D239/28)  (1998);  US  Appl.  807, 677 (1997);
Chem. Abstr., 129, 216625n  (1998).
225. Gangjee, Aleen;  Zhu, Yuanming; Queener and Sherry;
J.  Med. Chem.,  41(23), 4533-4541 (1998); Chem.  Abstr., 130, 13966x  (1996).
226. Ugarkar,  G. Bheemarao; Erion,  D. Mark; Gomez, and Jorge E. Galeno;
U.S.  US  5,  795, 977  (Cl.  536-27;  C07  H19/16)  (1998);  US  Appl.,  473  (1995);
Chem.  Abstr., 129,  175920j (1998).
227. Franco Hernandez, Laura;  Bal de Joffe, Elisa;  Purielli, Lydia; Tatian, Mareos; Seldes.
Alicia;
J. Nat. Prod.,  61(9)  (1998);  Chem. Abstr., 129,  260618m (1998).
240
228. John A. Secrist, Kamal N. Tiwari, Shortnacy-Fowler; Anita T.  Massini and Riordan;
J. Med. Chem.,  41(20), 3865-3871 (1998);   Chem. Abstr., 129,  290350k (1998).
229. Arnold Glazier,  Muka Yanachkova, Yanachkor and Ivan;
PCT  Int.  Appl.  WO  98  51,  692  (Cl.  C07  .965/61)  (1998);  US  Appl.  50,  220  (1998);
Chem. Abstr., 130, 14167z  (1999).
230. Janak Singh. Bisacchi,  S. Gregory,  Saleem Ahmad, Gadfrey and D. Jollie;
Org.  Process  Res.  Dev., 2(6), 393-399 (1998); Chem.  Abstr.,  130, 4011e (1999).
231.  Pan Senliang;  Michael Bukrinsky; Haffar and K. Omar;
U.S. US 5, 808, 068 (C07D239/24) (1998); Appl. 912, 076 (1997); Chem. Abstr., 129, 245162q
(1998).
232. S. N. Pandeya, Sriram D. Nath and E. De Clercq;
IL Farmaco,  54(9),  624-8 (1999).
233. R. Costi, R. Disanto, M. Artico,  A. Lavecchia and T. Marceddu;
Antivir  Chem. Chemother,  11(2), 117-33 (2000).
234. Z. Kazaimierczuk, A. Gorzka, T. Switaj and W. Lasek;
Bio.  org. Med.  Chem. Lett.,  11(19), 1197-200  (2001).
235. Alberto Bargiotti,  Antonella Ermoli,  Maria Menichincheri,  Ermes Vanotti, Bonomini,
Luisella and  Antonella;
PCT  Int.  Appl.  WO  02  90, 357  (Cl.  C07  D473/18);  GB  Appl.  2001/11, 071; Chem.  Abstr.,
137, 352825v (2002).
236. Aleem Gangjee;
U. S. US  6,  423  720(Cl.  514-272;  A61K31/505);  2002,  Appl.  775,  064,  7  .eb.  2001;
 Chem.Abstr., 137, 109289z (2002).
237. Zu Jianming,  Aleem  Gangjee, Kisliuk, William  H.  Haile,  Giukia  Sobrero and John  J.
McGuire;
J. Med. Chem., 46, 4 591 (2003).
238. Tsutsumi; Hideo, Yonishi, Satoshi,  Akahane and Atsushi;
PCT  Int. Appl. WO 03  57, 689 (Cl. C07 D403/04); AU Appl.  2002/2,  002, 2002;
Chem.  Abstr., 139,  117434z  (2003).
239. Miura Tooru, Wada Masaru, Uruya Masayuki and Nagato Teruyuki;
Jpn. Kokai Tokkyo Koho JP, 01, 160, 932 (1990); Chem. Abstr.,  112, 35332t (1990).
240. Matsuoka Rikitaro and Watanabe Kiyoshi;
Jpn. Kokai Tokkyo Koho JP, 04, 316, 556 (1993); Chem. Abstr., 118, 14749b (1993).
241.   Gemma Esteban, Mighei A. Lopez-Sanchez, Martinez Maria Engenia and Plumert Joaquin;
  Tetrahedron, 1998; Chem. Abstr.,  128, 114765v (1998).
241
242. Carieno M. Carmen, Perez Gonzalez, Maria Manual Ribagorda and K. N. Houk;
J. Org. Chem.,  1998;  Chem. Abstr.,  129, 54166j (1998).
243. E. M. Hammouda, E. G. Sadek and A. M. Khalij;
Indian J. Heterocycl. Chem.,1998; Chem. Abstr.,  130, 81476n (1999).
244. Francisco Palacious, Esther Herran and Gloria Rubiales;
J. Org. Chem.,  64(17), 1999; Chem. Abstr.,  131, 243104u (1999).
245. Taber Douglass, Kazuo Kanai, Qiro Jiang and Gina Bui;
J. Am. Chem. Soc., 2000; Chem. Abstr., 133, 178965x (2000).
246. N. Nanjundaswami, K. M. Lokanatha Rai and S. Shashikanth;
Indian J. Chem.,  40B, 274-277 (2001).
247. H. A. Eman,  S. M.Hassan and A. A. El- Mayhaby;
J. Serb Chem. Soc. 1997; Chem. Abstr., 127, 190698u (1997).
248. Shklyaev,  Yu. V. Nifortov, A. S. Shashkov and S. I. Firgang;
Russian  Chemical Bulletin 2002, 51(12), 2234-2237; Chem. Abstr., 139, 36429z (2003).
249. Gerald Duker, PeterFrundt, Hardu Markwitz and Gerald Henkel;
J. Org. Chem. 1998.
250. Philip C. Page, Allan P. Marchington, Lisa J. Graham, Shaun A. Harkin and William Wood;
Tetrahedron, 1993; Chem. Abstr., 120, 2448801d (1994)
251. Felix  A. Raymound;
U. S.  US  4, 336, 062  (Cl. 71-98,  A01  N31/00)  (1982); Chem. Abstr.,  97,  144458f (1982).
252. Lawrence S. Melvin and Michael R. Johnson;
U. S. US  4, 379, 783 (Cl. 424-184, A61K31/695); Chem. Abstr., 99, 22684x (1983).
253. K. Nagarjan and S. J. Shenoy;
Indian J. Chem., Sec. B, 1987; Chem. Abstr.,  108, 150224p (1988).
254. Keneth R. Scott, Jesse M. Nicholson and Ivan O. Edatiogho;
PCT Int. Appl. WO  93, 17, 678; Chem. Abstr.,  120, 233914u (1994).
255. M. G. Assy and A.A Hataba;
J. Indian Chem. Soc., 1997; Chem. Abstr.,  127, 5060v (1997).
256. Shimazaki Toshiyuki and Yamashita Hiroyashi;
Jpn. Kokai Tokkyo Koho JP, 09, 118, 653; Chem. Abstr.,  127, 3410j (1997).
257. Albaugh Pamela, Liu Gang and Alan Hutchison;
U.S. US  5, 723, 462 (1998); Chem. Abstr., 128, 204804m (1998).
258. Lilian Alcaraz and  Richard Taylor;
Chem. Commun. 1998; Chem. Abstr., 129, 95339m (1998).
242
259. Auton Copar et. al.;
Eur. Pat. Appl. EP. 854, 143; Chem. Abstr., 129, 148908e (1998).
260. Poul Jacobsen, Sevend Trappendahl, Bury Paul Stanley, Anders Kanstrup and  Lise
Brown  Christiansen;
PCT Int. Appl. WO, 98, 18,777; Chem. Abstr., 128, 321562s (1998).
261. T. N. Dzhalilov, T. A. Gasanov and  A. Budagyant;
U.S.S.R. 815, 007 (Cl. C07 C 103/19) (1981); Chem. Abstr.,  95, 80282t (1981).
262. Michael Keil, Ulrich Schirmer, Dieter Kolassa, Wilhelm Rademacher and Johan Jung;
Ger. Offen. DE 3, 604, 871 (Cl. C07 C 49/753); Chem. Abstr., 108, 37277v (1988).
263. Keishrio Nagao,  Akio Suzuki and Masazumi Nakagawa;
Jpn. Kokai Tokkyo Koho JP,  62, 89, 660 (1988); Chem. Abstr., 108, 94379d (1988).
264. David J. Collis, John D. Cullen and Graant M. Stone;
Aust. J. Chem., 1998; Chem. Abstr., 110, 94655g (1989).
265. E. L. Tvanov, P. Konupl,  L. A. Konup, D. E. Stepanov and K. V. Groshcha;
Khim. .arm. Zh., 1993; Chem. Abstr., 121, 35462w (1994).
266. V. K Ahluwalia, Pooja Sharma and Bindu Goyal;
I. J. Chem., 36B, 519, 1997.
267. L. M. Alkekseeva, E. S. Krinchevskii, O. S. Anisimova, V. A. Parshin, V. V. Ashina and
V. G. Granik;
Khim. .arm. Zh., 1997; Chem. Abstr., 128, 244027s (1998).
268. Joachim Rheinheimer, Maywald Volker, Ume Kardorff, Karl-Otto Westphalen and Ulf Misslitz;
PCT Int Appl. WO 98, 30, 565 (Cl. C07D493/04) (1998); Chem. Abstr., 129, 122655v (1998).
269. Kenzo Harimaya, Emiko Magome, Yuji Tabato and Toru Sasaki;
Eur. Pat. Appl. EP 820, 995 (Cl. C07D307/92)  (1998);  Chem. Abstr.,  128, 154254j (1998).
270. Stepfan Engle, Ernst Baumann, Von Deyn, Gang Wolf and Hill Regina Luice;
Chem. Abstr., 130, 450c (1999).
271. M. A. Salama and M. A. Atshikh;
Egypt J. Pharm. Sci. 1997; Chem. Abstr., 130, 81478q (1999).
272. Takehiro and Kamatani Akiolhara;
PCT Int. Appl. WO  99, 15,516; Chem. Abstr., 130, 237476a (1999).
273. Kimura Yasuo, Mizuno Takashi, Kawano Tsuyoshi and Shimada Alsami;
Z. Naturforsch. B. Chem. Sci., 1999; Chem. Abstr., 132, 35551b (2000).
274. Broughton Howard Barff, Br Yant Helen Jane, Chambers Mark Stuart and Curtis Neil Roy;
PCT Int. Appl. WO 99, 62, 899; Chem. Abstr., 132, 12259y (2000).
243
275. Stefan Hermann, Dorothee Hoischen et. al.;
Ger. Offen. DE 10,  136,449 (Cl. C07D 231/20) (2002); Chem. Abstr., 137,  353015t (2002).
276. Natalie D. Eddington, Donna S. Cox, Ralph  R. Roberts, Raymond J. Butcher, Iven O.
Edafiogho, James P. Stables and Neville Cooke;
Eur. J. Med. Chem.,  37, 635-648 (2002).
277. Bastiaan J. Venhuis, Durk Dijkstra, David  J. Wustrow,  Leonard  J. Meltzer, Hakeen V.
Wikstrom;
J. Med. Chem.,  46(4), 584-90 (2003).
278. Tadashi Honda, Nanjoo Suh  et. al.;
PCT Int.  Appl. WO 03,  59,339  (Cl.  A61K31/215) (2003); Chem. Abstr., 139, 133695r
(2003).
279. Jaladhi A.Vasavada and H. H. Parekh;
J. Ind. Chem. Soc.,  80(1), 55-56  (2003).
280. Chengzhi Zhang, Michael Burke et. al.;
PCT Int. Appl. WO 03, 72, 566 (Cl. C07D 307/92) (2003); Chem. Abstr., 139,  22166z (2003).
281. J. B. Dickey and A. R. Gray;
Org. Syn. Coll. 2, 60 (1943).
282. C. B. Reese and S. R. James;
Tetrahedron Letters, 29, 15 (1975).
283. Cao-Yan Weu, Chai Xain Dong, Jiang Yue-Shan et al.;
Gaodeng Xuexiao Huaxue Xuebao, 16(2), 225-29 (1995); Chem. Abstr., 123, 33021u (1995).
284. M. R. Mahamoud, Awatef E. F. Ebrahim, M. S. Abd El-Halim and A. M. Radwan;
Indian J. Heterocyclic Chem., 4, 131-36 (1994).
285. Funda Ougus and Liknur Dogan;
Chem. Abstr., 129, 16097e (1998).
286. S. C. Harvey in “The Pharmacological Basis of Therapeutics” ed. L. S. Goodmann and A.
Gilman; Macmillan, New York, 5th edition, p. 102 (1975).
287. S. C. Harvey in “The Pharmacological Basis of Therapeutics” ed. L. S. Goodmann and A.
Gilman; Macmillan, New York, 5th edition, p. 124 (1975).
288. L. Weinstein in “The Pharmacological Basis of Therapeutics” ed. L. S. Goodmann and A.
Gilman; Macmillan, New York, 5th edition, p. 1113 (1975).
289. C. I. Chappel and C. Von Seeman;
Prog. Med. Chem. 3, 89 (1963).
290. Malcom Daniels and Alec Grimison;
U. S. US Pat. 13, 150, 137 (1964); Chem. Abstr., 59, 7539c (1963).
244
291.  J. M. Cox, C. D. Snowling and M. C. Shepard;
German Often, 2, 812, 367 (1978); Chem. Abstr., 90, 82129u (1978).
292. Z. H. Khalil, A. I. M. Koraiem and R. M. Abu-El-Hammed;
J. Chem. Technol., Biotechnol., 36, 473 (1986).
293. Y. K. Gupta, K. P. Bhargava, K. Shanker and J. C. Agarwal;
Indian J. Chem., 20B, 714 (1981).
294. J. C. Agarwal, Y. K. Gupta, P. Kumar, C. Nath, K. P. Bhargava and K. Shanker;
Indian J. Chem., 22B, 955 (1983).
295. G. P. Gupta, Sharda Singh and K. Shanker;
Indian J. Chem., 24B, 1094 (1985).
296. Y. Furukawa;
European Patent Appl. EP. 88 413 (1983); Chem. Abstr., 100, 22688 (1983).
297. Ulf Wellmar, Anna-Britta Hornfield and Salo Gromowitz;
J. Heterocyclic Chem., 32, 1159 (1995).
298. D. Peters, A. B. Hornfield and S. Gromowitz;
J. Heterocycl. Chem., 27, 2165 (1990).
299. P. A. M. Herdwijin;
Antiviral Chem. Chemother., 5, 131, (1994); J. Heterocyclic Chem., 32, 1159, (1995).
300. Raymond P. Daine and Wei Wang;
J. Heterocyclic Chem., 30, 1399 (1993).
301. M. R. Mahmound, M. S. Abd, El-Halim and A. M. Radwan;
Indian J. Heterocyclic Chem., 4, 131-36 (1994).
302. R. F. Burns;
Biochim, Pharmacol., 30, 325 (1981); J. Heterocyclic Chem., 33, 1025 (1996).
303. A. G. Manukyan, R. G. Malik and B. T. Guribidzhanyan;
Khim-Pharm, Zh., 19, 685 (1985); Chem. Abstr., 104, 207622s (1996).
304. Wolf-Gang, Hanefeld and Helge Hurms;
Indian J. Heterocyclic Chem., 34, 509 (1997).
305. Andre Roland, Dollinger Markus and Erdelen Christopher;
Ger. Offen DE 19, 715, 017 (Cl. CO7D 401/12) (1998), Appl. 19, 715, 017, (1997);
Chem. Abstr., 129, 302655d (1998).
306. M. T. Omar;
Egypt J. Pharma. Sci. 1997, 38 (4-6), 281-89 (1997), Chem. Abstr., 131, 257514k (1999).
307. Sakai  Kunikazu and Satoh Yusuke;
PCT Int. Appl. WO 99 50, 252 (Cl. CO7D 239/62), Chem. Abstr., 131, 243286a (1999).
245
308. Ambrogio Oliva, De Cillis, Gianpiero; Grams Frank, Livi Valeria et. al.;
PCT Int. Appl. WO 98 58, 925 (Cl. C07D 401/12); Chem. Abstr., 130, 95560x (1999).
309. W. Weber, J. Jaeger, M. Doelker and K. Eger;
Pharmazie, 53(11), 771-75 (1998); Chem. Abstr., 130, 95531p (1999).
310. Frank Grams and Zimmermann Gerd;
PCT Int. Appl. WO 98 58, 915 (Cl. C07 D 239/00); Chem. Abstr., 130, 95559d (1999).
311. R. T. Pardasani, S. K. Jain, S. K. Yadav and I. Sharma;
Indian J. Heterocycl. Chem., 12, 179-180 (2002).
312. D. L. Levesque, E. C. wang, D. C. Wei, C. C. Tzeng and R. P. Panzica;
J. Heterocycl. Chem., 30(5), 1399-1404 (1993); Chem. Abstr., 120, 217540g (1994).
313. I. M. Wyzlic, W. Tjarks, A. H. Soloway and D. J. Perkins,
Inorg. Chem., 35(16), 4541-47 (1996); Chem. Abstr., 125, 168582q (1996).
314. Shivanyuk Alexander., D. M. Rudkevich and D. N. Reinhoudt;
Tetrahedron Lett., 37(52), 9341-44 (1996); Chem. Abstr., 126, 144028h (1997).
315. Gursu Esin and Ulusoy Nuray;
Acta. Pharm. Turc., 38(4), 107-9 (1996); Chem. Abstr., 126, 59802m (1997).
316. Elmar Bosies, A Eswein, Frank Gram and Willi Krell Hans;
Ger. Offen., DE 19, 548, 624 (Cl. C07D 401/04) (1997); Chem. Abstr., 127, 121746x (1997).
317. S. G. Abdel Hamide, A El-Hakim and A. A.El-Helby;
Al-Azhar J. Pharm. Sci., 17, 35-40 (1996).
318. Li Laizhong, Liu Qingjian, Huang Ruqi and Wang hailing;
Hecheng Huaxue, 5(2), 197-8 (1997); Chem. Abstr., 128, 217351m (1998).
319. Gepper Dangmar, Frank Grams et. al.;
PCT Int. Appl. WO 02 79, 170 (Cl. C07D 239/62); Chem. Abstr., 137, 294967e (2002).
320. B. S. Holla and R. Gonzalves;
Boll. Chim. Farm. 137 (11), 467-472 (1998). Chem. Abstr., 131, 6, 73606k (1999).
321. M. S. Murray;
Chemical Review 26, 297-338 (1940).
322. Strache;
Ber., 21, 2361 (1888).
323. Van Alphen;
Dec. Tran Chim., 54, 93 (1935).
324. Rosaleen J. Anderson, Anderi S. Batsanov, Natalia Belskaia, Paul W. Groundwoqer and
Andrey Zaytsev;
Tetrahedron Letters., 45(5),  943-946, Jan. 2004.
246
325. Oddo and Tognacchini;
Gazz. Chim. Ital., 52, II, 347, (1922).
326.  Arima Das, Eric J. Lien and Trousdale D. Melvin;
Chin. Pharm. J. (Taipet) 49 (2), 89-102 (Eng.) (1997) ; Chem. Abstr., 128 (18), 217259n
(1998).
327.  Ergenc, Nedime, Uinsoy, Nuray, Capangultate, Soruis, Aulten Tuk, Kiraz and Mnammer ;
Arch. Pharm. 329 (8-9), 427-430 (1996); Chem. Abstr., 126, 1, 8031b (1997).
328. Pascal Rathelst, Nadine Azos, Hussain El-Kashef and Forence Delwasi;
Eur. J. Med. Chem., 57, 671-679 (2002).
329. R. P. Pawar, N. M. Anduskary and V. B. Vibhute;
J. Indian Chem. Soc., 76(5), 271-72 (Eng.) (1999); Chem. Abstr., 131, 677, 271829y
(1999).
330. Alexandru Cascaval, Stocia, Gheorghe-Zaharia and Berdan Ioan;
Rom. RO, 106, 403 (Cl. CO7D 231/04) (1993), Appl. 143, 707, 15, (1990); Chem.Abstr.,
129, 2, 491, 16120g (1998).
331.  Adnan A. Bekhil, Heshan T. V. Fahwy, Azzaim Baraka et. al.;
Eur. J. Med. Chem., 38, 27-56 (2003).
332. Wang Yangang, Ye Wenfa, Yang Jun., Lou Aihong, Wuhan Daxue Xuebao and Ziran
Kexueban;
(1996), 191-194 (Ch.); Chem. Abstr., 125 (13), 167488b (1996).
333. Smalders, Robert Rene, Brunin Dominique and Sarten Frederic;
Bull. Soc. Chim. Belg. 1988, 97 (11-12), 941-4 (Fr); Chem. Abstr., 112, 511,  21055t  (1990).
334. M. S. Yadawe and S. A. Patil;
Indian J. Heterocycl. Chem. 1992, 2(1), 41-2 (Eng).; Chem. Abstr., 118, 688,  22189q (1993).
335. R. H. Mehta, Sonal Shah and Rajeev Vyas;
J. Indian. Chem. Soc., 1992, 69(9), 590-2 (Eng.); Chem. Abstr., 119, 1088, 95268f  (1993).
336. A. K. Khalafallah and M. E. Hassan;
Aswan Sci. Technol. Bull. 1991, 12, 82-90 (Eng.); Chem. Abstr., 118, 918,  191392s (1993).
337. El-Din Sharaf and Nabaweya;
Delta J. Sci., 1991, 15(1), 47-56; Chem. Abstr., 118, 168756e (1993).
338. Chohan, Zahid Hussain, Kusuar and Somina;
Chem. Pharm., Bull., 1993, 41(5), 951-3 (Eng.); Chem. Abstr., 120, 1034, 134406s (1994).
339. Joydip Das and Anilk Singh;
Indian J. Chem., Sec. B. Org., Chem. Incl. Med. Chem., 1994, 33B(7), 615-17 (Eng.);
Chem. Abstr., 121, 1212, 205726e (1994).
247
340. M. D Deshmukh and A. G. Doshi;
Orient. J. Chem., 1995, 11(1), 85-6 (Eng.); Chem. Abstr., 123, 1111, 256269g (1995).
341. Wang Yangang, Ye,Wenta, Yang Jun. Lou, Aihong;Wuhan Daxue Xuebao and Ziran
Kexueban 1996, 191-194 (Ch.); Chem. Abstr., 125(13), 167488b (1996).
342. Arima Das, Lien,  J. Eric, Trousdale and D. Melvin;
Chin. Pharm. J. (Taipei.), 1997, 49(2), 89-102 (Eng).; Chem. Abstr., 128(18), 217259n (1998).
343.  Anjani Solankee, Pankaj Mistry and V. M. Patel;
Orient. J. Chem., 1997, 13(3), 289-292 (Eng).; Chem. Abstr., 128, 16, 192584z (1998).
344. Ram Tilak,  Ritu Tyagi, Bhawna Goel, K. K. Saxena, V.  K. Shrivastava and Ashok Kumar;
 Indian Drugs., 1998, 35(4), 216-221 (Eng.); Chem. Abstr., 129, 9, 641, 109052r (1998).
345. Ali Yousif, Al-Rawi Annis, Al-Rawi Muna and Dirasat Nat.;
Eng. Sci., 1998, 25(1), 94-99 (Eng.); Chem. Abstr., 129, 21, 753, 276168q (1998).
346. Alexandru Cascaval, Stocia, Gheorghe-Zaharia and Berdan, Ioan;
Rom. RO, 106, 403, (Cl. C07D 231/04), 1993, Appl. 143, 707, 15, 1990;
 Chem.  Abstr., 129, 2,491, 16120g (1998).
347.  S. N. Pandeya and D. Sriram;
Acta. Pharm. Ture., 1998, 40(1), 33-38 (Eng.); Chem. Abstr., 129, 9, 641, 109060,  (1998).
348. Omar T. Mahmoud;
Egypt J. Pharm. Sci., 1997, 38(4-6), 271-280 (Eng.) Chem. Abstr., 131, 645,  257474x (1999).
349. R. P. Pawar, N. M. Anduskary and V. B. Vibhute;
J. Indian. Chem. Soc., 1999, 76(5), 271-72 (Eng). Chem. Abstr., 131, 677,  271829y (1999).
350. Chohan, H. Zahid and M. Praveen;
Net Based Drugs. 1999, 6 (3), 149-152 (Eng.) Chem. Abstr., 131, 511, 310722e (1999).
351. Ergenc Nedime, Uinsoy Nuray, Capangultate Soruis, Aulten Tuk, Kiraz and
Mnammer; Arch. Pharm. 329 (8-9), 427-430 (1996); Chem. Abstr., 126, 1, 8031b (1997).
352. B. S. Holla, M. K. Shivananda,  S. Shenoy and  A. Antony;
Boll. Chim. Farm. 137(7), 233-238 (1998); Chem. Abstr., 131, 23, 310543p  (1999).
353. Taruna Pandey, V.P. Singh, R.V. Singh;
Main Group met. Chem., 1999, 22(5), 315-320 (Eng.). Chem. Abstr., 131, 9, 696, 116271s (1999).
354. Bodke Yadav and S. S. Sangapure;
J. Indian. Chem. Soc., 80, 187-189, (2003).
355.  Holla B. Shivarama, B. Veerendra, M. K. Shivananda, Boja Poojary;
Eur. J. of M. C. 38, 759-767 (2003).
356. Ravindra V. Chambhare, Barsu, G. Khudse, Anil S. Bobde and Rajesh H. Bahekar;
Eur. J. Med. Chem., 38, 89-100 (2003).
248
357. Holla B. Shivarama,  K. V. Malini,  B. Sooryanarayan, B. K. Raw,  N. Sarojini and  Suchetha Kumari;
Eur. J. Med. Chem., 38, 313-318 (2003).
358. Iana Vazzana, Emanuela Terranova, Francesca Mattioli, Fabio Sparatore;
ARKIVOC (V) 364-374, (2004).
359. Neslihan Demirbas and Reyhan Ugurluogul;
Turk J. Chem., 28, 679-690 (2004).
360. R. S. Varma;
J. lnd.Chem. Soc., 81, 8, 627-638, Aug. (2004).
361. Parumal Panneerselvam, Rajasree R. Nair, Gudaparthi Vijaylakshmi,Ekambaram
Harishara Subramanian and Seshiah Krishnan sridhar;
Eur. J. Med. Chem., 40(2), 225-229 Feb. (2005).
362. Zhanyong Guo, Reng Chan, Ronge Chen, Renge Xing, Song Liu, Huahua Yu, Pibo
Wang, Cuiping Li and Pengcheng Li;
Carbohydrate research, 341(3), 351-354, Feb.(2006).
363. Zhanyong Guo, Reng Chan, Ronge Chen, Renge Xing, Song Liu, Huahua Yu, Pibo
Wang, Cuiping Li and Pengcheng Li;
Bioorg. & Med. Chem. Lett., 15(20), 4600-4603, Oct.(2005).
364. Sham M. Sondhi, Nirupama Singh, Ashok Kumar, Olivier Lozach and Laurent Meijel;
Bioorg. & Med. Chem., 14(11), 3758-3765, Jun (2006).
365. Jayendra Patole, Dipti Shingna Purkar, Subhash Padhye and Colin Ratledge;
Bioorg. & Med. Chem., 16(6), 1514-1517, Jun (2006).
366. Alaaddin Cukurovali, Ibrahim Yilmaz, Seher Gur and Cavit Kazaz;
Eur. J. Med. Chem., 41(2), 201-207 Feb. (2006).
367. Dharmarjan Sriram, Perumal Yogeeswari, Naya Sirisha Myneedu and Vivek Saruswat;
Bioorg. & Med. Chem. Lettt., 16, 2127-2129 (2006).
368. Huang Taishang and Xiaman Daxye Xuebao;
Ziran Kexueban, 33(G), 827-31 (1994); Chem. Abstr., 123, 9277m (1995).
369. A. Yu Ershor,  A. V. Gribanov and V. A. Gindin;
Russ. J. Org. Chem., 33(10), 1490-93 (1997); Chem. Abstr., 129, 202913t (1998).
370. Duncan H. Hunter, Roberts Chantelle Me and Jugadese J. Vittal;
Can. J. Chem., 76(5), 522-24 (1998).
371. J. S. Cusas, E. E. Castellano, M. S. Gracia Tasende, A. Sanchez et. al.;
Polyhedron, 17 (13,14), 2249-56 (1998); Chem. Abstr., 129, 155679n (1998).
372. A. B. Tomchin;
Russ. J. Org. Chem., 33(4), 567-68 (1977); Chem. Abstr., 128, 1925978 (1998).
249
373. Perumal Yogeeswari, Dharmarajan Sriram, Logantha Ramamoorthy Jeewanlal
Sunil Jit, Sathiyanesan Sathish Kumar and James P. Stables;
Eur. J. Med. Chem., 37(3), 231-236, (2002).
374. A. K. Bhatt, R. P. Bharmaria, M. R. Patel, R. A. Bellaro and C. V. Deliwala;
Indian J. Chem., 10, 694-98 (1972).
375. Hu, Wei-Xiao, Sun Nan and  Yu. Zhong;
Gaodeng Xuexiao Huaxue Xuebao 22(12), 2014-17 (2001); Chem. Abstr., 136, 294802b
(2002).
376. Hu Wei-Xiao, Sun Nan and Yu Zhong;
Chem. Abstr., 136, 279421h (2002).
377. Cesur Nersin, Cesur Zafar and Guersoy Aysel;
Arch-Pharm., 35(9), 623-24 (1992); Chem. Abstr., 118, 6327j (1993).
378. Zhong Mehg; Liu Luosheng, Wen, Xiao Xia and Ling Pei Xhe;
Huaxi Yaocue Zazhi 12(2), 85-86 (1997); Chem. Abstr., 127, 65635w (1997).
379. J. F. Bartosevich, T. S. Griffin, C. J. Manson and J. P. Scovill;
J. Med. Chem., 22, 855 (1979).
380. Martin Missbach;
PCT Int. Appl. WO 14, 686 (Cl. CO7D 27/06) (1995); CH Appl. 93/3, 524 (1993);
Chem. Abstr., 123, 169641d (1995).
381. B. Kanvechi, C. B. Johnson, .C Cellik and H. Yuksek;
Acta. Pol. Pharm. 54(4), 307-12 (1997); Chem. Abstr., 128, 396, (1998).
382. Maria E. Silva, Joselice Alves, Jose Antonio, D. O. Nasimento and C.  Silene;
Farmaco; 53(3), 241-43 (1998); Chem. Abstr., 129, 109012p (1998).
383. Sushma Singh I., R. V Singh, Amita Phor and J. P. Tondon;
Heterocyclic Chem., 20(10), 663-67 (1997); Chem. Abstr., 128, 22967j (1998).
384. B. Kanvechi, C. B. Johnson, C. Cellik  and H. Yukseh;
Acta Pol. Pharm., 54(4), 307-12 (1997); Chem. Abstr., 128, 396, (1998).
385. Maria E. Silva, Joselice Alves, Jose Antonio, D. O. Nasimento and C. Silene;
Farmaco; 53(3), 241-43 (1998); Chem. Abstr., 129, 109012p (1998).
386. K. Rao, Rastogi K. Srinivasa, D. R. Sridhar and M. C. Jain;
Indian J. Chem., 26(B), 596-98 (1987); Chem. Abstr., 108, 150395v (1988).
387. Wang Deteng, Wan Xinbo, Liu Cyiyibang and Zhao Quianquin;
Huxai Yaoque Zohi 13(2), 75-76 (1998); Chem. Abstr., 129, 336521a (1998).
388. Magalhaes Nereide, Stela Santos, Alves Antonio Jose, Alencar et. al.;
Rev. Cienc. Farm. 19(1), 49-66 (1998); Chem. Abstr., 130, 2230257 (1999).
250
389. Teoh-Siang-Guan, Ang. Show-Hing and Ongchiwi;
J. Orgmet. Chem., 580(1), 17-21 (1999); Chem. Abstr., 131, 73727a (1999).
390. A. Rajasekaran ans S. Murugesan;
J. Ind.Chem. Soc., 79(6), 544-45, (2002); Chem. Abstr., 137, 369945g (2002).
391. Kelvin J. Duffy, Juan I.Luengo, Stephan G. Miller and Julian Jenkins;
PCT Int. Appl. WO 02 49, 413 (Cl. A61K), (2002); Chem. Abstr., 137, 63077y (2002).
392. Nicolas Kolocouris, Antonios Kolocouris, George B. Foscolo et. al.
Bioorg. & Med. Chem. Letters, 12(5), 723-727 (2002).
393. Amir Azam, Neelam Bharti, Kakul Husain, M. T. Gonzalez Garza, Delia E. Cruz-Vega,
J. Castro-Garza, Benito D. Mata-Cardenas and Fehmida Naqvi;
Bioorg. & Med. Chem. Letters, 12(23), 3475-3478 (2002).
394. C. C. Garcia, B. N. Brousse, A. G. Maglioni, M. M. Alho and E. B. Damonte;
Antiviral Chemistry and Chemotherapy, 14(2), 99-105 (2003).
395. Hugo Cerecetto, Gabriela Aguirre, Luc1a Boiani, Marcelo Fernández, Mercedes Gonzalez,
Ana Denicola, Luc1a Otero, Dinorah Gambino, Carolina Rigol, Claudio Olea-Azar and
Mario Faundez;
Bioorg. & Med. Chem. 12(18), 4885-4893 (2004).
396. M.  Sznol et. al.;
Cancer Chemotherapy and Pharmacology, 54(4), 331-342 (2004).
397. P. Yogeeswari, D. Sriram, S. Mehta, D. Nigam, M. Mohan Kumar, S. Murugesan and J.P.  Stables;
IL Farmaco vol.60(1), 1-5 (2005).
398. R. Kiplin Guy, Naoaki Fujii, Jeremy P. Mallari, Elizabeth J. Hansell, Z. Mackey, Patricia
Doyle, Y.M. Zhou, Jiri Gut, Philip J. Rosenthal and James H. McKerrow;
Bioorg. & Med. Chem. Letters, 15(1), 121-123 (2005).
399. Alexandre J. S. Goes, Romulo P. Tenorio, Cristiane S. Carvalho, Carla S. Pessanha, Jose
G. de Lima, Antonio R. de Faria, Antonio J. Alves and Edesio J. T. de Melo;
Bioorg. & Med. Chem. Letters, 15(10), 2575-2578 (2005).
400. Dharmarajan Sriram, Tanushree Ratan Bal, Anand Balasubramani and Perumal Yogeeswari;
Bioorg. & Med. Chem. Letters, 15(20), 4451-4455 (2005).
401. Hu Wei-xiao, Wei Zhou, Chun-nian Xia and Xi Wen;
Bioorg. & Med. Chem. Letters, 16(8), 2213-2218 (2006).
402. Anand Varma;
Green Chem., 1, 43, (1999).
403. R. J. Gigure, A. M. Namen, B. O. Lopez,  A. Arepally, D. A. Ramos, G. Mayetich and J. Dfauco;
Tetrahedron Lett., 28, 6553 (1987).
251
404.  J. Berlan, P. Giboreau, S. Lefeurre and C. Marchand;
Tetrahedron Lett., 32, 2363 (1991).
405. J. Ipaktschi and M. Bruck;
Chem. Ber., 123, 1591 (1990).
406. A Srikrishna and S Nagarju;
J. Chem. Soc., Perkin Trans, 1, 311 (1992).
407. J. Singh, M Sharma, G. L Kud and B. R. Chhabra;
J. Chem. Res., 5, 264 (1997).
408. A. Orssaid and A. Loupy;
J. Chem. Res., 5, 342 (1997).
409.  A. K. Mitra and M. Karchavdhvri;
J Chem. Res., 5, 246 (1999).
410. A. K. Bose, B. K. Banik, K. J. Barakat and M. S. Manhas;
Synlett, 246 (1999).
411. C. D. Wang, Shixz and R. J. Xie;
Synth. Commun., 27, 3705 (1997).
412. T. Beregsaszi and  A. Molnar;
Synth. Commun., 27, 3705 (1997).
413. R. S. Varma, A. Chatergee and M. Varma;
Tetrahedron Lett., 34, 3207 (1993).
414. A. K. Mitra and N. Karchaundhuri;
Indian J. Chem., 39B (2000).
415. S. V. Leg and D. M. Mynett;
Syn. Lett., 793 (1993).
416. A. Loupy, P. Pigeon, M. Ramademi and Jaequaulip;
Synth. Commun., 24, 159 (1994).
417. A. K. Mitra and N. Karchaudhuri;
Synth. Commun., 29, 573 (1999).
418. A. K. Mitra and N. Karchaundhuri;
Synth. Commun., 29, 273 (1999).
419. S. Caddick;
Tetrahedron, Vol., 51, No. 38, 10403-10432 (1995).
420. E. Hoggarth;
In ‘Chemistry of Carbon Comp.’ Edited by E. H. Rodd., IV A. P. 452-63.
252
421.  V. Meyer and P. Jacopson;
‘Hand book of Organic Chemistry’, 2, Pt. 3, Soc. 1-2, 590, (1920).
422. G. M. Ramos Tombo, D. Bellus,
Angew. Chem., 703, 1219 (1991).
423. Kap-Sun Yeung, Michelle E. Farkas, John F. Kadow and Nicholas A. Meanwell;
Tetrahedron Letters vol.46(19) 3429-3432 (2005).
424. C. S. Andotra and Sukhbinder Kaur;
Indian Journal of Chemistry, 43B, March (2004).
425. Ahamad S. Shawali, Magda A. Abdallah, A. N. Mosselhi and Yasin F. Mohamed;
Z. Naturforch., 57b, 552-556 (2002).
426. Shin-ichi Nagai, Taiser Weda and Mastoshi Takamura;
J. Heterocyclic Chem., 35, 293 (1998).
427. Zhang Zivi and Lin Haixia;
Gaodeng Xuexiao Huaxue Xuebao, 7, 936 (1992); Chem. Abstr., 118, 10888f (1993).
428. Jack. R. Reid and Ned D. Heindel;
J. Heterocyclic Chem., 13, 925 (1976).
429. Correa Merce, Sanchis-Segura, Carles, Aragon and M. G. Carlos;
Physiology and Behavior., 73(4), July (2001).
430. S. M. Kudari, S. M. Beede and Munera Wahaja;
Asian. J. Chem., 9, 20 (1997); Chem. Abstr., 126 (1997).
431. Mark D. Abel, Randy T. Hewgill, Katherine J. Malczylc and Ronald G. Micetich;
J. Heterocycl. Chem., 35, 193 (1998).
432. N. Karali, G. Capan,  N. Ergene and A. Gursoy;
Sci. Pharm., 65, 277 (1997); Chem. Abstr., 128, 167389g (1998).
433. D. B. Reigz;
Eur. Pat. EP 508445 (Cl. A61k 31/44); Chem. Abstr., 118, 59716w (1993).
434. Bozo Eva, Szilagyi Geza and Janky Judit;
Arch. Pharm. (Weinheim. Ger.) 322, 583 (1989); Chem. Abstr., 112, 55731a (1990).
435. R. S. Verma, Vinita Bajpai and A. Kapil;
Indian J. Heterocycl. Chem., 10, 117 (2000).
436. Murthy Sreenivasa, V. A. N. Nagappa and L. V. G. Nargund;
Indian J. Hetrerocycl. Chem., 8, 23 (1998); Chem. Abstr., 130, 66448m (1999).
437. Michael J. Ellis, Stevens and F. G. Malcolm;
J. Chem. Soci., 23, 3180-3185 (Eng.) (2001); Chem. Abstr., 137, 185433g (2002).
253
438.  Jyoti S. Archana, S. Sanjay and V. K. Saxena;
J. Indian Chem. Soc., 68, 103 (1991).
439. F. Pourmorad and A. Shafiee;
J. Sci. Islamic Repub. Iran, 9, 30 (1998); Chem. Abstr., 129, 175593e (1998).
440. L. G. Chekovskaya, E. G. Khush and G. K. Rogyllchenko;
Farm. 2h (kiev) 5, 67-8 (1989); Chem. Abstr., 112, 198233a (1990).
441. Itoh Katsumi, Kitazaki Tomoyuki and Matsushita Yoshihiro;
Eur. Pat Appl. EP 884311; Chem. Abstr., 130, 66505c (1999).
442. Fusaka Takafumi, Ujikawa Osamu, Kajiwara Takeshi and Tanaka Yasushi;
PCT Int. Appl. WO 97, 11, 075; Chem. Abstr., 126, 293354p (1997).
443. Chu Chang Hu, Sun Xiao Wen, Zhang Zi Yi and Li Zhi Chun;
Chin Chem. Lett., 10, 361 (1999).
444. Neikamura Hiroshi, Kameda Soichi, Sato Takahiro, Ashizawa Naoki, Matsumoto Koji,
Iwanaga Takashi and Inoue Tsutomu;
PCT Int. Appl. WO 03, 64, 410 (Cl.CO7D 401/04) 7 Aug. (2003). Chem. Abstr., 139(11),
164794 b, (2003).
445. James M. Balkovec, Rolf Nundt Thieringer, S. Steven, Hermanowski-Vosatka Anne,
Donald W. Graham, Gool F. Patel et. al.;
PCT Int. Appl. WO 03, 65983 (Cl. A61K) (2003). Chem. Abstr., 139(12), 180065v-(2003).
446. P. V. Chepal, O. I. Pansonko, V. P. Buriak and V. I Galdash;
Chem. Abstr., 138, 137235t (2003).
447. Aoki Satosh, Nagakawa Toshiya and Konish Nobukiyo;
PCT Int. Appl WO 03 40110 (Cl. CO7D249/08) (2003); Chem. Abstr., 138, 368895z (2003).
448. Yaseen A. Al-Soud, Mohammed N. Al-Dweri and Najim A. Al-Masoudi;
IL Farmaco, 59(10), 775-783, Oct. (2004).
449. Neslihan Demirbas, Alpay Karaoghi Sengul, Ahmet Demirbas and Kemal Sancak;
Eur. Jou. Med. Chem., 39(9), 793-804, Sept. (2004).
450. Krzysztof Walczok, Andrzej Gondela and Jerzy Suarnski;
Eur. J. Med. Chem., 39(10), 849-853, Oct., (2004).
451. Dae-Kee Kim, Joonseop Kim and Hyun-Ju-Park;
Bioorg. and Med. Chem., 12(9), 2013-2020, May (2004).
452. Neslihan Demirbas, Ahmet Demirbas, Sengul Alpay Karaoglu and Elif Celik;
ARKIVOC, 75-91 (2005).
453. Marie-Odile Contour-Galcera, Alban Sidhu, Pascale Plas and Pierre Roubert;
Bioorg. and Med. Chem. letters, 15(15), 3555-3559, Aug. (2005).
254
454. K. M. Basavaraja, V. P. Vaidya and Y. S. Agasimundin;
Indian J. of Heterocyclic chem., 15(1), 1-6, (2005).
455. Guru S. Gadaginamath, Dundappa S. Donawade and A. V.  Raghu;
Indian J. of Chem., 45B(3), 689 (2006).
456. Haydar Yuksek, Sevgi Kolayly, Murat Kucuk, M. Ozgun Yuksek, Ummuhan Ocak, Esra
ahinba, Efecan Sivrikaya and Mirac Ocak;
Indian J. of Chem., 45B(3), 715 (2006).
457. Abbas Shafiee, Sara Tehranchian, Tahmineh Akbarzadeh, Mohammad Reza Fazeli and
Hossein Jamalifar;
Bioorg. and Med. Chem. letters, 15(4), 1023-1025, Feb. (2005).
458. Nawal A. El-Koussi, Safwat M. Rabea, Hoda Y. Hassan and Tarek Aboul-Fadl;
Archiv der Pharmazie, 339(1), 32-40 (2006).
459. B. S. Holla, N. K. Poorjary,  S. B. Rao and M. K. Shivananda;
Eur. J. Med. Chem., 37, 511 (2002).
460. Howard Sard, Peter C. Meltzer and Raj K. Razdan;
J. Heterocycl. Chem., 22, 361 (1985).
461. A. M. Barghash;
J. Pharm. Sci., 12(2), 256-262 (1996); Chem. Abstr., 126, 8041e (1997).
462. Jag Mohan, Anupama and Anju Rathee;
Indian J. Heterocycl. Chem., 10, 01-04 (2000).
463. Khosrow Zamani, Khaht Faghihi, M. Reza Sangi and Javed Zolgharenin;
Turk J. Chem., 27, 119-125 (2003).
464. Alla A. Hassan, Nasr K. Mohamed, Ahmed M. Shawky and Dietrich Dopp;
ARKIVOC, 118-128(i) (2003).
465. Mei-Hsiu Shih and Wu Cheng-Ling;
Tetrahedron, 61(46),10917-10925 (2005).
466. Madhukar S. Chande and Ravindra M. Joshi;
Indian J. Chem., 38(2), 218-220 (1999); Chem. Abstr., 131, 5224j (1999).
467. Sun Xiao-Wen, Yan Zhang and Zi-Yi Zhang;
J. Chin. Chem. Soc., (Taipei) 45(4), 535-538 (1998); Chem. Abstr., 129, 245102v(1998).
468. Igarushi Shinichi, Nishino Yasuto and Tsunoda Takuya;
Jpn. Kokai Tokkyo Koho JP 11 71, 361 [99, 71, 361] (1999); Chem. Abstr., 130, 223283y
(1999).
469. A. H. Mandour, K. M. Ahmed, T. K.  Mohamed and  Z. E. El-Bazza;
Egypt. J. Pharm. Sci., 37(1-6), 71-84 (1996); Chem. Abstr., 126, 251111b (1997).
255
470. Shi Hai-Jian, Shihao-Xin, Wang-Zhong and Youji Huazue;
Chem. Abstr., 131, 44716k (1999).
471. Byung H. Lee, Fred E. Dutton, Michael F. Clotheir and Jerry W. Bowman;
Bio. Org. Med. Chem. Lett., 9(12), 1727-1732 (1999).
472. Hatice N. Dogan, Arzu Duran, Sevim Rollas, Goksel Sener, Meral K. Uysal and Dumrul
Gulen;  Bioorg. and Med. Chem., 10, 2893-2898 (2002).
473. Erhan Palaska, Gulay Sahin, Pelin Kelicen, N. Tugba Durlu and Gulcin Altinok;
IL Farmaco, 57, 101-107 (2002).
474. Mohd Amir and Kumar Shikha;
European J. Med. Chem., 39, 535-545 (2004).
475. Silvia Schenone et. al.,;
Bioorg. and Med. Chem., 14, 1698-1705 (2006).
476. Schenone Silvia, Bruno Olga, Ranise Angelo and Bondvalli Francesco;
Framaco, 53, (8-9), 586-589 (1998); Chem. Abstr., 130, 296650q (1999).
477. Mohmoud T. Omar;
Egypt J. Pharm. Sci., 1997 (Pub 1998), 38 (4-6), 271-280 (1997); Chem. Abstr., 131,
257474x (1999).
478. Alireza Foroumadi, Ali Asadipour, Maryam Mirzaei, Javad Karimi and Saeed Emami;
IL Farmaco, 57, 765-769 (2002).
479. Alireza Foroumadi, Maryam Mirzaei and Abbas Shafiee;
IL Farmaco, 56, 621-623 (2001).
480. Alireza Foroumadi, Zahra Kiani and Fatemeh Soltani;
IL Farmaco, 58, 1073-1076 (2003).
481. Alireza Foroumadi et. al.;
Bioorg. and Med. Chem. Letters, 16, 1164-1167 (2006).
482. Karakus and Rollas;
IL Farmaco, 57, 577-581 (2002).
483. Alireza Foroumadi, Shahla Mansouri, Zahra Kiani and Afsaneh Rahmani;
European J. Med. Chem., 38, 851-854 (2003).
484. Alireza Foroumadi et. al.;
IL Farmaco, 58, 1023-1028 (2003).
485. Alireza Foroumadi et. al.;
European J. Med. Chem., 15, 4488-4492 (2005).
486. Lisa M. Thomasco et. al.;
Bioorg. and Med. Chem. Letters, 13, 4193-4196 (2003).
256
487. R. H. Udupi, V. Rama Mohan Gupta, P. Raviprakash, Rajesh B. Varnekar and N.
Srinivasulu; Indian J. Het. Chem., 14(4), 335-338 (2005).
488. Mond A. Mahram, El-Sherbeny Magda, El-Obaid Abdul-Rahman and Farid A. Badria;
Alexandria J. Pharm. Sci., 12(1), 39-44 (1998); Chem. Abstr., 129, 67756b (1998).
489. F. Malinoski and V. Stoller;
Virology, 110, 281 (1981); Chem. Abstr., 94, 186145v (1981).
490. Joanna Matysiak and Adam Opolski;
Bioorg. and Med. Chem., 14, 4483-4489 (2006).
491. Joanna Matysiak,Anna Nasulewicz, Marzena Pelczynska and Marta Switalska,
Iwona Jaroszewicz and Adam Opolski;  European J. Med. Chem., 41, 475-482 (2006).
492. S. Talath and A.K. Gadad;
European J. Med. Chem., xx, xxx (2006).
493. M. R. Mody, A. R. Prasad, T. Ramlingam and P. B. Sattur;
Chem. Abstr., 97, 2161310 (1982).
494. K. Hoggarth and Paul Rathgab;
J. Indian Chem. Soc., 52, 750 (1975); Chem. Abstr., 72, 127345 (1969).
495. A. K. Galad, I. M. Mahajan and  C. S. Shetti;
Indian J. Heterocycl. Chem., 2(1), 207-56 (1992).
496. C. Tony;
Gen. Offen., 2, 050, 479 (1971); J. Ind. Chem. Soc., 52, 750 (1975).
497. Alireza Foroumadi, Saeed Emami, Shirin Pournourmohammadi, Arsalan Kharazmi and
Abbas Shafiee; European J. Med. Chem., 40, 1346-1350 (2005).
498. Alireza Foroumadi et. al.,;
Bioorg. and Med. Chem. Letters, 15, 1983-1985 (2005).
499. Huebl Dieter, Pierob Ernst Albrecht, H. Jappien and D. Baument;
Ger. Chem. D. E., 3, 821, 953 (Cl. CO7D285/72); Chem. Abstr., 113, 6350n (1990).
500. Samir A. Carvalho et. al.,;
Bioorg. and Med. Chem. Letters, 14, 5967-5970 (2004).
501. Mazaahir Kidwai, Rajesh Kumar, Anil Srivastava and H. P. Gupta;
Bioorganic Chemistry, 26, 289-294 (1998).
502. Li-Xue Zhang , An-Jiang Zhang, Xian-Xing Chen, Xin-Xiang Lei, Xiang-Yun Nan,
Dong-Yong Chen and Zi-Yi Zhang;
Molecules, 7, 681-689 (2002).
503. Neslihan Demirbas, Ahmet Demirbas, Sengul Alpay Karaoglub and Elif Celik;
ARKIVOC, 75-91 (2005).
257
504. Abdel-Rahman Farghaly, Erik De Clercq, and Hussein El-Kashef;
ARKIVOC, 137-151 (2006).
505. Kanchugarakoppal S. Rangappa et. al.,;
European J. Med. Chem., 41, 531-538 (2006).
506. B. Kalaiya and  A. R. Parikh;
J. Inst. Chem., (India), 63, 161, (1985); Chem. Abstr., 104, 109527u (1986).
507. P. M. Parasharya and  A. R. Parikh;
J. Inst. Chem. (India), 65, 106 (1993).
508. P. M. Parasharya  and  A. R. Parikh;
J. Inst. Chem. (India), 63, 196 (1991); Chem. Abstr., 117, 171386u (1992).
509. V. L. Panchhamia and  A. R. Parikh;
J. Inst. Chem. (India), 61, 54 (1989); Chem. Abstr., 112, 198229d (1990).
510. P. M. Parasharya and  A. R. Parikh;
J. Inst. Chem. (India), 64, 140 (1992).
511. R. N. Vansdadia, K. P. Roda and Hansa Parekh;
J. Inst. Chemists (India), 60, 232-34 (1988).
512. H. J. Vikani and Hansa Parekh;
J. Indian Chem. Soc., 67, 859-861 (1990).
513. R. N. Vansdadia, K. P. Roda and Hansa Parekh;
J. Inst. Chemists (India), 61, 89-92 (1989).
514. Kartik Ladwa, Ranjan Khunt and Hansa Parekh;
Oriental J. Chem., 18(1), 135-138 (Eng.) (2002); Chem. Abstr., 137(21), 310873d (2002).
515. S. Trivedi, H. Kubavat and H. H. Parekh;
Indian J. Chem., 83B, 295 (1994).
516. Chubb et. al.,;
U. S. Pat. 3,965,173 (1976);
517. Din-Iza;
Dictionary of Organic Compounds 3, 1270 (1953).
518. C. Aniswarth;
J. American Chem. Soc., 87, 5800 (1965).
519. A. Hetzheim and K. Mockel;
Adv. Heterocycl. Chem., 7, 183 (1966).
520. Cugureanu Constantin;
Rev. Chim., 47(5) (1996); Chem. Abstr., 125, 195512y (1996).
258
521.  Shivarama B. Holla, Narayana K. Poojary , Balakrishna Kallaraya and Vankattramana  P.
Gowda; Indian J. Heterocycl. Chem., (1996); Chem. Abstr., 125, 221742v (1996).
522. Christoper T. Brain, Jahen M. Paul and Yuonne Loong;
Tetrahedron Lett., (1999) ; Chem. Abstr., 130, 352229i (1999).
523. Mahmohd Al-Talib and Sultan Able Orabi;
Indian J. Heterocylc.Chem., (1999); Chem. Abstr., 131, 129950n (1999).
524. Fonad Bentiss and Michel Lagence;
J. Heterocycl. Chem., (1999); Chem. Abstr., 132, 35656j (2000).
525.  S. N. Kovalenko,  K. M. Sytnik, V. M. Nikit-Chenko and S. V. Rasanova;
Chem. Heterocycl.Compound (N. Y.) (1999); Chem. Abstr., 132, 35657r  (2000).
526. A. A. Ziyaen and G. G. Galustyan;
Chem. Heterocycl. Compd. (N. Y.) (1999); Chem. Abstr., 132, 334416e (2000).
527. Yu Jian-Xin, Liu Fang-Ming, Lu Wen-Jie, Li Yan-Ping and Zao Xin-Min;
Youji Xuaxue (2000) ; Chem. Abstr., 132, 194358k (2000).
528. K. Mogilaiah and B. Sakram;
Indian J. Heterocyclic Chem., 13, 289-292, June (2004).
529. D. Ramesh  and B. Sreenivasuhi;
Indian J. Heteroxyel. Chem., 13, 163-164, Dec. (2003).
530. Hansong Chen, Zhengming Li and Yufeng Han;
J. Agric. Food Chem., 48(11), 5312-5315 (2002).
531. Gaurav Grover and  Suriarana G. Kini;
Indian J. Heterocycl. Chem., 12(3), 289-290 (2002); Chem. Abstr., 139(13) 197430h  (2003).
532. Weinder Wells, A. Michuc, Henninger Todde and Dennis Hlasta;
U.S. Pat Appl. Publ. US 49, 213 (Cl. 514-e52.05l eo7D413/02) (2002).
533. A. Kocabalkanli  et. al.;
IL Farmaco, 56, 975-979 (2001).
534. Kocabalkanli Ayse, Ates Oznur and Otuk Gulten;
IL Farmaco, 56(12), 978-979 (2001); Chem. Abstr., 137(1), 6127r (2002).
535. Gaurav Grover and  Suriarana G. Kini;
Indian J. Heterocycl. Chem., 12(3), 289-290 (2002); Chem. Abstr., 139(13) 197430h (2003).
536. Amarika Singh and Upama Mishra;
Proc. Indian Natt. Sci. acad., Part-A 57(5), 573-8 (1991); Chem. Abstr., 116, 151711x  (1992).
537. Cignarella Giorgio, Pinna Gerado and Murineddu Gabriele;
PCT Int. Appl. WO 03, 66, 628 (Cl. CO7D413/04) (2003); Chem. Abstr., 139(12), 180069z (2003).
259
538. F. A. Omarl, N. M. Mahfouzl and M. A. Rahman;
European J. Med. Chem., 39, 819-825 (1996).
539. Gülay ªahin, Erhan Palaska, Melike Ekizoìlu and Meral Özalp;
IL Farmaco, 57, 539-542 (2002).
540. ª. Güniz Küçükgüzel,  E. Elçin Oruç, Sevim Rollas, Fikrettin ªahin and Ahmet Özbek;
European J. Med. Chem., 37, 197-206 (2002).
541. M.S.Y. Khan, M. Akhtar;
Indian J. Chem., Sec-B, Org, Chem. Ind. Med. Chem., 42B(4), 900-904 (2003).
542. H. P. Shah, B. R. Shah, J. J. Bhatt, N. C. Desai, P.B. Trived and N.K. Undavia;
Indian J. Chem., Sec-B; Org. Chem., Incl. Med. Chem., 37B(2), 180-182 (1998).
543. Jegham Samir, Lochead Alistair, Nedelec Alain, Galli Frederich and Gallet Thierry;
PCT Int. Appl. WO 98, 50383 (1998); Chem. Abstr., 129, 343500t (1998).
544. Battarini France, La Porta Piero, Meazza Giovanni and Zanardi Giampaolo;
Eur. Pat EP 769, 845 (1997); Chem. Abstr., 127, 318878y (1998).
545. G. W. Adelstein, C. H. Yen, E. J. Dajani and R. G. Bainchi;
J. Med. Chem., 19, 221 (1976).
546. M. I. Hussain and Mohd. Raghib Jamali;
Indian J. Chem., 27B(1), 43-6 (1988); Chem. Abstr., 109, 128913 (1988).
547. M. S. Y. Khan, R. M. Khan and Sushma Drabu;
Indian J of Heterocycl. Chem., 11(2), 119-122 (2001); Chem. Abstr., 137(23), 337829f  (2002).
548. R. Nyfeler, W. Eckhardt, Ernst Benger and Odd Kristiansen;
Eur. Pat. Appl. EP 255, 565, 05 (1988); Chem. Abstr., 110, 114837y (1989).
549. Erhan Palaska, Gülay ªahin, Pelin Kelicen, N. Tuìba Durlu and Gülçin Altinok;
IL Farmaco, 57, 101-107 (2002).
550. Virginija Jakubkienè, Milda Malvina Burbulienè, Giedrutè Mekuškienè, Emilija Udrènaitè,
Povilas Gaidelis and Povilas Vainilavièius; IL Farmaco, 58, 323-328 (2003).
551. Milda Malvina Burbuliene,Virginija Jakubkiene, Giedrute Mekuskiene, Emilija Udrenaite,
Romualdas Smicius and Povilas Vainilavicius; IL Farmaco, 59, 767-774 (2004).
552. Ali Almasirad, Sayyed A. Tabatabai, Mehrdad Faizi,  Abbas Kebriaeezadeh, Nazila
Mehrabi,  Afshin Dalvandi  and Abbas Shafiee; Bioorg. and Med. Chem., 14, 6057-6059 (2004).
553. Afshin Zarghi, Sayyed A. Tabatabai, Mehrdad Faizi, Avideh Ahadian, Parisa Navabi, Vahideh
Zanganeh and Abbas Shafiee; Bioorg. and Med. Chem., 15, 1863-1865 (2005).
554. Ali A. El-Emam, Omar A. Al-Deeb, Mohamed Al-Omar and Jochen Lehmann;
Bioorg. and Med. Chem., 12, 5107-5113 (2004).
260
555. Xiaohu Ouyang et. al.;
Bioorg. and Med. Chem. Letters, 16, 1191-1198 (2006).
556. Theresa May Chin Tan, Yu Chena, Kah Hoe Kong, Jing Bai, Yang Li, Seng Gee Lim,
Thiam Hong Ang and Yulin Lam; Antiviral Research, xx, xxx (2006).
557. S.L. Gaonkar, K.M.L. Rai and B. Prabhuswamy;
European J. Med. Chem., xx, xxx (2006).
558. Güniz Küçükgüzel, Ayla Kocatepe, Erik De Clercq, Fikrettin ªahin, Medine and Güllüce;
European J. Med. Chem., 41, 353-359 (2006).
559. Yan Li,  Jie Liu, Hongquan Zhang,  Xiangping Yang and Zhaojie Liu;
Bioorg. and Med. Chem., 16, 2278-2282 (2006).
560. V. L. Pachhamia and A. R. Parikh;
J. Indian Chem. Soc., 65, 357-61 (1988); Chem. Abstr., 109, 230899y (1988).
561. H. S. Joshi and A. R. Parikh;
J. Indian Chem. Soc., 67, 858 (1990); Chem. Abstr., 114, 247210f (1991).
562. T. P. Dabhi, V. H. Shah, N. A. Chauhan and A. R. Parikh;
Indian J. Pharm. Sci., 54(3), 98 (1992); Chem. Abstr., 118, 69644w (1993).
563. T. P. Dabhi, V. H. Shah and A. R. Parikh;
J. Inst. Chem (India) 64, 47 (1992); Chem. Abstr., 119, 28062w (1993).
564. T. P. Dabhi, N. A. Chauhan and A. R. Parikh;
J. Inst. Chem (India) 64, 51 (1992); Chem. Abstr., 119, 72546t (1993).
565. C. L. Patel and Hansa Parekh;
J. Indian Chem. Soc., 65, 606-67 (1988).
566. R. N. Vansdadia, K. P. Roda and Hansa Parekh;
J. Indian Chem. Soc., 65, 809-11 (1988).
567. R. N. Vansdadia, K. P. Roda and Hansa Parekh;
J. Indian Chem. Soc., 65, 782-83 (1988).
568. M. A. Shah Safi, M. H. Meshkat Al Sadat and Hansa Parekh;
J. Inst. Chemists (Indian), 61, 114-116 (1989).
569. Nailesh Joshi, Sushil Korgaokar and Hansa Parekh;
Indian J. Heterocyc. Chem., 5, 241-242 (1989).
570. Nailesh Joshi, Atul Bapodra and Hansa Parekh;
J. Indian Chem. Soc., 1st July (1996).
571. Kartik Ladwa, Pankaj Patel, Paresh Upadhyay and Hansa Parekh;
Indian J. Chem., 35B, 1062-1066 (1996).
261
572. Dharti G. Joshi, Haresh B. Oza and Hansa Parekh;
Heterocycl. Commu., 3(2), 169-174 (1997).
573. Haresh Oza, Dharti Joshi and Hansa Parekh;
Heterocycl. Commu. 3(6), 421 (1997).
574. Preeti Kagathara, Niraj Shah, Rajeev Doshi and Hansa Parekh;
Indian J. Chem., 38B(5), 572-576 (1999).
575. Viral R. Shah, Milan Vadodariya and A. R. Parikh;
Indian J. Chem., 36B, 101 (1998).
576. V. M. Parikh;
“Absorption Spectrosocpy of organic molecules”, addition-wesley pub. Co., London,
243-256 (1978).
577. C. N. R. Rao;
“Chemical application of infrared Spectroscopy” Academic press, New York (1963).
578. A. R. Kartizky and R. Alan Jones;
J. Chem. Soc., 2942 (1960).
579. F. V. Loffe;
Khim. Geterokeiki Sodein, 6, 1089, (1968);
Chem. Abstr., 70, 72338 (1986).
580. V. G. Thakare and K. N. Vadodkar;
Indian J. of Chem., 25(B), 610-612 (1986).
581. Silverstein Bassler and Morrill;
Spectrometric Identification of Organic Compounds, Fifth Edition (1991) by John Wiley & Sons.
582. B. D. Mistry;
A Handbook of Spectroscopic Data Chemistry, First Edition (2000) by ABD Publishers.
LIST OF NEW
COMPOUNDS
262
N
N
R
O
F
C6H5-
4-OCH3-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-OH-C6H4-
2-OH-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-Br-C6H4-
4-NH2-C6H4-
C4H3S-
N
N
F
NNH
R
C6H5-
4-OCH3-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
4-F-C6H4-
4-OH-C6H4-
2-OH-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-Br-C6H4-
4-NH2-C6H4-
C4H3S-
N
N
N N
R
F
O
C6H5-
4-OCH3-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
4-Br-C6H4-
4-OC2H5-C6H4-
2-F-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-NH2-C6H4-
2-OH2-C6H4-
4-OH-C6H4-
R R R
263
N
N
N N
R
F
N
O
N
N
F
NNH
R
S
N
N
F
NN
R
NH2
C6H5-
4-OCH3-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
4-Br-C6H4-
4-OC2H5-C6H4-
2-F-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-NH2-C6H4-
2-OH2-C6H4-
4-OH-C6H4-
R R R
C6H5-
4-OCH3-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
4-Br-C6H4-
4-OC2H5-C6H4-
2-F-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-NH2-C6H4-
2-OH2-C6H4-
4-OH-C6H4-
C6H5-
4-OCH3-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
4-Br-C6H4-
4-OC2H5-C6H4-
2-F-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-NH2-C6H4-
2-OH2-C6H4-
4-OH-C6H4-
264
N
N
R
F
O
O
OCH3
N
N
F
R
N
H
NH
O
O
O
N
N
CH N
R
F
C6H5-
4-OCH3-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
4-Br-C6H4-
4-OC2H5-C6H4-
2-F-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-NH2-C6H4-
2-OH2-C6H4-
4-OH-C6H4-
R R R
C6H5-
4-OCH3-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
4-Br-C6H4-
4-OC2H5-C6H4-
2-F-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-NH2-C6H4-
2-OH2-C6H4-
4-OH-C6H4-
C6H5-
4-OCH3-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
4-Br-C6H4-
4-OC2H5-C6H4-
2-F-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-NH2-C6H4-
2-OH2-C6H4-
4-OH-C6H4-
265
R R R
N
N
NH
R
F
NH S
NH2
C6H5-
4-OCH3-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
4-Br-C6H4-
4-OC2H5-C6H4-
2-F-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-NH2-C6H4-
2-OH2-C6H4-
4-OH-C6H4-
C6H5-
4-OCH3-C6H4-
4-CH3-C6H4-
4-Cl-C6H4-
4-Br-C6H4-
4-OC2H5-C6H4-
2-F-C6H4-
4-NO2-C6H4-
3-NO2-C6H4-
4-NH2-C6H4-
2-OH2-C6H4-
4-OH-C6H4-
N
N
CH2
NH
R
F N N
N
N
S
R
O
CH3
Cl
2-CH3-C6H4-
3,4-(OCH3)2-C6H3-
4-CH3-C6H4-
C5H4N-
4-OCH3-C6H4-
 4-Cl-C6H4-
4-Br-C6H4-
4-NO2-C6H4-
3-Cl-C6H4-
2,4-(Cl)2-C6H3-
C5H4N-
2-Cl-5-NO2-C6H3-
266
R R
N N
N
N
S
R
O
CH3
Cl
N N
O R
O CH3
Cl
2-CH3-C6H4-
3,4-(OCH3)2-C6H3-
4-CH3-C6H4-
4-C5H4N-
4-OCH3-C6H4-
4-Cl-C6H4-
4-Br-C6H4-
4-NO2-C6H4-
3-Cl-C6H4-
2,4-(Cl)2-C6H3-
2-C5H4N-
2-Cl-5-NO2-C6H3-
4-CH3-C6H4-
4-C6H5-
3,4-(OCH3)2-C6H3-
4-N-(CH3)2-C6H4-
4-OCH3-C6H4-
4-OH-C6H4-
4-Br-C6H4-
4-F-C6H4-
3-Cl-C6H4-
4-Cl-C6H4-
3-NO2-C6H4-
2-OH-C6H4-
